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Abstract 
 
Alzheimer’s disease (AD) is the most common form of dementia disorders and, yet, there is no 
preventative or curative treatment. It is associated with the progressive loss of memory and cognition 
and clinically divided into sporadic and familial forms. Familial Alzheimer’s disease (FAD) has 
predominantly a genetic predisposition with inherited mutations in the amyloid-β precursor protein 
(APP) and presinilin genes, which promote APP processing through the amyloidogenic pathway. This 
results in the release of the Aβ peptide, a major neurotoxic agent in AD progression.   
Accumulation of unfolded and misfolded disease-specific proteins (including Aβ and tau proteins) in 
neuronal cells perturbs endoplasmic reticulum (ER) homeostasis, leading to the onset of a cellular stress 
cascade called unfolded protein response (UPR), markers of which are upregulated in AD brain 
specimens. This suggests a possible role for ER stress in activation and the pathogenesis of AD.  
The research aimed to investigate the dynamic response of the UPR in an experimental model system of 
the disease combined with a computational model. For this purpose human neuroblastoma cell lines 
overexpressing the wild-type (APPWT) and two mutant forms of APP (APPMUT) associated with FAD were 
generated. Gene expression analysis of UPR markers revealed that overexpression of APP induces 
preconditioning of ER stress in all cell lines but with a stronger response in FAD-associated mutants. The 
progression sequence of UPR in APPWT and APPMUT was investigated in a time-course manner following 
the application of chemical stress. The results revealed that APPMUT exhibited the highest global 
response to chemically induced stress with a similar pattern. A computational model of the mammalian 
UPR was then generated and used to understand the dynamics of UPR. The model was able to 
reproduce our experimental data, which included pre-existing genetic factors (mutations in APP-
associated with FAD) and a mimic of environmental triggers (induction of stress) consequently triggering 
the stress response. It suggested a different protein load and magnitude of transcriptional activation 
upon stress among the three cell lines. This was followed by in silico case studies exploring the effect of 
drugs targeting different branches of the UPR.   
This study proposes a novel multidisciplinary platform that could be further used for the development of 
therapeutics for AD. As the familial and sporadic form of the disease have similar neuropathological 
characteristics, drugs efficacious for FAD will also be beneficial for the most common form of AD.
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𝛽𝛽𝑋𝑋𝑚𝑚𝑢𝑢   Basal transcription rate of unspliced XBP1 mRNA (molecule sec
-1) 
𝛽𝛽𝑋𝑋𝑢𝑢             Translation rate of XBP1u  𝛽𝛽𝑋𝑋𝑐𝑐             Protein complex formation rate of XBP1c 
𝛾𝛾𝐴𝐴𝐴𝐴𝐴𝐴4 Decay rate of ATF4 protein (sec-1) 
𝛾𝛾𝐴𝐴𝐴𝐴𝐴𝐴4𝑚𝑚 Decay rate of ATF4 mRNA (sec
-1) 
𝛾𝛾𝐵𝐵   Decay rate of BiP protein (sec-1) 
𝛾𝛾𝐵𝐵𝑚𝑚 Decay rate of BiP mRNA (sec
-1) 
𝛾𝛾𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 Decay rate of CHOP protein (sec-1) 
𝛾𝛾𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑚𝑚  Decay rate of CHOP mRNA (sec
-1) 
𝛾𝛾𝑒𝑒𝑒𝑒𝐴𝐴2𝛼𝛼 eIF2α dephosphorylation rate (sec-1) 
𝛾𝛾𝑓𝑓𝑇𝑇𝑇𝑇𝑓𝑓 Protein folding rate (sec-1) 
𝛾𝛾𝐴𝐴𝐵𝐵 Dissociation rate of BiP from ATF6 (sec-1) 
𝛾𝛾𝑒𝑒𝐵𝐵  Dissociation rate of BiP from IRE1 (sec-1) 
𝛾𝛾𝐶𝐶𝐵𝐵 Dissociation rate of BiP from PERK (sec-1) 
𝛾𝛾𝑅𝑅𝐵𝐵 R  Dissociation rate of BiP from ATF6 or/and IRE1α or/and PERK (sec-1) 
𝛾𝛾𝑠𝑠 R  Decay rate of spliced XBP1 mRNA (sec-1) 
γu  Decay rate of unspliced XBP1 mRNA (sec-1) 
𝛾𝛾𝑈𝑈𝐵𝐵   Dissociation rate of BiP from unfolded protein (sec-1) 
𝛾𝛾𝑋𝑋𝑢𝑢             Decay rate of unspliced XBP1 protein (sec-1) 
𝛾𝛾𝑋𝑋𝑠𝑠             Decay rate of spliced XBP1 protein (sec-1) 
𝛾𝛾𝑋𝑋𝑚𝑚𝑠𝑠  Modified decay rate of spliced XBP1 mRNA (sec
-1) 
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Introduction 
 
 
 
1.1  General background 
 
Cells throughout their lifetime must have the ability to sense a range of environmental changes 
such as hypoxia, nutrient deprivation, oxidative stress, calcium (Ca2+) dyshomeostasis, radiation 
and microbial pathogens and adapt to them by mounting a distinct and effective response [1, 
2]. Endogenous sources of stress such as those arising from the endoplasmic reticulum (ER) of 
cells overloaded with misfolded proteins in the ER lumen have also been identified and are of 
great importance. Cells have evolved several mechanisms to counteract the noxious effects, 
restore homeostasis and promote survival. However when the stress is unresolved or chronic 
they trigger programmed cell death (apoptosis) [3, 4]. Each subcellular compartment senses 
stress conditions differently and thus elicits complex responses accordingly.     
Programmed cell death is a highly orchestrated molecular process the regulation of which is 
vital for several physiological functions and homeostasis control in multicellular organisms [5]. 
Several lines of evidence have showed that dysregulation in this mechanism causes or 
contributes to a range of human diseases. For instance, cell-cycle arrest defects may induce 
uncontrolled proliferation as seen in cancer, whereas increased apoptosis may contribute to 
neurodegenerative disorders [3]. Apoptosis involves a series of biochemical events, which lead 
to morphological changes that include cell shrinkage, cytoplasmic and chromatin condensation, 
nuclear fragmentation, chromosomal DNA fragmentation, plasma membrane blebbing and cell 
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death. These changes result in the release of membrane-enclosed particles known as apoptotic 
bodies which are rapidly engulfed by phagocytes and cleared out without eliciting an 
inflammatory response [6]. 
Eukaryotic cells comprise a set of membrane-enclosed organelles, where around half of the 
total membrane area is enclosed by the ER, forming a continuous network with the nuclear 
envelope. The ER is the exclusive site of synthesis of secreted and membrane proteins in 
mammalian cells. The newly synthesised proteins, after entering the ER undergo post-
translational modifications such as N-glycosylation and are then folded into their secondary and 
tertiary conformation through non-covalent interactions, in order to be able to carry out their 
tasks. The native three-dimensional structure of proteins, which is the state that is energetically 
more favourable, is in some cases stabilised with disulphide bonds, interactions that are mainly 
present in the extracellular proteins rather than the intracellular ones. The folding processes 
occur under both physiological and stress conditions. They involve a range of molecular 
chaperones and folding enzymes that aid the ER quality control process (Figure 1), but the 
complexity of this multisystem often makes it prone to errors [7]. Perturbation of the ER-
associated functions that affect protein folding causes the accumulation of unfolded and 
misfolded proteins in the ER lumen, a cellular conditions known as ER stress [8]. 
The ER quality control system comprises several specialised molecular chaperones and folding 
enzymes, the five predominant ones named glucose-regulated protein 94 (GRP94), binding 
immunoglobulin protein (BiP/GRP78), protein disulphide isomerase (PDI/ERp59), endoplasmic 
reticulum protein 72 (ERp72) and calreticulin [9, 10]. GRP94 is a member of the 90 kDa heat 
sock protein (HSP90) family and is itself a chaperone. It is the most abundant protein in the ER 
lumen, transcriptionally co-regulated with BiP and induced by glucose deprivation or under 
conditions of significant accumulation of unfolded proteins. GRP94 can also interact with 
substrates after they have been released from BiP, showing its ability to identify elements with 
more complex folding intermediates [11]. BiP is a master regulator of ER stress due to its 
function as a major ER chaperone exhibiting anti-apoptotic properties as well as monitoring the 
activation of the UPR [12]. It regulates protein folding by recognising unfolded regions on 
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proteins containing exposed hydrophobic residues and suppressing their aggregation [13]. PDI 
catalyses the disulfide bond formation and it may act as a chaperone like BiP as demonstrated 
by in vitro and in vivo studies [14]. ERp72 shares sequence identity with PDI at discrete regions 
and its function involves facilitating disulfide bond formation and exchange.  The last important 
chaperone is calreticulin, one of the major Ca2+ binding ER proteins, which also acts as a 
chaperone responsible for the folding of glycoproteins and nascent peptides [15, 16]. 
There are several diseases caused by genetic mutations, which affect the folding process 
leading to the accumulation of misfolded proteins. An overwhelming load of misfolded proteins 
in the ER lumen during protein synthesis increases the risk of aggregation and may further 
compromise ER functionality. Despite the cellular mechanisms assisting the protein folding 
process, a significant amount of newly synthesised polypeptides, fail to acquire correctly their 
native conformation and must be rapidly degraded. To date, there are no known ER-resident 
proteases involved in the elimination of misfolded proteins present in the ER lumen [17].  It is 
believed that these proteins re-translocate in the cytosol where they are targeted for ubiquitin-
mediated protein degradation by the proteasome through a process of events collectively 
called ER associated degradation (ERAD) system (Figure 1) [18].  In some cases misfolded 
proteins have structural constraints that prevent their ability to translocate and enter the 
cylindrical proteolytic chamber. Such proteins are not optimal ERAD clients and entrance in the 
secretory pathway and the mediated autophagy may occur via the lysosomal degradation 
system [19]. Cells’ ability to counteract the excessive deposits of misfolded proteins is vital and 
required for maintaining its functional and structural integrity [7].  
Emerging evidence suggests that stress perturbing ER physiology, is involved in diverse 
pathological conditions ranging from brain disorders, cancer, inflammation, autoimmune 
disorders to diabetes and neoplasia affecting millions of people worldwide. Mammalian cells 
cope with this complex ER stress adaptive response by activating a transcriptional response 
transduced from the ER to nucleus and cytosol collectively called the unfolded protein response 
(UPR) [20, 21].  
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The UPR is triggered by the activation of three major stress sensors named inositol-requiring 
protein-1 (IRE1), activating transcription factor 6 (ATF6) and protein kinase R-like ER kinase 
(PERK) and three main downstream responses (Figure 1) [22-24]. Firstly, the cellular machinery 
reduces the protein load entering the ER with transient adaptation, achieved by attenuating 
protein translation. Secondly, it increases the capacity of the ER to cope with the unfolded 
proteins with a long-term adaptation, which entails increasing transcription of UPR target genes 
such as chaperones. In cases where ER stress cannot be alleviated, a third mechanism is 
activated, apoptosis, to eliminate damaged cells and protect the organism [21]. Irreversible pro-
apoptotic signalling events cause chronic cellular damage, a characteristic of neurodegenerative 
diseases [25]. The pathways involved in ER stress have therefore been proposed as potential 
targets for therapeutic intervention [26]. 
 
 
 
Figure 1: Protein folding and quality control in the endoplasmic reticulum. Solid arrows correspond to enzymatic 
catalysis, dotted arrows correspond to protein interaction and dashed arrows correspond to transport. 
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1.2  Alzheimer’s disease (AD) 
 
AD was first reported on the 3rd of November 1906 by a German psychiatrist and 
neuroanatomist, Dr. Alois Alzheimer. It is a devastating and progressive dementia disorder 
affecting mainly the elderly population and has a doubling incidence every five years beyond 
age 65. More specifically, the disease affects one in 10 people aged over 65 and around 50% of 
people over 85 [26].  
Alzheimer’s at the clinical level is classified into two main types, based on the age of the onset 
and the genetic predisposition. Sporadic AD is the most common form of the disease, has a late 
onset and is caused from a synergistic effect of both environmental and genetic factors. On the 
other hand, FAD accounts for around 5% of cases, has an early onset and manifests as a 
dominant inherited trait. Regardless of the mechanism of action, both forms exhibit phenotypic 
similarities and share a final pathophysiologic mechanism of action [27, 28]. Nevertheless, the 
mechanistic relationships between the two AD forms described remains to be elucidated [29, 
30].         
AD at the neuropathological level is characterised by the progressive and irreversible loss of 
neuronal cells and synapses in the cortex and hippocampal gray matter of the brain. The 
disease relies on the accumulation and aggregation of extracellular amyloid-β (Aβ) peptides, 
the main component of amyloid plaques (also known as senile plaques) and of intracellular 
deposits of hyperphosphorylated microtubules-associated tau protein, the principal component 
of neurofibrillary tangles (NFT).   
The first hallmark of AD is the accumulation of Aβ plaques, extracellular fibrous-containing 
aggregates composed of insoluble amyloid fibrils. Although plaques are found extracellularly, 
Aβ42 peptides also accumulate intracellularly and are known to correlate better with the 
severity of the toxicity caused in the brain [31]. The Aβ peptide ranges from 39 to 43 amino-
acids residues in length and derive from the parental proteolytic processing of the amyloid 
precursor protein (APP). The APP is localised in the ER, the Golgi network, the plasma 
membrane and the early and late endosomes where the Aβ is processed. Missense mutations 
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identified in the APP lead to progressive overproduction of Aβ deposits also causing dysfunction 
in the degradation mechanism, resulting in the pathogenesis of the disease [32].     
The second hallmark of AD is the accumulation of neurofibrillary tangles, intracellular deposits 
composed of the hyperphosphorylated microtubule-associated tau protein. Tau is a 
microtubule stabilizing protein and phosphorylation disrupts its ability to regulate the axonal 
transport. This leads to the accumulation of NFT, causing dysfunction of neuronal cytoskeleton 
and of the neuronal transport system. Aβ protein may directly inhibit the degradation of 
hyperphosphorylated tau by the proteasome, implicating these two proteins in the progression 
of the disease [33].  
Brain tissue analysis from AD patients has showed the upregulation of UPR markers, suggesting 
an involvement of ER stress activation in AD. However, the involvement of the pathway in 
disease progression is still speculative as the majority of research data obtained so far are 
either correlative or based on in vitro experiments [34]. This project focuses on unravelling the 
progression of the UPR in familial Alzheimer’s disease (FAD), using a systematic approach of 
experimentation and mathematical modelling. 
1.3  Aim and objectives
The progressive pro-apoptotic role of ER stress by activating the UPR signalling has highlighted 
this stress mechanism as a potential cause of neurodegeneration and its potential as a 
prominent therapeutic target. Given a possible role of ER stress in AD pathogenesis, the present 
study aimed to assess the progression of the UPR induced by ER stress in FAD, using an 
experimental approach coupled with a kinetic model. SK-N-SH neuroblastoma cells subjected to 
pre-existing genetic factors (mutations in genes associated with FAD), neuronal differentiation 
and a mimic of environmental triggers (induction of chemical stress) were assessed. Targets for 
the signalling pathway of the UPR were selected as such to provide specificity of the arm 
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activated and distributed according to the progression of the UPR. Emphasis was placed on the 
early timing of the response following the application of chemical stress. 
The specific objectives to conduct this analysis were the followings: 
1. Generate a cell model system of FAD with human SK-N-SH neuroblastoma cells 
overexpressing wild-type APP695 or the FAD-associated mutants Swedish and Swedish-Indiana 
APP695. Following confirmation of successful transfections, specific primers for UPR markers 
were designed to analyse and characterise the gene expression changes of stress markers of 
three parallel ER arms governed by IRE1, PERK and ATF6 receptors. 
 2. Investigate whether overexpression of APP695 induces any pre-upregulation in the levels of 
ER stress markers and if so whether these levels differ between cells overexpressing wild-type 
and FAD-mutant APP695 protein. The mRNA was isolated and subjected to quantitative real time 
PCR (qRT-PCR) for gene expression analysis. This was performed in a stress-free environment, 
and allowed us to evaluate whether the APP695 overexpression and/or mutation itself was 
enough to cause preconditioning of ER stress. 
3. Assess the progression sequence of UPR in the FAD cell model system under an 
environmental stress stimulus. In order to obtain a neuronal-like phenotype, optimisation of 
the differentiation (with retinoic acid exposure) and of artificial induction of stress by the 
addition of tunicamycin were evaluated. The response of the system was investigated by 
analysing the UPR mRNA levels following the application of chemical stress at different time 
points over the course of 24 h.  
4. Understand the dynamics of the elaborate UPR system by constructing a model for the 
mammalian UPR. This model was based on mass-action kinetics, resulting in ordinary 
differential equations integrating the response of three signalling branches; PERK, IRE1 and 
ATF6. In order to find the parameters allowing the model fitting to the experimental data, the 
software gPROMS ModelBuilder® was used to run the estimations. The model was fitted to the 
relative mRNA experimental data of the first eight hours of the TM time-course stress 
experiment for each of the APPWT, APPS and APPS.  
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5. Examine whether our mathematical model can capture the biological effects of known 
therapeutics. In silico experimentation was performed in a series of case studies compounds 
and simulated for each of the cell lines individually.  
 
1.4  Structure of the thesis 
 
This project focused on identifying the progression and dynamics of the UPR with respect to 
FAD. Chapter 1 provides a general background of the molecular mechanism and the disease 
studied as well as the aim and objectives of the thesis. A thorough literature review was 
discussed in Chapter 2, initially describing the epidemiology and the clinical characteristics of 
the three most common neurodegenerative diseases but with a focus on AD (2.1 and 2.2).  
Subsequently, it discusses the main factors affecting AD, while focusing on the role of the 
amyloid precursor protein in this disease (2.3 and 2.4).  As neurodegenerative disorders affect 
neuronal cell death, these cells were characterised to better understand their structure as well 
as the function of the ER (2.5). The aim of the project was to investigate the dynamic UPR- 
induced from ER stress in FAD thus an extended review on the UPR was made with a detailed 
description of each of the pathways activated along with the effect of their activation (2.6). To 
understand the link between FAD and UPR, the pathways inducing apoptosis were not only 
listed but also described (2.7). Eventually the link of ER stress with AD as well as the stressors 
related with AD were presented with the use of the respective evidence from previous studies 
(2.8 and 2.9). As there is no cure for AD, it is important to know the proposed treatments 
related to the UPR and the potential targets for future drug development (2.10 and 2.11). 
Furthermore, the literature analysis consisted on identifying some of the possible experimental 
(both in vitro and in vivo) and computational models already developed to study the UPR along 
with their limitations (2.12 and 2.13).  
Following the literature review, we presented in Chapter 3 the materials and methods used to 
achieve the experimental objectives of our project. The next two chapters describe and discuss 
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the results obtained by the experimental model developed with the use of the aforementioned 
methodological approaches.  
Chapter 4 presents the approach taken to develop a stable cell model system of FAD with SK-N-
SH cells overexpressing either the wild-type of FAD-associated APP mutations. The optimising 
transfections and RNA extraction protocol were also presented. Then, we discussed the 
optimisation of the primer annealing temperatures, amplification efficiencies but also identified 
out of a range of housekeeping genes, the best one to use for our cell model system in the real-
time quantification reactions. Although SK-N-SH cells can be differentiated with several agents, 
we present the possible molecules that can be used and the choice of the most adequate one in 
our system and the respective dosing and number of days requiring incubation. These were 
validated with neuronal and biochemical characterisation of our cells treated with different 
amount and/or days with RA. After establishing these protocols, cells were evaluated to test 
whether overexpression of wild-type of mutant FAD-associated APP pre-upregulated the UPR 
induced by ER stress. As the project aimed to evaluate the progression of UPR during stres, 
evaluation of the possible stress inducing drugs was performed and presented. In order to 
achieve our objectives related to cells’ metabolic activity, the MTS assay conditions were also 
optimised with respect to the effect of different chemicals and the number of cells used (4.2). 
The results were then discussed (4.3) and summarised in the conclusion section (4.4). 
Chapter 5 focuses on the progression of UPR in the experimental model of FAD. Differentiated 
cells were analysed for the stress response imposed by the intra and extra cellular stresses at 
six different time points with respect to their viability (with trypan blue exclusion method), their 
metabolic activity (with MTS assay) and the gene expression levels of several UPR markers (with 
qRT-PCR). The results presented demonstrate at first the cells’ initial response to stress to be an 
attempt to adaptation and the UPR progression to have a different pattern in FAD cells. The 
qRT-PCR analysis illustrates the fold increase of the UPR markers downstream of PERK, IRE1 and 
ATF6 within each cell line during TM treatment (5.2.2). Then the same data are presented in a 
way to illustrate the fold increase of the UPR markers between the cell lines during TM 
treatment (5.2.3). Finally, the data are normalised to the wild-type cells at each time point of 
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TM treatment as we wanted to evaluate whether mutant cells exhibit a stronger upregulation 
of the UPR marker (5.2.4). The statistical analysis for each of the aforementioned sections was 
also presented accordingly. The results were discussed and included the sequence of UPR 
activation as well as the key players in UPR induced by ER stress (5.3). A conclusion in this 
section summarised the findings. 
Chapter 6 describes the development of our computational model of the mammalian UPR 
network.  Firstly, the importance of the generation of such a system is described (6.1) followed 
by the general characteristics of the kinetic model along with the assumptions made (6.2). Next, 
the development of the model was presented with the description of the protein folding 
dynamics, the IRE1, the PERK and ATF6 pathways (6.3). This was followed by a detailed 
description of the formation, the degradation and the translation of XBP1 complex (6.4). The 
calibration of the model was described while including the parameter values used, the initial 
conditions, and the estimated parameter values (6.5).  The simulation results of the model were 
presented and compared with the experimental data for each of the APPWT, APPS and APPS-I cell 
lines. Description of the simulation analysis reflecting the UPR mechanism was achieved with an 
ATF6 sensitivity analysis, a quantitative analysis of unfolded protein load and an understanding 
of the effect of XBP1 protein complex. The model was then used as a basis to explore 
treatments in silico. Three case studies are presented and include the effect of salubrinal and of 
lithium and valproate. A conclusion, which summarised all of the aforementioned on the 
computational model, was presented in the end (6.9). 
Chapter 7 is the final discussion, which provides a summary the experimental and 
computational results demonstrating the novelty of the project followed by the main 
conclusions gained from these two systems, the limitations and the future directions.  
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Literature Review 
 
 
 
2.1  Epidemiology of neurodegenerative diseases 
 
Neurodegenerative disorders describe a range of conditions characterised by cellular and 
molecular changes that occur in specific brain regions leading to loss or dysfunction of the 
nerve populations. Although they exhibit different clinical symptoms and neuronal loss at 
specific brain regions, they share common characteristics including excessive deposition of 
misfolded proteins, cytoskeletal and mitochondrial dysfunction, suggesting similar therapeutic 
intervention for their cure. Such conditions include Alzheimer’s (AD), Parkinson’s (PD) and 
Huntington’s (HD) diseases [35]. The number of people affected is rapidly increasing and, as the 
world population ages, they are projected to reach epidemic proportions imposing a major 
public health issue. An average of 65.7 million people will be living with dementia by 2030 and 
the estimated worldwide cost for 2010 was already US$604 billion as reported in the World 
Alzheimer Report 2010. Along with the high economic costs of professional dementia care 
come high social costs including decreased quality of life for patients and stress placed on 
family members who serve as informal caregivers [26].    
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2.2  Clinical characteristics 
 
Numerous neurodegenerative disorders show accumulation of abnormal protein aggregates in 
the brain over time and this usually dictates the hallmark of the disease. The clinical 
manifestations reflect the distinct regions of the brain affected, and are apparent when more 
than 80% of the neuronal cells are lost. Thus, cerebral cortexatrophy (i.e. AD) results in memory 
loss and progressive aphasia, while defects in the basal ganglia (i.e. PD, HD), a region controlling 
the motor system, results in movement disorders. Even though most of these diseases have 
specific prime brain targets, they can often disrupt other parts of the brain as the disease 
progresses [26] (summarised in Table 1). 
 
Table 1: Summary of clinical characteristics of three neurodegenerative disorders: 1) Alzheimer’s, 2) Parkinson’s 
and 3) Huntington’s diseases.  
 (a) Alzheimer’s (b) Parkinson’s (c) Huntington’s 
Protein -Aβ -Tau -α-synuclein -Huntingtin 
Clinical 
characteristics 
-Senile plaques 
-Neurofibrillary tangles 
-Lewy bodies 
-Lewy neuritis 
-Glutamine repeats of 
 HTT gene 
Location -Neurons of many regions of the brain 
-Dopaminergic 
neurons -Cortical neurons 
Areas of the brain 
affected 
-Entorhinal cortex 
-Basal forebrain 
-Hippocampal gray matter 
-Amygdala 
 
-Substantia nigra 
 
-Basal ganglia 
Symptoms -Memory loss -Progressive aphasia 
-Tremor at rest 
-Bradykinesia 
-Muscular rigidity 
-Postural instability 
 
-Chorea/dystonia 
-Dementia 
-Depression 
 
Population 
affected 25-30 million 4 million 5-8 cases/100,000 
General fact 
 
1 in 3 seniors die with AD or another Dementia disorder 
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2.2.1  Alzheimer’s disease 
 
AD is an incurable neurodegenerative and terminal disease characterised by impairment of 
cognitive abilities and changes in behaviour and personality [36]. It is the most common form of 
dementia disorder affecting 5-10% of over 65s and decreasing their life expectancy by half [37, 
38]. It affects approximately 25 to 30 million people worldwide; it is the sixth leading cause of 
death in the USA where every 67 seconds an individual develops the disease. AD is anticipated 
to triple in prevalence by 2050 [29, 39].  
 
Patients with AD exhibit brain shrinkage in regions involved in memory, learning and emotional 
behaviours resulting from neuronal degeneration [40]. The course of the disease is unique in 
each person, yet there are several common symptoms and patterns that emerge. It is 
histopathologically characterised by the accumulation of Aβ plaques, NFT, progressive neuronal 
and synaptic loss on the entorhinal cortex, basal forebrain, hippocampal gray matter and 
amygdala [41-43]. Central to AD pathophysiology are mutations in three different genes and 
variation in another gene all responsible for the susceptibility of several neuronal cellular 
changes including oxidative damage, production of reactive oxygen species (ROS) and 
inflammation (Figure 14) [44]. These genes include amyloid-β precursor protein (APP), 
presinilin1 (PS-1), presinilin 2 (PS-2) and apolipoprotein E4 (ApoE4) localised on chromosomes 
21, 14, 1 and 19 respectively. These genes are associated with FAD, an inherited form of early-
onset AD [45].   
 
Recent studies have reported that single nucleotide polymorphism in the neuronal sortilin-
related receptor gene (SORL1) located on chromosome 11 are implicated in the susceptibility of 
late onset AD. SORL1 expressed in the central and the peripheral nervous system is involved in 
the intracellular trafficking of APP as seen in vitro and in vivo experiments [46]. 
Underexpression of SORL1 has been demonstrated to cause overexpression of Aβ, increasing 
the risk of developing AD [47]. Additionally, this gene was found to be differentially expressed 
in people affected with AD compared with the controls providing evidence of being causally 
associated with the late onset AD [48].  
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Mutations in genes encoding transmembrane proteins that form part of the γ-secretase 
complex alter the extensive APP proteolytic processing and result in the extracellular 
production of short and long Aβ fragments named Aβ40 and Aβ42, respectively. Aβ40 is the most 
abundant peptide, whereas Aβ42 is more hydrophobic and therefore prone to aggregation into 
fibrils. It has been shown that intraneuronal Aβ42 peptides form soluble oligomers that are the 
key toxic species precede mature fibril plaque formation and may be a significant step in the 
deposition of extracellular Aβ and formation of plaques in the brain [49, 50]. Aβ accumulation 
can also occur within cells. Not only can extracellular Aβ be re-internalised, but there is also 
evidence of Aβ40 and Aβ42 being produced in the endosome system, interacting with SORL1 
that is linked to late onset AD [51], and along the secretory pathway of neuronal cells [52-55].  
 
AD is also characterised as a tauopathy due to accumulation of abnormally folded and 
aggregated tau protein. Tau protein undergoes chemical changes; becomes 
hyperphosphorylated and results in a decrease of tau binding to microtubules. This causes 
dysfunction of neuronal cytoskeleton, disintegration of the neuronal transport system and thus 
degeneration [56]. There is also evidence that intracellular accumulation of tau protein may be 
promoted by the accumulation of Aβ, which has been shown to inhibit the ubiquitin– 
proteasome system [57]. An overview of the interconnectivity between Aβ oligomer formation, 
ER and oxidative stress, Ca2+ dyshomeostasis and tauopathy is provided in Figure 2 whereas the 
generation of Aβ peptides to various subcellular compartments and the cytosol is provided in 
Figure 7. 
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Figure 2: Overview of the mechanisms involved in the progression of Alzheimer's disease: Mutations in genes 
encoding transmembrane proteins that form part of the γ-secretase protease complex, result in the production 
of short and long amyloid-β fragments named Aβ40 and Aβ42, respectively. Intraneuronal Aβ42 peptides are more 
hydrophobic and therefore prone to forming soluble oligomers that are the key toxic species. Oligomers precede 
mature fibril plaque formation and may be a significant step in the deposition of extracellular Aβ and formation 
of plaques in the brain. Progressive accumulation of intracellular Aβ in mitochondria is associated with altered 
mitochondrial membrane potential, a reduced rate of oxygen consumption and increased release of ROS. 
Compromised ER activity also leads to excessive Ca2+ in the cytosol, which is taken up by the mitochondria, 
dysregulating Ca2+ signalling. There is also evidence that intracellular accumulation of tau protein may be 
promoted by the accumulation of Aβ, which has been shown to inhibit the ubiquitin–proteasome system (UPS) 
[26]. Reproduced with permission. 
2.2.2  Parkinson’s disease 
PD is the second most common form of neurodegenerative disorders after AD and affects 4 
million people worldwide [58]. It is a late onset disease with multifactorial aetiology and a 
prevalence of 16–19 cases per 100,000 people in a male to female ratio of 1.5:1 [59].  It 
progressively degenerates the motors of the substantia nigra, an area in the basal ganglia 
where dopaminergic neurons are found. The clinical phenotype of PD is parkinsonism and is 
characterised by tremor at rest, bradykinesia, muscular rigidity and postural instability [59, 60]. 
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Neuropathologically, PD is characterised by the death of these dopaminergic neurons, which 
results in neurotransmission failure, and the progressive formation and accumulation of fibrillar 
cytoplasmic spherical and rod-shaped protein aggregates called Lewy bodies and Lewy neurites, 
respectively, which are mainly composed of the presynaptic nerve terminal α-synuclein as well 
as ubiquitin proteins as seen in Figure 3 [61]. Even though familial PD is known to occur due to 
mutations in seven different genes including α-synuclein, parkin, leucine-rich repeat kinase 2 
and PTEN-induced putative kinase 1 [59, 62, 63], the vast majority of PD cases are sporadic and 
believed to occur due to a combination of genetic and environmental factors. Due to the 
similarity of the pathological symptoms between familial and sporadic PD, it has been 
postulated that both types of patients undergo a similar cascade of events [64]. 
 
 
 
Figure 3: Overview of mechanisms involved in the progression of Parkinson’s disease: Dysfunction of the 
mitochondria and the ER is the main manifestation of PD, even though the temporality of events is still poorly 
understood, partly because of the interdependence of the role of these two organelles. Overexpression of wild-
type α-synuclein, a membrane protein that goes through the ER during normal processing, or expression of 
mutant proteins that are prone to misfolding (due to a variety of genetic and environmental factors) leads to 
activation of ER stress. Aggregation of α-synuclein results in the progressive formation of spherical and rod-
shaped protein aggregates called Lewy bodies and Lewy neurites, respectively. Overexpression of α-synuclein is 
usually detected by dopamine neurons early enough to trigger a defence mechanism against its toxicity. 
However, the increased production of ROS due to ER stress and mitochondrial dysfunction, which is 
predominant in PD, impairs dopamine function, rendering the cells more susceptible to the effects of protein 
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aggregation. These symptoms are exacerbated by the fact that a fraction of inherited PD can be attributed to 
mutations in the gene for Parkin, a protein thought to be part of the ubiquitin proteasome degradation system 
(UPS), which therefore impede the degradation of malfolded proteins [26]. Reproduced with permission. 
 
2.2.3  Huntington’s disease 
 
HD is a late-onset autosomal dominant inherited disorder that affects approximately 5-8 per 
100,000 people in their third to fifth decade and has a 10-20 year lifespan after the onset of the 
disease. Pathologically, HD is characterised by a gradual premature loss of the medium spiny 
neurons of the striatum and, to a lesser extent, cortical neurons mainly in the basal ganglia, 
which manifests in patients as involuntary motor movements (chorea), dementia, and in some 
cases psychiatric disturbances including depression [65-67]. It is the most well-known of the 
‘polyglutamine disorders’ characterised by an expansion of the number of glutamine repeats 
(CAG) in the 5’ coding region of Huntingtin gene (HTT) located on the short arm of chromosome 
4 that encodes the Huntingtin protein (Htt) (Figure 4). The number of CAG repeats is highly 
polymorphic and varies between 11 to 34 repeats under normal conditions, but it is expanded 
beyond 40 to 180 copies in HD [68]. Mutation in this gene is completely penetrant and leads to 
aggregation of Htt in the cytoplasm and the nucleus (cell body), which is toxic to the cells and 
eventually results in cell death [69, 70]. Although genetic mutations are significantly responsible 
for the onset of the disease with an inverse correlation between the number of glutamine 
repeats and the age of onset [71], environmental factors have also been demonstrated to affect 
the age onset variation [72]. 
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Figure 4: Overview of protein trafficking and stress activation in Huntington’s disease: Expression of mutant 
Huntingtin (mtHtt) protein with larger polyglutamine tracts or N-terminal truncations of the Huntingtin protein 
with expanded repeats (mtHttN) triggers ER stress. Upon stress activation, Huntingtin appears to detach from 
the ER membrane and translocate to the nucleus. The first 17 or 18 amino acids form an amphipathic alpha helix 
that associates with membraneous organelles in the cytoplasm, including the ER, Golgi, and mitochondrial 
membranes. Studies have also demonstrated the colocalisation of Huntingtin aggregates and Ubiquitin-
proteasome system (UPS) components, as well as impairment of UPS function in cells expressing proteins with 
expanded polyglutamine domains of pathological size [26]. Reproduced with permission. 
 
2.3  The role of amyloid precursor protein in Alzheimer’s disease 
  
2.3.1  APP structure 
 
APP is a highly conserved type-I single pass transmembrane glycoprotein composed of 695–770 
amino acid residues and belongs to a superfamily of proteins that includes the APP-like proteins 
APLP1 and APLP2 [73, 74]. APP has a large hydrophobic extracellular N-terminal domain, a 
single transmembrane composed of 23 amino acids and a small intracellular C-terminal domain 
[75]. Alternative mRNA splicing of exon 7, 8 and 15 generates eight APP isoforms of which the 
most prevalent ones are APP695, APP750 and APP751. APP695 is predominantly expressed in the 
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central nervous system (CNS), whereas the other two isoforms are ubiquitously expressed in 
peripheral tissues [76]. Most APP forms contain a protease inhibitor domain (encoded by exon 
7) responsible for inhibiting trypsin and other coagulation factors. APP695 lacks this inhibitor 
indicating that this isoform is found almost exclusively in the brain [77]. Although the primary 
function of APP is unknown, it has been implicated in the regulation of synaptic formation and 
synaptic function [78]. 
  
2.3.2  APP proteolytic processing 
 
Strong evidence from neuropathological and genetic studies implicates a product of APP 
metabolism, Aβ, as a major contributor in the pathogenesis of AD. APP can be proteolytically 
cleaved adjacent to the lipid bilayer through three different proteases named α-, β- and γ- 
secretase. Cleavage by α- or β- secretase at the luminal/extracellular domain yields large 
soluble APP derivatives (sAPPα or sAPPβ) and sheds almost the entire ectodomain generating 
membrane-tethered α- or β- C-terminal membrane embedding fragments (CTFs) [79]. 
 APP processing can occur via two separate pathways; the non-amyloidogenic or the 
amyloidogenic pathway as demonstrated in Figure 5. Under physiological conditions, APP 
undergoes non-amyloidogenic processing. Cleavage occurs by α-secretase at the amino acid 
residue 17 of the Aβ domain resulting in the release of a soluble NH2 fragment (sAPP) and 
preventing the formation of the toxic Aβ molecule. Following the extracellular cleavage, the 
COOH domain produced is cleaved by γ- secretase within the transmembrane domain resulting 
in a short 3 kDa peptide termed p3 and the release of the APP intracellular domain (AICD). In 
the amyloidogenic pathway, APP first cleavage occurs by the β-site APP cleaving enzyme at the 
extracellular domain leading to the release of sAPPβ. This is followed by the γ-secretase 
cleavage in the transmembrane domain leading to the generation of AD-associated Aβ peptides 
with various sizes, with Aβ40 and Aβ42 being the most common ones [40, 80, 81]. This is a key 
event in the processing of AD pathology.  
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Figure 5: APP metabolic processing pathway. APP can undergo sequential proteolytic cleavage by α-, β-, and γ- 
secretases. Depending on whether Aβ peptides are generated from the APP, the pathway is named non-
amyloidogenic or amyloidogenic. a) In the non-amyloidogenic pathway APP process occurs by α- secretase 
cleavage at amino acid number 17 of the Aβ domain and yields a soluble N-terminal (NH2) APPa fragment 
(sAPPα) and a transmembrane C-terminal (COOH) fragment (α-CTF) which has neuroprotective as well as 
neurotrophic functions. The COOH domain produced from α- cleavage is subsequently cleaved by γ-secretase 
within the transmembrane domain and generates a non-amyloidogenic short peptide of three kDa termed p3 
and an APP intracellular domain (AICD). b) In the amyloidogenic pathway APP is cleaved by β-secretase and 
yields a secreted N-terminal fragment APP ectodomain (sAPPβ). The intracellular COOH domain is subsequently 
cleaved by γ-secretase and generates multiple Aβ peptides, the most frequent being Aβ40 and Aβ42. 
 
2.4  The role of Aβ in Familial Alzheimer’s disease 
 
2.4.1  Different FAD-associated APP mutations 
 
A subclass of FAD is due to dominant missense mutations in APP and presenilin genes, which 
alter the extensive APP proteolytic processing by γ-secretase complex resulting in an increased 
Aβ42/Aβ40 ratio [82-84]. Aβ42 has been previously demonstrated in vivo to aggregate into fibrils 
more quickly than Aβ40, which may explain why small changes in this ratio induce AD 
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pathogenesis [82, 83]. The most common FAD cases are due to missense mutations in APP in 
codons 670 (K670N) and 671 (M671L) (Swedish mutation) or in codon 717 (V717F) (Indiana 
mutation), affecting not only the cleavage by γ-secretase, which increases Aβ42 secretion, but 
also the catabolic pathways responsible for the degradation of these fragments [84-86]. 
Previous studies have shown that cells carrying the Swedish APP mutation have a six- to eight-
fold increase in the Aβ40 and Aβ42 production compared to cells expressing wild-type APP. This 
increase is caused from the abnormal APP cleavage at the β-secretase cleavage site [87]. On the 
other hand, the Indiana mutation affects the γ-secretase cleavage site and enhances the 
relative ratio of Aβ42/Aβ40 [86, 88]. Other FAD mutations have also been found including London 
(V717I) [89], Austrian (T714I) [90], Florida (I716V) [91], Italian (E693K) [92], Arctic (E22G) [93], 
Flemish (A692G) [92], and Iowa (D23N) [94]. These mutations were isolated from families living 
in different regions around the world that exhibited an early-onset AD (Figure 6) [86, 95].  
 
 
 
Figure 6: Familial Alzheimer’s disease associated APP mutations. Early onset FAD mutations are marked with an 
asterisk. Most mutations are clustered around the secretases sites. The Aβ sequence is the one highlighted in 
red. 
 
Several transgenic mice expressing a single or numerous FAD-associated APP mutations have 
been previously developed [96]. One of the most well studied transgenic mouse-model is the 
Tg2576 developed by Hsiao et al. [97] overexpressing the Swedish APP mutation driven by the 
hamster prion protein promoter. These mice exhibited an age-dependent Aβ40 and Aβ42 
increase, which caused the formation of senile plaques, as seen in AD-brain patients. Aβ 
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plaques were not formed until 11 months of age, which through time spread in cortical and 
limbic regions [97].  At the age of four years, they exhibited a decrease in spine density and 
impairment in memory probably caused by the synaptic dysfunction. At the early age of four to 
five months, they also showed an increase in the ratio of Aβ42/Aβ40 [98]. Intraneuronal 
accumulation of Aβ was increased during aging, and was correlated with abnormal synaptic 
transmission before the formation of Aβ plaques at the age of 18 months [99]. 
Other FAD transgenic mice were also generated, in which their APP expression was driven by 
strong APP promoters. Chishti et al. [100] developed TgCRND8 mice, overexpressing both the 
Swedish and the Indiana APP mutations, driven by a prion promoter. They exhibited an 
aggressive clinical phenotype and at the early age of three months developed parenchymal Aβ 
deposits, following by formation of Aβ plaques inducing neuritic dystrophy at the age of five 
months. The mice generated an increased load of Aβ42 relative to Aβ40, with the excess of Aβ42 
being associated with behavioural deficits at six month of age. These included impairment in 
learning and memory with respect to spatial recognition. NFT were not detected and 
neurodegeneration was absent [100]. 
 
2.4.2  Contributions of post-translational modifications in familial Alzheimer’s disease 
 
APP is synthesised in the ER, subjected to various post-translational modifications such as 
glycosylation, phosphorylation and sulfation during the intracellular transit through the 
secretory pathway that precedes its transport to the cell surface. The APP exists in two isoforms 
the immature of around 110 kDa and the mature of around 130 kDa. The immature APP is 
mainly N-glycosylated and is concentrated in the ER and the cis-Golgi compartment. On the 
other hand, the mature APP is N- and O-glycosylated as well as tyrosyl-sulfated, localised in the 
trans-Golgi and on the plasma membrane [101]. 
Tienari et al. [102] treated transfected hippocampal neurons with TM, a N-glycosylation 
inhibitor inducing misfolding of the wild-type APP protein, providing evidence for the axonal 
sorting of wild type and mutant APP. Another study by Yazaki et al. [103] used CHO cells and 
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demonstrated that deletion of the two N-glycosylation sites of the asparagine sites (Asn467 and 
Asn496) of APP decreases its secretion. These supported the hypothesis that correct 
glycosylation is essential for both axonal sorting and processing of the APP. Importantly, both 
the Swedish and the London APP mutations had alterations in the N-glycosylation of APP, with 
a high number of N-acetylglucosamine (GlcNac) residues.  
In addition to N-glycosylation, O-glycosylation is also required for the correct APP function. As 
O-glycosylation is necessitated for cleavage by γ-secretase [104], its interference may lead to 
increased sAPP and decreased production of Aβ. APP cleavage mediated by α-, β- and γ-
secretases in most cases occurs after the O-linked glycosylation. This takes place during the 
passage of APP through the Golgi where O-glycosylation takes place or in trans-Golgi 
compartments during the processing of the APP in the secretory pathway [105]. In agreement 
with this, brains from AD patients showed an increased mRNA expression of the GlcNac 
transferase III (enzyme responsible for the addition of N-acetylglucosamine residue in O- 
glycosidic linkage) compared to healthy individuals [106].  
A fraction of nascent APP molecules in the ER may be proteolytically cleaved by γ-secretase to 
yield Aβ40/Aβ42 products. From the newly synthesised APP, only a fraction of around 10% has 
been shown to reach the plasma membrane, as the majority transits to the Golgi apparatus and 
the trans-Golgi network [107]. This organelle is another site where Aβ processing can occur and 
crucial for AD pathogenesis (Figure 7). For instance, the APP Swedish and PS-1 mutations mainly 
generate Aβ molecules in the Golgi [108]. When at the plasma membrane, the majority of APP 
molecules are cleaved by α-secretase or by the β- and γ-secretases together, thus either 
releasing the s-APP or generating Aβ fragments, respectively. Uncleaved APP can get re-
internalised within minutes due to the presence of the ‘YENPTY’ internalization motif located 
near the C-terminus site of APP (residues 682-687 of APP695 isoform). The internalisation can 
lead to recycling of the APP to the cell surface or to sorting it for degradation via the ERAD 
system [109, 110]. This internalisation process may also result in the generation of Aβ 
fragments.   
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It is now clear that APP processing may occur in various subcellular compartments generating 
Aβ. These include organelles along the intracellular secretory pathway such as the ER, trans-
Golgi, plasma membrane, early, late and recycling endo-lysosomes [111, 112]. Evidence from 
post-mortem brain tissue analysis has shown that aggregated Aβ fragments generated are 
produced extracellularly and/or are accumulated intracellularly. Intracellular Aβ accumulation 
acts as a key factor for the progression of AD [113]. An increased intracellular accumulation of 
such misfolded proteins may cause the proteasome to reach a saturation point and promote 
autophagy as a compensatory response. This in turns leads to dysfunction of the ERAD and 
contributes to the increase of misfolded proteins, which together with the autophagy decline 
promote chronic ER stress in several neurodegenerative diseases [114]. 
 
 
 
Figure 7: Schematic representation of the generation of Aβ peptides by APP proteolytic processing. APP is 
synthesised and secreted in the ER and can be processed through the amyloidogenic pathway (green arrows) 
leading to production of Aβ (red squares) and the non-amyloidogenic (black arrows) pathway leading to 
secreted APP. The APP can be proteolytically cleaved in the ER releasing Aβ molecules. When it transits to the 
Golgi, it can be cleaved to produce Aβ or it may continue to traffic in the plasma membrane. When APP is in the 
plasma membrane, its cleavage is mostly favoured by α-secretase and generating the sAPP (blue hemicycle with 
red tail) or it is processed by β- and γ-secretases generating Aβ peptides. The intact APP in the plasma 
membrane can get re-internalised into endosomes where it can either get recycled to the PM or degraded 
through a process that may also lead to Aβ production.  
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Intraneuronal Aβ42 toxic peptides form soluble oligomers that precede mature fibril plaque 
formation and could be a critical step in the deposition of extracellular Aβ and formation of 
plaques in the brain [45, 115]. The APP mutations cause Aβ toxicity, which can directly result in 
synaptic impairment but can also increase hyperphosphorylation of microtubules-associated 
tau protein and cause aggregation and formation of intracellular tangles. These Aβ peptides 
present in senile plaques and the intracellular aggregates of tau protein present in 
neurofibrillary tangles in the brains of AD patients are the hallmarks of AD and are responsible 
for induction of cellular toxicity [42, 116, 117]. 
 
2.5  Characteristics of neuronal cells 
 
2.5.1  Cellular physiology 
 
The mammalian CNS consists of two major cell populations; neurons and glial cells associated 
with the execution of the cognitive functions of the brain. Differentiated neurons are known to 
be post-mitotic as they are incapable of dividing even under chemical stimulation. As the CNS 
circuit remains fixed, neuronal growth (mitotic division) or repair cannot occur even after 
damage has occurred in chronic conditions such as neurodegenerative diseases. Therefore, the 
molecular mechanism responsible for the mitotic inactivity of the already differentiated 
neurons is a crucial feature faced in the brain-related diseases [118].   
Neurons have a highly regionalised organisation where subcellular domains have distinct 
functional importance. These comprise: a) the cell body (soma) which is the metabolic centre 
responsible for the protein synthesis and the preservation of the whole cell mass, b) branching 
dendrites, which function in receiving and processing electrochemical inputs, and c) axons, 
acting as the information transmitters, spreading over distances bigger than the cell’s diameter. 
Neurites (axons and dendrites) have a cytoplasmic volume greater compared to the cell body 
[119]. Preserving the complex morphology and the cellular subspecialisation of nerve cells is 
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essential for their numerous functions. The majority of the neuronal macromolecules are 
synthesised in the cell body whose function is dependent upon the correct function of three 
intracellular systems. These comprise: a) the rough ER, which utilises the attached ribosomes 
for the synthesis of the backbone polypeptides, b) the smooth ER and c) the Golgi apparatus a 
principal site for membrane differentiation, secretory vesicle formation and addition of 
prosthetic groups (i.e. sugars, lipid, sulphate) to a protein complex  (Figure 8) [119, 120]. 
 
 
 
Figure 8: Structure of a neuron with the respective functions of each part.  
 
2.5.2  ER structure and function 
 
The ER is a specialised subcellular compartment responsible for the synthesis, post-translational 
modification and transport of secreted and transmembrane proteins to their target cellular 
sites. The majority of these nascent proteins translocate into the ER lumen as unfolded 
polypeptide segments. Immediately after entering the ER, many oligosaccharides but most 
commonly N-linked glycans are added to modify the protein chains. Once modified, proteins 
are folded into their secondary and tertiary structure and in many cases assemble into a 
multimeric assembly. The secondary protein conformation is stabilised by hydrogen bonds 
while the tertiary by hydrophobic interactions between amino-acid side chains and in some 
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cases through disulfide bonds, the latter mainly found in extracellular proteins for maintaining 
their native state [121]. 
The oxidising environment of the ER lumen (relative to the cytosol) promotes the formation of 
disulfide bonds and further facilitates protein folding. Additionally, ER-resident chaperones 
such as BiP function to inhibit the protein aggregation process by directly leading the proteins 
to folding pathways. The ER also serves as the major intracellular Ca2+ storage compartment, is 
responsible for the biosynthesis of lipids (i.e. steroids, cholesterol), and for executing the 
biogenesis and signalling of the organelle with the nucleus and the cytosol. 
Execution of quality control ensures that only the properly folded proteins are transferred to 
their target cellular location, thus ensuring cellular homeostasis. Folding of the proteins into 
their proper tertiary structure is essential for their biological functions. A number of 
physiological and pathological conditions can affect protein folding, leading to activation of ER 
stress. 
2.6  The unfolded protein response 
ER stress caused by the accumulation of abnormally folded proteins in the ER activates the UPR 
to counteract the build-up of the un/misfolded proteins. This is a multi-branched pathway that 
is activated in the ER, acting via three distinct signalling mechanisms to attempt to restore 
homeostasis. The first involves the upregulation of protein folding chaperones and proteolytic 
enzymes, while the second causes the suspension of protein synthesis (translational 
attenuation). The former facilitates the process of protein folding, while the latter helps the ER 
cope with the stress by decreasing the amount of proteins that enter the folding process [122, 
123]. The third mechanism triggers apoptosis if the stress has not yet been resolved. There are 
therefore several possible outcomes of ER stress, some protective and some detrimental. 
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In higher eukaryotes the UPR is regulated by at least three different classes of ER-
transmembrane stress transducers. These include the IRE1 (IRE1α and IRE1β), ATF6 (ATF6α and 
ATF6β) and PERK (Figure 9). In the absence of ER stress, these three proteins are sequestered in 
an inactive state by binding BiP, an ER chaperone. Under conditions of ER stress, however, BiP 
interacts preferentially with misfolded proteins and dissociates from IRE1/ATF6/PERK, thereby 
priming UPR activation. The three UPR arms regulate the transcription of distinct transcription 
factor (TF) and the signalling cascades that control several responses downstream of the UPR. 
 
 
 
Figure 9: Structural domains of the three ER-transmembrane stress sensors: IRE1, ATF6 and PERK. S/T: 
serine/threonine kinase, bZIP: basic region-leucine zipper motif, eIF2α: eukaryotic translation-initiation factor. 
 
2.6.1  IRE1 signalling 
 
IRE1 is a type-I transmembrane protein consisting of an ER luminal domain, a single 
transmembrane domain and a cytoplasmic domain subdivided into the autophosphorylating 
serine/threonine kinase and the carboxy-terminal endoribonuclease (RNase) domain (Figure 9). 
The mammalian genome encodes two isoforms of the IRE1; IRE1α and IRE1β. The IRE1α is 
ubiquitously expressed in most cells and tissues with high expression levels in the pancreas and 
the placenta. In turn, IRE1β is expressed in the intestinal epithelial cells. Deletion of either or 
both IRE1 isoforms from mouse genome in cell culture, did not affect the transcription of 
several UPR markers following ER stress. Deletion of IRE1α (hereafter referred to IRE1) in mice 
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animal models resulted in embryonic lethality, while deletion of IRE1β did not cause any 
developmental effect.   
 
Upon activation, the luminal domains of the IRE1-monomers dimerise/oligomerize, bringing the 
cytoplasmic domains in close proximity allowing autophosphorylation to occur. This activates 
their endoribonucleolytic activity, which catalyzes the unconventional splicing of a 26-base 
intron from X-box binding protein 1 (XBP1) mRNA. This reaction causes a translational 
frameshift that changes a stop codon in the mRNA and generates the spliced XBP1 (XBP1s), a 
functionally active TF. XBP1 is capable of binding to different cis-acting elements and enhancing 
the transcription of UPR-related genes. Binding to the ER stress-response element (ERSE) 
promoters in the nucleus induces expression of ER chaperones such as BiP, GRP94 and 
calreticulin while binding to the unfolded protein response element (UPRE) –only dependent on 
XBP1- regulates the expression of genes that trigger ERAD components [124]. In contrast to 
XBP1s, unspliced XBP1 variant (XBP1u) is translated into an unstable protein that negatively 
regulates XBP1s and ATF6 signalling. In addition to mediating XBP1 mRNA splicing, IRE1 also 
employs the regulated IRE1-dependent decay (RIDD) process to degrade mRNAs encoding ER-
targeted protein and reduce the load of protein influx and unfolded protein load in the ER 
during stress. Hence, activation of RIDD is also responsible for regulating cell fate [125]. In a 
transition phase between the adaptive and apoptotic responses, the mediated XBP1 mRNA 
splicing event is attenuated. If stress cannot be resolved, IRE1 activates the proapoptotic 
caspase 2 (CSP2) signalling causing induction of cell death [125]. IRE1 activation also regulates 
the c-Jun N-terminal kinase (JNK) pathway mediated by the stress responses. This subsequently 
leads to the activation of several cell death pathways (described in 2.7.1).  
 
Although IRE1 acts as a positive regulator in cell survival by the splicing of XBP1 mRNA, it may 
also trigger programmed cell death. In contrast to mammalian cells, yeast studies have revealed 
that activation of IRE1 branch may also occur by the direct interaction of misfolded proteins 
with its luminal portion [25]. Kimata et al. [126] investigated the yeast IRE1 activation by using 
mutant IRE1 with a deleted BiP binding site. As this deletion did not affect the IRE1 activation, 
 
 
51 
Literature Review 
they showed that BiP was not the only factor triggering IRE1 activation and thus that IRE1 could 
recognise a variety of sensors. 
The phosphorylation sites are essential for the RNase splicing function of IRE1. Prischi et al. 
[127] elucidated the role of the phosphorylation status and the ligand binding upon the splicing
activity of the IRE1.  Three distinct phosphorylated regions of IRE1 were purified which were
the linker, the activation loop and the RNase domain. They demonstrated that phosphorylation
of the activation loop was essential to attain high levels of splicing in vitro, and mutation in this
site resulted in loss of XBP1 splicing compared to the wild-type IRE1. On the other hand, the
linker and the RNase domain showed little or no effect on the catalytic activity of the splicing
reaction by IRE1.
2.6.2  ATF6 signalling 
ATF6 is a type II ER transmembrane protein, and in the cytosolic region encodes a basic leucine 
zipper domain (bZIP), which under physiological (non-stressed conditions) is located in the ER 
(Figure 9). In mammalian cells, ATF6 is encoded by two isoforms ATF6α and ATF6β, which are 
ubiquitously expressed. ATF6 null mice do not experience any phenotypic abnormalities under 
normal conditions. Analysis of ATF6α (hereafter ATF6) deficient cells that experienced ER stress 
revealed their inability to recover homeostasis, while ATF6β knock-out (KO) did not have any 
phenotypic abnormalities, even under conditions of stress. Finally, mice with gene KO deficient 
in both of the two isoforms were lethal at the embryonic stage, suggesting an essential role for 
these genes in the embryonic development [128].   
In response to ER stress, ATF6 protein translocates from the ER to the Golgi apparatus through 
vesicular transport in a coat protein complex II vesicle and sequentially undergoes cleavage by 
site 1-(S1P) and 2-(S2P) Golgi resident proteases. This cleavage causes the release of the 
transcriptionally active cytosolic N-terminal 50 kDa fragment (p50) that contains the DNA 
binding bZIP, dimerization and transactivation domains. p50 translocates to the nucleus where 
it binds to and activates the ERSE consensus sequence CCAAT-N9-CCACG (N9 represents a 9 bp 
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region rich in GC) found in the promoter of several UPR-target genes including BiP, 
CCAAT/enhancer-binding protein (C/EBP) homologous protein (CHOP) and XBP1 [129, 130]. 
2.6.3  PERK signalling 
PERK is a type-I ER transmembrane protein similar in size to IRE1, but with a low degree of 
sequence similarity. As their structure is similar, it has been postulated that they share a similar 
mechanism in response to stress. Indeed, PERK like IRE1, undergoes oligomerisation following 
ER stress-induced dissociation of BiP, which leads to the trans-autophosphorylation and 
activation of the PERK kinase module. Activated PERK phosphorylates the eukaryotic translation 
initiation factor-2α (eIF2α) at serine 51 residue (Ser51) and decreases protein synthesis by 
inhibiting the binding of the initiator methionyl tRNA (met-tRNA) to the ribosomal initiation 
complex [127, 131]. Therefore by reducing the amount of active eIF2α (and thus, the rate of 
translation initiation), PERK signalling prevents the further accumulation of proteins in the ER.  
Coincident with repression of global translation, p-eIF2α selectively enhances the translation of 
a number of mRNAs containing short upstream open reading frames (uORFs) in the 5’ 
untranslated region. One of these proteins is the activating transcription factor-4 (ATF4) that 
plays a role in the adaptation to stress by regulating the transcription of several genes. These 
include genes counteracting oxidative stress such as nuclear factor erythroid 2-related factor 
(Nrf-2), chaperones such as BiP, the pro-apoptotic CHOP as well as amino-acid transporters 
[131]. In addition to translational regulation, ATF4 expression is also subjected by 
transcriptional control. ER stress induces transcription of ATF4 through a mechanism that is not 
well understood, leading to more mRNA available for preferential translation. Thus both 
transcriptional and translational control mechanisms enhance the expression of ATF4 and its 
downstream genes [132, 133].  
The downstream gene CHOP can trigger apoptosis in stressed cells but can also upregulate the 
expression of growth arrest and DNA damage -inducible protein-34 (GADD34). The latter forms 
part of the protein phosphatase 1 that dephosphorylates eIF2α following resolution of ER 
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stress, thus restoring general protein translation in the ER. Importantly both ATF4 and CHOP 
contain a bZIP protein domain and can bind to promoters to induce the expression of apoptotic 
target genes [134].  
 
The importance of p-eIf2α has been illustrated in several studies. Gene knock-in mouse models 
heterozygous for the inserted Ser51 mutation of the eIf2α phosphorylated region, were lethal 
within 18 h of birth, due to hypoglycaemia. Furthermore, a new function of CHOP was 
introduced by a recent study by Han et al. [135], which was to interact with ATF4 and bind to 
promoter sequence of genes promoting increase of protein synthesis. Furthermore, they 
provided evidence for a cooperative ATF4 and CHOP mechanism of action, which was 
confirmed with qRT-PCR analysis. This illustrated that deletion of either ATF4 or CHOP in 
tunicamycin (TM) treated cells attenuated the expression of target genes responsible for the 
apoptotic program. As the expression of both ATF4 and CHOP is upregulated prior to cell death, 
they postulated that the increase in protein synthesis and oxidative stress are required signals 
to induce apoptosis. This suggests that reducing protein synthesis may be a step in therapeutic 
intervention [135].  
 
2.6.4  Overview of the UPR 
 
Misfolded proteins in the lumen of the ER are recognised by three ER transmembrane 
components: PERK, IRE1 and ATF6 (Figure 10). Activation of the PERK pathway results in the 
phosphorylation of eIF2α, which represses protein synthesis [136, 137] but can also result in 
the transcription of ATF4, in turn triggering the expression of the pro-apoptotic factor CHOP. 
IRE1 signalling is the most conserved pathway and a key element responsible for the duration 
as well as the magnitude of the UPR [138, 139]. When activated it leads to the unconventional 
splicing of a small intron from the XBP1 forming the XBP1s mRNA [140]. The resulting protein is 
an active TF, which upregulates the genes associated with the ERAD pathway as well as 
chaperones and foldases. Once activated ATF6 is translocated to the Golgi apparatus, where it 
is cleaved by resident proteases releasing the p50 TF. This protein induces the expression of 
XBP1, along with ER chaperones [124].  
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Figure 10: The UPR signalling cascades in response to ER stress. The ER stress-associated accumulation of 
misfolded proteins in the ER lumen is counteracted by the activation of stress transducer proteins (IRE1, PERK, 
and ATF6). Activation of the former proteins is triggered by the dissociation of BiP from them and it’s binding to 
unfolded/misfolded proteins in the ER lumen. BiP dissociation causes oligomerization and autophosphorylation 
of stress transducers, each triggering a distinct downstream response. 1) Activation of IRE1 induce the 
dimerization and trans phosphorylation of its cytosolic kinase domain which in turn activates the endonuclease 
domain of XBP1 transcription factor mRNA, generates spliced XBP1 (XBP1s) and upregulates the expression of 
ER chaperones. 2) PERK like IRE1 when activated undergoes oligomerization, which results in 
transphosphorylation of the alpha subunit of elF2 kinase - a eukaryotic translation initiation factor - which 
upregulates the expression of ER chaperones and inhibits translation initiation preventing further protein 
accumulation in the ER. PERK can also induce apoptosis in terminally stressed cells. Lower levels of eIF2α 
promote expression of the activating transcription factor-4 (ATF4), which drives CHOP protein expression. 3) 
ATF6 under ER stress is transported from the ER to the Golgi apparatus where it undergoes cleavage by site 1 
and site 2 Golgi resident proteases. This cleavage causes the release of N- terminal cytosolic portion p50. This 
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cytosolic fragment p50 contains the DNA binding, dimerization and transactivation domain and translocates to 
the nucleus where it activates molecular chaperone genes, which contain the ERSE domain. 
2.7  ER stress link with apoptosis 
2.7.1  ER stress signalling pathways inducing apoptosis 
Analyses of post-mortem brain tissue samples, of in vivo and in vitro experimental models have 
demonstrated the involvement of apoptosis and signs of ER stress in the aforementioned 
disorders [141]. Saying this, it is challenging to convincingly show the effect of apoptosis in 
diseased brains, as experiments cannot be done directly in humans. For these reasons, the 
evidence confirming the role of ER stress induced apoptosis in neurodegeneration comes from 
studies on animal and cell culture models. However as neuronal death happens very quickly 
varying from many hours to a day it is difficult to identify cells with apoptotic characteristics 
[142]. 
Apoptosis is activated after a prolonged ER stress response when cells pro-survival mechanisms 
aiming to reduce the protein load and re-establish homeostasis fail. The point at which the cells 
trigger apoptosis from the prolonged ER stress response remains unknown. Cell death 
pathways can be either mitochondrion- dependent or independent. The ER serves as a site 
where pro-apoptotic signals are formed through multiple mechanisms. These include: 1) CHOP, 
activated from ATF6 and PERK pathways, 2) IRE1 mediated tumour necrosis factor receptor-
associated factor 2 (TRAF2)- activating apoptosis signal regulating kinase (ASK1) cascade 3) the 
B-cell lymphoma 2 (Bcl-2)-associated X protein (BAX) / Bcl-2 antagonist/killer (BAK) dependent
Ca2+ release and 4) activation of procaspase (PCSP12) which are further described below. Under
excessive ER stress, CHOP is one of the most overexpressed genes. Although it is induced from
ATF6 and PERK activation, the latter pathway is central for its activation [143]. Studies have
shown that the induction of the TF CHOP does not directly promote apoptosis. It has been
shown that a number of CHOP-induced genes including GADD34 and the ER oxidase 1a (ERO1α)
induce hyperoxidising ER stress conditions causing an increase in unfolded protein load in the
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ER and thus promoting ER stress [144]. On the other hand, overexpression of CHOP itself does 
not trigger apoptosis following TM and thapsigarin (Tg) treatment [145]. These findings 
postulate that additional CHOP independent mechanisms are responsible for regulating the cell 
death response downstream of the PERK pathway.  
It has been previously demonstrated that upon IRE1 activation, the adaptor molecule TRAF2 is 
recruited and regulated by c-Jun NH2-terminal inhibitory kinase the JIK [146]. This subsequently 
triggers ASK1, a ubiquitously expressed mitogen-activated protein kinase kinase kinase, which 
activates the downstream c-Jun N-terminal kinase (JNK) pathway and subsequently leading to 
cell death. The role of ASK1 has been demonstrated in ASK1-/- primary neurons and MEFs cells 
which exhibited resistance in response to stress stimuli and were defective in JNK activation 
and in the induction of cell death [147]. Association of the TRAF2 to IRE1 receptor also 
mediates activation of PCSP12 by its release from this caspase. 
 
Up to date studies have proposed two pathways by which the cellular Bcl-2 associated proteins 
Bax/Bak may induce apoptosis. The first mechanism involves the ER membrane, where upon 
stress both Bax and Bak undergo a conformational change allowing the opening of the channel 
pore and the release the Ca2+ ion fluxes into the cytoplasm [148]. Nakagawa et al. in [149] used 
mixed glial cells from embryonic mice treated with TM or with Tg to provide more evidence on 
the above idea. Treatment of the cells with the stress agents caused an increase in the Ca2+ 
concentration in the cytoplasm from micromolar (μM) to milimolar (mM) levels, which 
subsequently activated the Ca2+ dependent cysteine protease enzyme (m-Calpain) responsible 
for activating the mammalian neuronal pheochromocytoma cell line PCS12. Moreover, MEFs 
cells lacking m-calpain showed reduced ability to cleave and activate PCSP12 cells as well as an 
increased resistance in the ER stress associated apoptosis [150] like the CSP12 deficient cells 
[151]. Even though CSP12 and CHOP deficient mice did not present any physiological defects, 
deletion of these genes provided protection against genetic modifications and environmental 
ER stress stimuli [151, 152].  
 
The Ca2+ flux release from the ER also leads to Ca2+ entry into the mitochondria causing 
depolarization of the inner mitochondria membrane and subsequently release of cytochrome C 
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(CytC) from the mitochondria into the cytosol. Studies have shown that the expression of Bax or 
Bak is also required for CytC release [153] by promoting emptying the ER Ca2+ stores. This 
triggers the mitochondria Ca2+ uptake, which induced CytC release. CytC binds to apoptotic 
protease activating factor 1 (Apaf-1) and in the presence of deoxyribonucleotide adenosine 
triphosphate dATP/ATP promotes the assembly of an oligomeric complex named the 
apoptosome, which induces activation of PCSP9. CSP9 in turn activates effector caspases such 
as CSP3 causing DNA fragmentation and apoptosis (Figure 11) [154-157].   
 
 
 
Figure 11: ER stress pathways mediating cell death. 1:  Activation of the PERK and ATF6 pathways trigger to the 
expression of CHOP, which inhibits the expression of the proapoptotic Bcl-2 and promotes GADD34 and ERO1α 
expression. The GADD34 and ERO1α promote the formation of misfolded proteins and induction of stress. 2: 
IRE1 activation in response to ER stress binds to TRAF2 with the aid of JIK adaptor molecule and activates ASK1 
and JNK. JNK phorsphorylates Bcl-2 causing its suppression (not shown) leading to mitochondria induced 
apoptosis. 3: The recruitment of the adaptor TRAF2 from IRE1 also enables its dissociation from the ER-resident 
procaspase 12 (PCSP12) allowing its activation. In addition, upon ER BAX and BAK in the ER membrane undergo 
conformational changes promoting Ca2+ release from the ER lumen to the cytosol, which subsequently activates 
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m-Calpain and the PCSP12 eventually leading to CSP9 and CSP3 activation. Cytosolic Ca2+ fluxes can be also
taken up by the mitochondria inducing the release of the CytC in the cytoplasm. This promotes the formation of
the ‘apoptosome’, which activates caspases and leads to cell death.
2.7.2  Role of Translational Attenuation 
Translational attenuation is mediated by PERK via phosphorylation of eIF2α and destruction of 
its ability to form the pre-ribosomal initiation complex. The capacity for translational 
attenuation exists in all metazoan cells, but PERK is particularly abundant in cell types that 
synthesise and secrete large levels of proteins (e.g. immune cells, pancreatic β-cells). For these 
cells, translational attenuation plays a large role in their survival by preventing nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-kB) induced apoptosis [158]. In vitro 
experiments with neuronal cells have shown that long-lasting downregulation of translation in 
stressed neurons exposed to an energy crisis may play a key role in the pathological process 
culminating in neuronal cell injury. This occurs by preventing them from responding to transient 
ischemia by synthesising neuroprotective proteins [159]. However, this inhibition of protein 
synthesis also affects the proteins with rapid turnover such as cyclins involved in cell cycle 
progression. This then leads to cell cycle arrest, which gives the cell time to cope with the 
adverse conditions. Although suppression of protein synthesis is considered to be a proactive 
mechanism, experimental findings show that prolonged suppression eventually leads to 
programmed cell-death [151, 160-163]. 
2.7.3  Influence of XBP1 unspliced protein in the UPR 
XBP1 is a major regulator of the accumulation of unfolded proteins in the ER. Its expression 
occurs by unconventional mRNA splicing carried out by phosphorylated IRE1, a site-specific 
endonuclease. The XBP1 pre-messenger RNA (pre-mRNA) is cleaved at two sites by 
unconventional splicing (in the cytoplasm) mediated by IRE1 endonuclease. Subsequently, the 
two exons are ligated by a specific RNA ligase to form the mature RNA and excise the 26-
nucleotide intron [164]. During translation the pre-mRNA encodes XBP1u protein (pXBP1u). The 
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hydrophobic region (HR2) of pXBP1u, attaches the protein to the ER membrane and may recruit 
the XBP1u mRNA to localise it in close proximity to the ER membrane (and to IRE1 receptor) as 
part of the mRNA-ribosome-nascent chain complex. This mechanism facilitates the IRE1 
mediated XBP1 mRNA splicing (Figure 12). Moreover, the presence of the translational pausing 
motif in the C-terminal region (CTR) ensures termination of translation enabling the splicing 
process. It is evident that upon translation of XBP1 mRNA the pre-mRNA and mature mRNA 
encode different proteins named pXBP1s and pXBP1u the size of which are 54 and 33 kDa, 
respectively [165]. 
 
 
 
Figure 12: Functions of unspliced XBP1u protein. XBP1u mRNA induces translation of XBP1u protein (pXBP1u), 
which binds to spliced XBP1 protein (pXBP1s) and promotes its degradation. Under the translation process, a 
hydrophobic region (HR) of pXBP1u -which is a membrane targeting signal- places the protein into close 
proximity to the ER membrane and IRE1 receptor as part of the mRNA ribosome nascent chain complex. The 
pXBP1u interacts with the ribosome with the C-terminal region (CTR); a translational pausing motif that inhibits 
translation and facilitating IRE1 mediated XBP1 splicing. 
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Both pXBP1s and pXBP1u contain a nuclear localization signal (NLS) required for its 
translocation to the nucleus (Figure 13). The pXBP1s also has a transcriptional activation 
domain that mediates DNA binding to the ERSE and UPRE sites. Binding to these elements 
induces transcription of ER chaperones genes and of other ERAD components [166, 167]. As 
pXBP1s is responsible for the transcription of its own genes during the stress response, its 
stabilization and accumulation is part of a positive feedback loop [167].  
On the other hand, the pXBP1u contains a nuclear export signal (NES) and a degradation motif 
(Figure 13). These enable the protein to shuttle between the nucleus and the cytoplasm and 
facilitate its proteasomal degradation in the cytoplasm. Besides that, it may also interact with 
and sequester pXBP1s from the nucleus to the cytoplasm, forming the pXBP1u-pXBP1s complex 
(pXBP1c) and enhancing its degradation. Thus, pXBP1u acts as a dominant negative regulator of 
the endogenous pXBP1s. This mechanism causes transcriptional repression of target genes, 
which are normally activated during the recovery phase of the stress response by the TF [164, 
166]. 
 
 
 
Figure 13: Structure of XBP1u and XBP1s mRNA, which translate the pXBP1u and pXBP1s respectively. The 
XBP1u mRNA contains a nuclear localization signal (NLS), a nuclear export signal (NES) and a degradation 
domain. The XBP1s mRNA contains a NLS and a transactivation domain. 
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2.8 ER stress link with Alzheimer’s disease 
The ER stress response is upregulated in neurons of patients with AD, with elevated levels of 
BiP and phosphorylated PERK (pPERK) detected in the brain tissue of patients compared with 
controls. For instance, Hoozemans et al. [42] demonstrated the activation of UPR in human 
brain specimens of AD patients. For this study 15 control cases (age range 41-91, mean age 76) 
and 18 clinically diagnosed with AD (age range 65-90, mean age 78), were analysed. Markers of 
ER stress activation including BiP and pPERK were used to investigate UPR activation in the 
temporal cortex and hippocampus. Their data demonstrated significant increase in the overall 
protein expression levels of BiP in AD neurons of the hippocampus and temporal cortex 
compared to control cases. pPERK was only observed in AD post-mortem material, which 
strengthens the hypothesis of ER stress activation in AD human brains [42]. Furthermore, the 
accumulation of unfolded protein in the ER lumen, phosphorylation of eIF2α, inhibition of 
protein synthesis, and Ca2+ depletion from the ER lumen in tissues from mice subjected to 
transient focal cerebral ischemia suggested an active role for the ER in neuronal cell death after 
ischemia [168-172]. In addition, experiments in neuroblastoma cells demonstrated that high 
levels of APP expression pre-prime the cells for UPR induction and appeared to result in 
shunting toward apoptosis as detected by the upregulation of proapoptotic marker CHOP [173]. 
Colombo et al. [174] further showed that JNK is a proapoptotic output of the activated ATF6 
and IRE1 signalling, as by mediating APP phosphorylation and increasing Aβ secretion 
contributes to ER stress mediated apoptosis.  
A number of factors can contribute to ER stress activation in AD. First, accumulation of 
aggregation-prone mutant APP in the ER and/or Golgi apparatus has been demonstrated to 
occur in some cases of FAD. Additionally, Ferreiro et al. [175] showed that Aβ peptides trigger 
ER stress by stimulating the release of Ca2+ from ER stores. Oh et al. [176] have also shown that 
Aβ peptides inhibit the proteasome, which is essential for the ERAD of misfolded proteins. This 
may be one reason why AD-related mutations in PS-1 can lead to a different APP processing 
and greater Aβ production, and therefore potentiate ER stress-induced apoptosis. Mutations in 
APP are also known to promote apoptosis via ER stress specific caspases, namely CSP12 in mice 
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and CSP4 in humans, suggesting that ER stress may contribute to neurodegeneration in AD. 
Indeed, Nakagawa et al. [151] showed that murine neuronal cells lacking CSP12 are resistant to 
Aβ- induced cell death. Moreover, wild-type APP (as well as some PS-1 mutations) has also 
been shown to upregulate the expression of the apoptotic-triggering factor CHOP [177].  
In addition to the intracellular effects of amyloid and its aggregates, recent work has implicated 
the binding of some forms of extracellular oligomeric Aβ to the plasma membrane as one of the 
mechanisms of amyloid-mediated toxicity [178]. Aβ binds to the phospholipid membrane itself 
and disrupts it [179] by causing the formation of pores called Aβ channels leading to increased 
ion transport and possibly Ca2+ dyshomeostasis [180, 181]. It has been proposed that the ions 
imbalances (including Ca2+) caused from the Aβ channels, may be an early event in the Aβ-
induced neurotoxicity [182]. There is also strong evidence that extracellular Aβ oligomers can 
be re-internalised [112] via a variety of mechanisms, including interaction with lipid rafts and 
their associated receptors or by endocytosis [183, 184].  
A link between extracellular Aβ oligomers and ER stress has been demonstrated in cell culture. 
Human embryonic kidney HEK293 cells cultured in the presence of extracellular oligomers (but 
not fibrils) allowed their internalisation and resulted in mild ER stress in some but not all 
members of the cell population as measured by increased XBP1 splicing. However, in cases 
where cells were treated with mild amounts of a stressing agent (like TM) in addition to the 
presence of oligomers, a marked decrease in viability was observed. This suggested that 
extracellular Aβ oligomers worsen the ER stress in the already pre-primed cells, by inducing 
higher levels of apoptosis than if treated under each condition separately [185]. In a 
pathological scenario, this could mean that the presence of Aβ oligomers could diminish the 
capacity of the cell to deal with normal insults effectively and cause the ER stress response to 
be overactive, leading to neuronal cell loss.   
A second link between ER stress and the presence of extracellular Aβ oligomers comes through 
the lipid rafts. Lipid rafts contain a lot of cholesterol, depletion of which has been shown to 
slow Aβ production, by altering the rate of α-secretase processing. High levels of cholesterol, 
conversely, cause an increase in the amyloidogenic processing of APP, leading to a higher 
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accumulation of Aβ42 oligomers [184]. During the course of ER stress activation, lipid 
biosynthesis, including cholesterol synthesis, is upregulated as the ER attempts to expand in 
order to accommodate the overcrowding due to unfolded proteins [186]. This activation is 
independent of the actual lipid content of the cells. Therefore, it could easily lead to 
hypercholesterolemia, and thus, further production of toxic amyloid species.  
As a whole, the aforementioned evidence of ER stress in AD suggests that a possible treatment 
avenue for neurodegeneration is to increase the ability of the UPR to deal with stress by 
preconditioning the response, upregulating chaperones to enhance protein folding, and/or 
blocking apoptosis by targeting the appropriate enzymes with small molecules [187]. However, 
it is also known that some genetic mutations associated with AD, such as in the PS genes, 
perturb the ER function and likely reduce its capacity to deal with stress by shifting the balance 
of cellular fate toward the apoptotic pathways rather than recovery [187]. Specifically, 
mutations in PS-1 are associated with increased susceptibility to ER stress and aberrant UPR 
signalling, while a PS-2 splicing variant associated with sporadic AD also interferes with UPR 
signalling via IRE1 [166, 188]. Indeed, PS-1, which localises to the ER membrane, is proposed to 
form complexes with BiP and UPR stress transducers, precluding BiP dissociation and 
preventing transducers from sensing the folding environment of the ER [189, 190]. 
2.9 ER related stressors in AD 
The deposition of Aβ aggregates in AD has been demonstrated to induce aberrant Ca2+ signaling 
activating ER stress as well as oxidative stress (Figure 14). As Aβ aggregates can result in 
neuronal apoptosis, they have an important role in the underlying AD pathology.  
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Figure 14: The implication of Aβ in Alzheimer’s disease. Increased Aβ deposits are formed either by genetic 
mutations (i.e. APP, presinilin genes) or the presence of apolipoprotein-4 (ApoE4) gene or other signalling 
pathways such as oxidative stress or calcium (Ca2+) dyshomeostasis. It can affect the ER causing ER stress and 
alter the mitochondria flux balances. Alternative it may directly induce oxidative stress reflected by the ROS 
accumulation and Ca2+ dyshomeostasis (altering mitochondria fluxes and inducing oxidative stress). These show 
the pathways through which Aβ may implicate neuronal cell death and eventually Alzheimer’s disease.  
2.9.1  Reactive Oxygen Species 
Growing evidence indicates oxidative stress to be linked with AD initiation and progression as 
increased concentration of ROS has been detected in post-mortem brain tissue samples of AD 
patients [191].  However, it is not known whether oxidative stress is a cause of neuronal cell 
death or a downstream manifestation of other pathological pathways.  
ROS are cytotoxic products that can arise from two different organelles, the ER and the 
mitochondria. Under normal physiological conditions, ROS are released within the ER as part of 
the natural function for proper oxidative protein folding. Accumulation of these ROS could 
damage important ER-resident chaperones such as BiP, PDI, and calreticulin, resulting in 
impairment of function [192-194]. On the other hand, mitochondria release ROS as a natural 
by-product of aerobic metabolism. The mitochondria play a prominent role in the regulation of 
cellular metabolism, production of ATP and are intricately involved in buffering cellular levels of 
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Ca2+ and in cross- signalling with the ER. Deficiencies in mitochondrial function could thus 
significantly affect cell viability, Ca2+ homeostasis and ER function. The involvement of 
mitochondria in neurodegeneration centres on the inhibition of the electron transport chain 
[195, 196] and the concomitant increased release of the ROS. These species in turn damage 
mitochondrial proteins such as mitochondrial DNA, thus reducing the efficiency of oxidative 
phosphorylation [197]. 
It has been proposed that progressive accumulation of Aβ in mitochondria is associated with 
diminished enzymatic activity of respiratory chain complexes and therefore altered 
mitochondrial membrane potential, a reduced rate of oxygen consumption [198] and the 
associated increased release of ROS [197]. Accumulation of nitrotyrosine and protein carbonyls 
caused from oxidative protein damage along with markers of oxidised mitochondrial and 
nuclear DNA such as 8-hydroxy-2′-deoxyguanosine of cortical areas and the cerebellum were 
increased in AD brains [199]. These suggest oxidative stress to be an important factor 
contributing in the development and progression of AD.  
2.9.2  Calcium Dyshomeostasis 
Accumulating evidence suggests that many FAD associated PS mutations perturb intracellular 
Ca2+ mechanisms with the most significant signalling cascade disrupted involving the ER Ca2+ 
homeostasis. This impairment occurs in both FAD and sporadic cases prior to the manifestation 
of the disease hallmarks [200]. 
The concentration of Ca2+ in the cell is finely tuned by several mechanisms keeping it low in the 
cytosol (~10-7 M), whereas its concentration in the extracellular medium (~10-3 M) and in the ER 
lumen is high. These concentration gradients across the plasma and ER membrane allow Ca2+ to 
be used as a signal. There are three key transport mechanisms in maintaining Ca2+ homeostasis. 
Firstly, Ca2+ pumps in the plasma membrane help in keeping cytosolic Ca2+ concentration low in 
resting cells. Neuronal cells have an additional Ca2+ transport protein on their plasma 
membrane, the sodium-calcium pump mechanism that couples the efflux of Ca2+ to the influx of 
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sodium (Na+). A second high affinity, ATP-dependent pump exists on the ER membrane, which 
enables the transport of Ca2+ into the ER against a steep concentration gradient and finally a 
low-affinity, high capacity pump on the inner mitochondrial membrane, responsible for 
restoring Ca2+ concentration after a signalling event. This third pump relies on the 
mitochondrial membrane potential generated by oxidative phosphorylation [8].  
Even though recent evidence points to the ability of neurons to maintain Ca2+ homeostasis at 
early stages of neurodegeneration (AD in particular), possibly by altering its handling in the ER 
[201], prolonged dysregulated Ca2+ signalling has been shown to lead to neuronal cytoskeleton 
alteration, synaptic loss and neuritic atrophy. Compromised ER activity leads to excessive Ca2+ in 
the cytosol, which is taken up by the mitochondria. This build-up eventually leads to opening of 
mitochondrial permeability-transition pore and apoptosis. The mitochondrial pro-apoptotic 
pathway acts via the multidomain proapoptotic molecules Bax or Bak that form the main 
gateway of the Ca2+-mediated apoptosis. Although the mechanism by which they are activated 
is incompletely understood [202, 203], it is known that activation of either Bax or Bak is 
sufficient to trigger apoptosis [204]. Their activation is manifested as intramembranous 
homooligomerization, resulting in the permeabilization of the outer mitochondrial membrane 
and, in turn, releasing the intermembrane space proteins including CytC. The latter binds with 
Apaf-1 and CSP9 forming a post-mitochondrial apoptosome complex that amplifies effector 
caspase activation. 
It has been suggested that the role of the ER and mitochondria in Ca2+ homeostasis may 
contribute to premature death of neurons. Ca2+ buffering processes require energy and 
compromised mitochondrial activity may therefore impair the restoration of homeostasis. Even 
in cases where mitochondrial function is not initially affected, the high metabolic demand 
incurred by the cell’s effort to restore Ca2+ homeostasis would inevitably increase oxidative 
phosphorylation and, thus, the production of ROS. In parallel, ROS could damage ER proteins, 
while the decrease in ATP levels due to reduced efficiency of oxidative phosphorylation would 
compromise ER and proteasomal function, causing the accumulation of misfolded proteins 
[205]. As Ca2+ dysregulation leads to failure of synaptic functions and neuronal loss, 
 67 
Literature Review 
characteristics of neurodegenerative disorders, it would be vital to elucidate its mechanism of 
action in the impairment of ER Ca2+ homeostasis for the development of therapeutics at early 
stages of the disease pathogenesis [206].  
2.10  Treatment of ER-stress induced diseases 
2.10.1  Proposed treatments related to ER stress mechanisms 
Because ER stress is involved in so many different diseases including many highly prevalent 
ones such as neurodegeneration, diabetes, and cancer, the development of drugs that affect 
UPR signalling has attracted a lot of interest. In principle, it should be possible to manipulate 
any of the three branches of the ER stress response for the desired effect, but it has been 
difficult to find specific treatments in practice because of the high degree of cross signalling 
between the pathways. Some promising discoveries have been made in the past decade, 
however, which suggest that ER stress represents a valid drug target [207]. In the specific case 
of neurodegenerative diseases, it is likely that interfering with ER-stress induced apoptosis 
would be a means of slowing disease progression.  
One logical strategy is to increase protein-folding capacity by stimulating the overexpression of 
protein folding chaperones without the associated activation of other, more detrimental, ER 
stress events. Related to this is the use of small molecule chaperones to directly affect the 
solubility and/or folding of the accumulated proteins. Both of these strategies appear 
promising. A body of evidence from the field of psychiatry suggests that certain mood-altering 
drugs used in the treatment of diseases such as bipolar disorder are able to selectively increase 
BiP levels without triggering ER stress. These include lithium [208, 209], valproate (VPA) [209, 
210], and possibly very high (supratherapeutic) doses of carbamazepine [210], but not 
lamotrigine [209]. The effects of VPA appear to be particularly noticeable in the frontal cortex, 
an area affected by AD, and the CA1 region of the hippocampus [210]. A study of the 
mechanism of VPA showed that it also increases the expression of protein disulfide isomerase 
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and the HSP90 homologue GRP94, two folding chaperones, as well as calreticulin, which acts in 
protein quality control [211]. Interestingly, the effect of VPA seems mainly to act through 
lipid/ER membrane biosynthesis by inhibiting the enzyme glycogen synthase kinase 3a [211]. 
How this is linked to differential upregulation of chaperones remains unclear.  
Similarly, Kudo et al. [189] screened a library of 10,000 compounds for the potential to 
upregulate BiP expression using a reporter assay. They identified one compound, which they 
named BiP Inducer X (BIX, 1-(3, 4- dihydroxyphenyl)-2-thiocyanate-ethanone), which selectively 
increased BiP expression levels and protected cultured neuroblastoma cells from chemically 
induced ER-stress mediated death. Further testing of BIX showed that it was also 
neuroprotective in a mouse model of cerebral ischemia. BIX appeared to function via ATF6 
binding to the ERSE response element and slightly increased overexpression of GRP94, 
calreticulin, and CHOP [189]. A similar high-throughput screen of antioxidant compounds to 
combat ER stress, identified one, norbergenin-11-caproate, which increased BiP expression 
about five-fold. The effect appeared to be at least partially independent of ROS production 
[212].  
Small molecule chaperones, low-molecular weight chemical compounds that help promote 
protein folding; have also shown promise in their ability to alleviate ER stress by helping to fold 
accumulated proteins in the ER. These include phenylbutyric acid (PBA), taurine derivatised 
ursodeoxycholic acid, and glycerol [213-215]. Both PBA and glycerol prevent the formation of 
protein aggregates and plaques in cell culture models of AD, leading to a demonstrably lower 
level of oxidative stress [215]. PBA has the ability to alleviate ER-stress induced defects in APP 
trafficking and γ-secretase processing, without a significant increase in amyloid production 
[216]. PBA also protects against ER-stress induced cell death after ischemic shock both in 
neuroblastoma cell culture and mouse models. The protection was clearly associated with a 
reduction in PERK signalling, resulting in lower levels of CHOP and CSP12 activation. 
Interestingly, the effect of PBA in this study appeared to rely on the presence of functional 
mitochondria, as cell treated with mitochondrial inhibitors were not protected [213]. This 
suggested a possible hurdle in using PBA to treat diseases where mitochondrial function is 
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clearly impaired (e.g. Alzheimer’s disease), although depending on the timing of the 
pathological events, it could be useful in treating early stage disease (i.e. before mitochondrial 
function is lost).  
Another approach has focused on screening compound libraries, natural products or their 
derivatives for the ability to prevent ER-stress mediated apoptosis. Salubrinal, which acts 
selectively on the PERK-mediated signalling pathway, was discovered in a high-throughput 
screen of 19,000 small molecules for compounds that protected against ER-stress induced 
apoptosis in PC-12 cells. Salubrinal is a selective inhibitor of ER-stress mediated apoptosis. It 
enhances eIF2α phosphorylation levels by inhibiting the eIf2α phosphatases. It decreases 
translation rates without, however, triggering UPR target genes such as XBP1 and chaperones 
(BiP, GRP94) and finally enhances downstream ATF4 signalling. While data on salubrinal have 
been mixed [217] key in vivo as well as in vitro [218] studies suggested its potential in the 
treatment of neurodegenerative conditions including AD [219], PD [220] and HD [221] by 
preventing apoptosis. Salubrinal therefore inhibits protein synthesis without activating the 
transcription-mediated cascade of the UPR. In addition, another compound named guanabenz 
also acts on the eIF2α-ATF4 arm [222, 223] by inactivating just the stress-induced eIf2α 
phosphatase complex of the GADD34 associated with the protein phosphatase 1 catalytic 
subunit (GADD34-PP1c complex) and thus showing selectivity for ER stress activation only [222, 
224]. These observations illustrate that guanabenz is a better pharmacological compound in the 
long term due to its specificity, as salubrinal may cause unwanted effects due to the 
unrestrained translational attenuation [223].  
 
Other high-throughput screens have isolated several compounds with potential to decrease ER 
stress-mediated death in cell culture models with chemically induced ER stress [225-230]. Many 
of the compounds that have been identified are flavones [231-233]. Interestingly, the 
biochemical effects of the compounds appear to vary widely. Some appear to have very non-
specific effects on ER stress activation, effectively suppressing the activation of the entire set of 
responses [233, 234]. Others have very clear specific effects, often outside of the main ER stress 
signalling pathways including targeting ATF4 activation and the Nrf-2 antioxidant response 
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without activating ER stress [231], inhibiting glycogen synthase 3 [232], or activating the anti-
inflammatory response [235]. The latter observation, while somewhat surprising, is consistent 
with the observation that non-steroidal anti-inflammatory medications can decrease ER stress 
mediated cell death in culture [236]. While many of the results need to be confirmed in tests 
that are more representative of disease conditions, this suggests that ER stress can be 
alleviated by manipulating other biochemical pathways which link to ER homeostasis, rather 
than by targeting the three transmembrane signalling proteins directly.  
Finally, a recent study tested the ability of existing medications to affect ER stress signalling. 
Sanz et al. [237] explored the ability of monoamine oxidase (MAO) inhibitors, which are 
currently used to alleviate PD symptoms, on ER stress activation in cell culture. Pre-treatment 
with a MAO inhibitor decreased XBP1 splicing and expression of CHOP and reduced cell death 
following subsequent chemical induction of ER stress [237]. This suggests that some current 
treatments of PD symptoms may work through ER stress signalling. 
2.11  Potential targets for future drug development and clinical implications 
In addition to the treatment strategies discussed above, another strategy for developing new 
therapeutics that target ER stress could be to try and define the cellular control points that 
determine the point of no return for cells and irreversibly initiate apoptosis. In one very 
important study, Lin et al. (2007), showed that prolonging IRE1 signalling improved cellular 
viability and delayed the onset of apoptosis, suggesting that developing drug targets that 
stimulate IRE1 signalling could be a viable strategy for preventing cell loss. The importance of 
IRE1 as a target was also recognised by Bouchecareilh et al. [238], who developed a high-
throughput screening assay to monitor the dimerization/oligomerization and phosphorylation 
properties of the cytosolic domain of IRE1. They showed in vitro that 
dimerization/oligomerization of the cytosolic domain of IRE1 correlates with the 
autophosphorylation ability of this domain and its endoribonuclease activity towards XBP1 
mRNA [238]. The assay could be used to test compounds for their ability to modulate IRE1 
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activity. An inhibitor of the IRE1 activation was found to be the 4μ8C (4-methyl umbelliferone 8-
carbaldehyde) compound, an aldehyde acting by binding covalently to a unique IRE1 
endonuclease residue, lysine 907 (K907), via an imine forming a Schiff base. This binding causes 
the blockade of any substrate binding to the IRE1 active site and thus inhibits IRE1 activation 
and subsequent gene expression downstream of this receptor [239]. 
Recently, Wang et al. [240] identified small molecules that inhibit PERK mediated 
phosphorylation in vitro using a virtual library screen. Following this, the group investigated the 
structure activity relationships for the most potent inhibitors and, based on these, pinpointed 
the desired and necessary inhibitor characteristics, in the hope that this will accelerate selective 
inhibitor design. A potent and selective PERK inhibitor was found to be GSK2606414 with the 
chemical name 1-(5-(4-amino-7-methyl-7H-pyrrolo [2, 3-d] pyrimidin-5-yl) indolin-1-yl)-2-(3-
(trifluoromethyl) phenyl) ethanone molecule. This drug was orally administered to mice, 
showing its ability to penetrate the blood-brain barrier and spread widely to all areas of the 
brain [241]. The pharmacological effect was inhibition of the PERK signalling and delay of the 
prion disease affected mice, thus exhibiting a neuroprotective effect. Toxicity of the drug was 
not investigated as the mice were sacrificed early due to weight loss and high levels of glucose 
in the blood [241]. 
ER stress is believed to be involved in a number of diseases apart from neurodegeneration, 
including cancer and diabetes. As such, its molecular mechanisms, functional implications and 
treatment methods are the topic of on-going studies. As mentioned above, various small 
molecules are being tested for their ability to halt the response progression. Interventions at 
the point of mutant/overexpressed protein interaction with glucose regulated chaperones and 
foldases may not be a sufficiently targeted approach and can affect general cellular 
homeostasis. Drug development for cancer applications focuses on promoting the pro-
apoptotic features and therefore selecting molecules that inhibit the cell survival IRE1-XBP1 
pathway. This pathway mediates cell survival under conditions of hypoxia that induce ER stress. 
However, drug development and clinical studies on neurodegenerative disorders need to focus 
on promoting the survival mechanisms and inhibiting the pro-apoptotic pathways downstream 
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of XBP1 splicing. Essentially, it would be useful to develop therapeutics that would modulate 
the same signalling pathway, but with opposite effects to treat different diseases. 
2.12  Model organisms in AD 
Scientists use a wide variety of model organisms for their experimental investigations, which 
range across the evolutionary tree of life. More specifically, they range from relative simple 
organisms such as yeast and bacteria up to mammalian cells and animal models [242]. Although 
animal models are essential in the pharmacological studies, they provide many challenges. They 
are relatively expensive as well as labour- and time-intensive as they require a lot of care and 
necessitate a high volume of screens with several generations of breeding [243]. 
Progress has been made in elucidating AD pathology and the genes implicated by developing 
genetically modified mouse models. These models have allowed the understanding of many 
molecular mechanisms and are essential in the assessment of novel therapeutics [244]. 
Although these studies bring us a step forward in elucidating AD, they are not suited for 
interactions of gene products and their analysis is restricted to a limited number of genes, as 
not every gene can be KO. Alternatives to the animal models are cell culture based models. 
They are highly used as they permit high throughput screening, which help the discovery of 
important compounds and drug targets. These systems act as unique tools in elucidating genes 
and proteins affecting the progression of the disease [245]. Several cell models have been 
established in order to study the role of ER stress in neurodegeneration, with the most common 
ones employed being those with genetic mutations [26, 246]. 
2.12.1  SK-N-SH cells 
Biedler, developed human neuroblastoma SK-N-SH cells in 1973 from the brain tissue of a 4-
year old girl patient, who suffered from neuroblastoma. They were originally established from 
metastatic neuroblastoma tissue preserved in vitro and have now been extensively used in 
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assessing neurotoxicity and neuroprotection [247]. SK-N-SH cells exhibit biochemical 
characteristics of neuronal cells and have an average doubling time of 44 h [247, 248]. Their 
neurochemical characteristics are a) their high dopamine-β-hydroxylase activity (an enzyme 
present only in the nervous system), b) their neurochemical markers and c) induction of 
possible damage caused from Aβ treatment [247, 249]. The methods developed for culturing 
such cells during extended periods gave the luxury to discover many biological phenomena.  
 
2.13  Computational modelling in biology  
 
Modelling is the process of constructing and representing simplified versions of biological 
phenomena via mathematical simulations. Computational approaches combined with 
experimental ones are essential to get a thorough understanding of the complex biological 
systems and the molecular interactions involved in fatal diseases such as AD and cancer [250]. 
Such approaches are pivotal to understand better how such complex molecular mechanisms 
are connected and how their interruption may contribute to the development and progression 
of the disease [251]. 
Generation of such models is achieved by choosing specific mathematical strategies in 
conjunction with selective software tools. Execution of a model over time (simulation), allows 
not only assessing specific hypotheses with in silico experimentation but also forecasts 
outcomes that can be validated by in vitro and in vivo studies.  
A high fidelity model is characterised by its ability to provide information on the behaviour and 
dynamics of a cellular process without the need to test it in real life. For such a model, it seems 
ideal to include all biological reactions mechanisms but in reality, representation of too many of 
them may be counterproductive. This may be due to the high underlying computational 
demand and to poverarameterisation, as the number of parameters used typically exceeds the 
number of variables that can be measured. Realistically, most of the biological mechanisms are 
often too convoluted or simply unknown and so experimental data are not available. As 
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formulation of the model must be accomplished with the available literature data, it is often 
constrained [252].     
Prior to selecting a modelling approach, it is essential to understand the nature of the 
underlying reactions of the biological system of interest. The system behaviour may be solved 
with different modelling approaches. In a deterministic approach, the output is uniquely 
defined by the initial conditions and the parameter values used. However, the behaviour of 
systems characterised by low concentrations of reactants or that of extremely small systems 
comprised of a small number of molecules is intrinsically stochastic. Hence, although 
deterministic models in this case may provide reasonable results for long-term observations 
they are not applicable in general. Instead, one has to resort to stochastic simulation 
approaches that incorporate the random nature of individual events into the computed output. 
As stochastic models add more computational complexity, the simpler approach (deterministic 
behaviour) is preferred. 
Deterministic models describe processes at several levels of temporal variations. These are 
defined as i) dynamic models describing time-dependent measurements and ii) static (or steady 
state) ones describing time-independent measurements. Most of the biological reactions have 
dynamic processes as they describe time-dependent phenomena such as environmental 
changes or essential dynamic cellular functions. Modelling dynamics of cascades that capture 
the aforementioned changes depend on differential equations (ordinary or partial, time-
dependent differential equations) [250, 253]. In cases where the timing and frequency of 
measurements is repetitive and occurs under the same rather than varying conditions, the 
model has poor dynamic. Thus, dynamic models may also have constraints even with the 
presence of a plethora of data.  
Another consideration to be made is the scale, choosing either single-cell or cell-population 
model. A collective behaviour in the cell population can be further characterised as 
homogenous or heterogenous the latter incorporating a more realistic behaviour but adding 
computational complexity. Analysis of heterogeneous cell population system is permitted by 
flow cytometry, a powerful single-cell characterization technique [254].   
 75 
Literature Review 
In studies where the question to be answer depends on non-homogenous cell populations, the 
simplest computational approach is preferred. For instance, expansion of polyclonal cultures to 
study the UPR progression induced by ER stress, would generate time-course data incorporated 
in a heterogenous cell-population model.   
2.14  Previous UPR models 
To date, there are five mathematical models describing the ER stress and UPR signalling in 
yeasts and mammalian cells, as shown in Table 2. 
Table 2: Computational UPR models. 
UPR model Pathway System Year Reference 
Raden IRE1 Yeast cells 2005 [255] 
Pincus IRE1 Yeast cells 2010 [138] 
Trusina PERK Yeast & mammalian cells 2008 [158] 
Rutkowski BiP, CHOP & GADD34 Mammalian cells 2006 [256] 
Erguler IRE1, PERK & ATF6 Mammalian cells 2013 [257] 
2.14.1  Raden model for IRE1 in yeast 
Activation of the IRE1 pathway was first described by a model for yeast by Raden et al. [255]. 
The model assumed that BiP dissociates from IRE1 causing IRE1 activation by dimerization and 
autophosphorylation (Figure 15). The authors acknowledged that this model was unable to 
reproduce the experimental data from a stress-induced experiment in Saccharomyces 
cerevisiae [255]. Thus, they concluded that the single BiP-IRE1 interaction by itself is not 
sufficient to describe the activation of the IRE1 pathway. The dual activation of IRE1 has been 
demonstrated in both biological and model systems [255, 258]. Gardner et al. [258] proposed 
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that in yeast, IRE1 may sense the unfolded or misfolded proteins in a BiP independent manner 
through direct binding with an N-terminal luminal domain. 
Figure 15: Raden model for IRE1 activation regulated by BiP in yeasts. BiPf is the pool of free BiP, Ire1 is the 
kinase inactive Ire1 (nonphosphorylated IRE1), while Ire1* is the activated Ire1 (phosphorylated IRE1) [255]. 
2.14.2  Pincus model for IRE1 in yeast 
Pincus et al. [138] developed a mechanistic model based on in Saccharomyces cerevisiae to 
better understand the IRE1 pathway. This model justified the role of unfolded proteins in 
activating IRE1 in yeasts. This model was based on the experimental observations of Gardner et 
al. [138] and so corroborated the assumption of two-step activation mechanism for IRE1 in 
yeast. The first step involved BiP dissociation form IRE1 and its binding to unfolded proteins. 
Next, IRE1 directly sensed the unfolded proteins with its peptide-binding domain and activated 
the IRE1-dependent UPR pathway, as has been previously experimentally confirmed [258].  
More specifically, the constructed model shown in Figure 16 considered three forms of the 
IRE1: a) free inactive IRE1i, b) inactive IRE1 in a complex with BiP (IRE1i●BiP) and c) active IRE1 
in a complex with an unfolded protein (IRE1a●UP). The unfolded proteins can activate the IRE1 
either in their reduced (UPr) or oxidised state (UPo), but only the proteins in the oxidised state 
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get folded (FP). The number of unfolded proteins depends on the unfolded protein flux as well 
as the redox potential, determined by the ratio of Ero1 versus dithiothreitol (DTT). The Ero1 
(transcribed by the yeast HAC1 TF, the XBP1 in mammals) is a molecule oxidising the proteins 
and inducing their proper folding while DTT does not make part of the natural system and was 
used to disrupt homeostasis. DTT impairs homeostasis by catalysing the reduction of disulphide 
bonds causing the production of unfolded proteins that trigger ER stress. IRE1 activation occurs 
by its direct interaction with the unfolded proteins inducing the splicing of HAC1 (a yeast TF 
similar to XBP1 in mammals) and upregulating the production of Ero1 and BiP. BiP, which allows 
the protein folding process, exists in three forms: a) monomer (BiP), b) in a complex with IRE1 
(BiP●Ire1i) and c) bound to unfolded proteins (BiP●UP) (Figure 16). Although BiP is able to bind 
both UPr and UPo proteins, it only facilitates the folding of the former ones. The interactions of 
the model were described as simple chemical equilibrium and the different variables were 
taken either from the literature or from experimental data.    
Three mutant yeast cells lines created to validate the model, which were the followings: a) wild-
type, b) IRE1 bipless (where the IRE1 lacked the BiP interaction motif) and c) HAC1Δ (which lack 
the ability to increase BiP and ERO1 activity). The model was able to predict the role of BiP in 
IRE1 activation and to fit a posteriori the data from a DTT titration time-course experiment in 
the wild-type, IRE1 bipless and HAC1Δ. 
This model is explicative as it describes the IRE1 activation. It is also predictive as it was able to 
demonstrate the role of BiP in IRE1 activation and deactivation as well as to reproduce the data 
from the mutant cell lines a posteriori. Overall, this is a dynamic UPR model showing the dual 
role of BiP in activating/deactivating the IRE1. BiP acts as 1) a buffer lowering the sensitivity of 
the system by preventing UPR activation in the low concentration of unfolded proteins and 2) 
ends the UPR upon low unfolded protein concentration by binding the IRE1. However the 
authors recognise that the model is a simplification of reality and that other functions of IRE1 
need to be included [138]. 
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Figure 16: Pincus schematic model for IRE1 activation. Blue arrows show the feedback points and red arrows the 
IRE1/BiP interactions. UP: unfolded proteins, UPr: unfolded proteins in their reduced state, UPo: unfolded 
proteins in their oxidised state, FP: folded proteins [138]. 
2.14.3  Trusina model for PERK 
A simplified model created by Trusina et al. showed the importance of PERK [158] (Figure 17). It 
described the UPR in yeasts and in mammalian cells by presenting all protein interactions with a 
single variable and several reaction rate constants. This model explained 1) the dynamics of 
PERK and IRE1 receptors in mammalian UPR, 2) how the absence of PERK in yeasts (also 
observed in extreme cases of mammalian non-secretory cells) affects the stress response and 3) 
the effects caused from both the synthesis of chaperones and translational attenuation on 
preventing stress. 
The assumptions made were the following: a) translational attenuation was activated prior to 
eIF2α phosphorylation which occurs five minutes later according to experimental observations 
and b) inactivation of IRE1 and PERK activity occur by the chaperones in a similar manner. 
Previous studies have shown that chaperones may act as inhibitors towards their receptors 
causing inhibition of their dimerization and their activation [259].  
The changing rate of the free unfolded proteins was dependent on several factors. These 
consisted of: 1) the translation rate of the proteins entering the ER, 2) the induction of stress 
caused either by physiological changes or by artificial induction in the lab, 3) the influence of 
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the chaperones in folding/unfolding and degradation of unfolded proteins and 4) the dilution 
process of the unfolded proteins during division of the cells.   
This model showed the importance of the PERK pathway through its ability to reduce the load 
of unfolded proteins caused by the inhibition of translation and thus of the proteins entering 
the ER. They demonstrated that upon low ER stress, translational attenuation is not required, as 
is the case in non-secretory cells like neurons. On the other hand, they postulated that for cells 
pre-conditioned to ER stress as occurs in AD, this mechanism is necessary in order to inhibit cell 
death. Finally, this model was not well detailed and was solely a test to understand the 
importance of translational attenuation in the monitoring of ER stress [158]. 
Figure 17: Trusina model of the UPR A) in yeasts and B) in mammalian cells. The model is presented C) in the 
absence of translation attenuation (TA) whereas in D) with the translation attenuation (TA) mechanism. Green 
arrows indicate positive regulation while red ones indicate negative regulation [158]. 
2.14.4  Rutkowski model for BiP, CHOP and GADD34 
Rutkowski et al. [256] constructed a simple UPR model describing transient activation of BiP, 
CHOP and GADD34 under mild ER stress. They demonstrated that an adaptive response to ER 
stress is tuned by the discrepancy in stability of the prosurvival (i.e. chaperones) and 
proapoptotic (i.e. CHOP and GADD34) mRNAs and proteins. The experimental system used 
involved the treatment of MEFs cells with TM or Tg in order to induce stress. They 
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demonstrated that the mRNA and protein of ATF4 and GADD34 (upstream and downstream of 
CHOP) as well as of CHOP was unstable and degraded quickly. On the other hand the mRNA and 
protein of BiP, GRP94, p58IPK (a cellular inhibitor of PERK) were quite stable showing little 
degradation. A model consisting of the ATF6-BiP and ATF4-CHOP-GADD34 axis was generated in 
which the mRNA and degradation rates were manipulated in order to determine the effects of 
their protein expression. 
The model is based on experimental data and on the following assumptions. These included: 1) 
XBP1 splicing acts as a marker for the level of stress as has been previously been demonstrated 
[260], 2) upon ER stress ATF4 and the activated form of ATF6 are expressed and degraded at an 
equal rate (simplified assumption) and 3) all proteins in the model would be translated and 
degraded at a uniform rate constant (simplified assumption).  
One of the model’s limitations is that it does not consider some of the feedback regulatory 
mechanisms such as the GADD34 that mediates dephosphorylation of the eIF2α or p58IPK 
inhibiting PERK-mediated translational attenuation. Finally, from this model they observed an 
adaptive behaviour of the UPR and suggested that this response is the result of the differential 
stability of chaperones compared to the rest of the UPR players. However, some important 
regulatory events required for the adaptation and recovery state are missing.  
 
 
 
Figure 18: Rutkwoski model of the mammalian UPR. It predicts protein expression of BiP, CHOP, GADD34 using 
experimentally derived degradation rates [256].  
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2.14.5  Erguler model 
Recently, Erguler et al. [257] created a mechanistic model with the aid of ordinary differential 
equations and reproduced a detailed version of the mammalian UPR combining all three 
signalling cascades (Figure 19). They linked the severity of the UPR state, translational 
attenuation and apoptosis.  
The model is based on four elements that are linked to each other and are as follows: 1) the 
control of the activation of the receptors was assumed to occur from BiP by acting as a positive 
regulator based on competitive interaction to the receptor and the unfolded proteins. 
However, BiP was also able to act as a negative regulator by switching the active complex to its 
monomeric form, 2) the states that UPR can adopt were assigned from low to intermediate and 
high activities. During the intermediate state, the UPR oscillated between translational 
attenuation and induction of apoptotic stimuli. Under severe or prolonged stress, the system 
was able to cause continuous eIF2α phosphorylation (p-eIF2α). This in turn resulted in the quick 
ATF4 activation and the inhibition of translation attenuation mediated by PERK, 3) the IRE1 and 
ATF6 receptors, mediated the adaptive response by controlling the molecular dynamics of XBP1 
and the expression of BiP and 4) evaluation of the timing of the apoptosis process, was 
achieved by using the apoptotic model [261] based on the mitochondrial BAX/BAK/BH3 while 
also assuming that CHOP inhibits Bcl-2 expression and activates the Bcl-2-interacting mediator. 
Emphasis was given on ER stress situations where the ERAD system was incapable of decreasing 
the unfolded protein load in the ER. Furthermore, by separating UPR activation from its 
response, the connection between the inputs and outputs was assessed. The majority of 
parameter values were not determined from experimental data but instead assigned as 
arbitrary units (AU). The model was justified by simulating the UPR in arbitrary stress scenarios. 
Finally, this model suggested the ability of the UPR to switch from survival to death by 
generating oscillations and the timing of apoptosis. It also showed how mild ER stress may 
protect cells by preventing apoptosis and provided a novel approach for therapeutic 
intervention of UPR-associated disorders. However, this study lacked quantitative experimental 
data and thus the experimental validation was not possible. 
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Figure 19: Erguler model comprising the complete mammalian UPR. It describes the UPR using 27 species, which 
are connected with 62 biochemical reactions and 82 parameters in total. The reactions take place in four cellular 
compartments including the nucleus, the cytoplasm, the endoplasmic reticulum and the Golgi apparatus [257]. 
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Materials and Methods 
3.1  Cell lines and growth conditions 
SK-N-SH human neuroblastoma cells (ATCC® HTB-11™, New York, USA) either non-transfected 
or overexpressing wild-type, Swedish or Swedish-Indiana APP695 were maintained in 75-
cm2 tissue culture flasks in Minimum Essential Medium Eagle (MEM) (Sigma-Aldrich, Dorset, UK) 
supplemented with 10% foetal bovine serum (FBS) (Sigma-Aldrich, Dorset, UK). Cells were 
grown in a monolayer in a humidified incubator at 37 °C with 5% CO2  (NuAire) (Triple Red, Long 
Crendon, UK). Each culture was seeded in a new tissue culture flask at a density of 
7.2x105 cells/ml and passaged every three to four days. Cells were dissociated from culture 
flasks by incubating with 5 ml 0.25% trypsin (Invitrogen Ltd, Paisley, UK) for 5 min at 37 °C, 
followed by the addition of 5 ml fresh culture medium to neutralise trypsin. Cells were then 
centrifuged at 2,000 rpm for 5 min to separate the trypsin-containing solution. The supernatant 
was discarded; cell pellets were re-suspended in fresh medium containing FBS in a 1:4 dilution 
and cultures were seeded in new culture flasks. Viable cell concentration was determined by 
light microscopy using the trypan blue dye exclusion method. 
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3.2  Constructs of mutant APP695 
 
3.2.1  Site directed mutagenesis 
 
Generation of Point Mutants –Swedish mutation: from lysine (AAG) to asparagine (AAC) and 
from methionine (ATG) to leucine (CTG) at amino acid residues 670 and 671, respectively, and 
of the Indiana mutation: from valine (GTC) to phenalanine (TTC) at amino acid residue 717 were 
generated. These were introduced to APP695 cDNA in pCI-neo mammalian expression vector 
(Promega, Hampshire, UK) by site-directed mutagenesis using the QuikChangeTM kit (Stratagene 
Ltd, Cambridge, UK) according to the manufacturer’s instructions (Figure 20).  
 
 
 
Figure 20: Schematic representation of the site-directed mutagenesis procedure. 
 
Primers were designed according to human APP695 sequence. Each mutation was inserted 
separately and the Swedish double mutant plasmid was used as a template for insertion of the 
Indiana mutation in a second round of polymerase chain reaction (PCR) to produce 
the Swedish-Indiana variant. In a final volume of 50 µL, the following substances 1 µL of DNA 
template (5 ng/µL), 1.25 µL of each 100 ng/µl oligonucleotide primer, 1 µL of 10 mM dNTP (pre-
mixed), 40.5 µL distilled water and 1 µL of Pfu DNA polymerase (2.5 U/µL) were mixed. The 
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sample was incubated for 5 min at 98 °C in order to denature the DNA secondary structure and 
enable annealing of oligonucleotide primers. Then the amount of 1 µL of 2.5 U/µL Pfu DNA 
polymerase was added to the reaction mix in order to amplify each of the primers that were 
complementary to opposite strands of the vector, resulting in a final volume of 50 µL according 
to the manufacturer’s recommendations. The sample was then immediately amplified with 
PCR. A control reaction containing no DNA polymerase was included to gauge the level of 
background reaction and to monitor template removal by DpnI. The reactions were run for 18 
cycles 95 °C for 30 sec, 50 °C for 1 min, 68 °C for 10 min. Samples were left at 15 °C when PCR 
cycles finished.  
 
3.2.2  Digestion of the PCR product 
 
Following the amplification reaction, the plasmid was treated with 1 µL DpnI (10 U/µL) 
endonuclease, digesting the parental DNA template and selecting for the plasmid containing 
the mutated synthesised DNA. After mixing, the solution was incubated at 37 °C for 1 h to 
digest the parental double stranded DNA and thus to select for the plasmid containing the 
desired mutation. 
 
3.2.3  Plasmid transformation and isolation   
 
A volume of 1 µl of the DNA plasmid from the PCR reaction was added to 50 µl of chemically 
competent XL-1 Blue Supercompetent (Stratagene Ltd, Cambridge, UK) cell aliquots. The cells 
were incubated on ice for 20 min, followed by a heat pulse at 42 °C for 45 sec to induce DNA 
uptake. Following the heat pulse, the reaction was placed on ice for 2 min supplemented with 
0.5 ml of LB at room temperature and was then incubated at 37 °C for 1 h and 30 min with 
shaking at 225 rpm. A volume of 250 µl of the reaction was plated on LB-ampicillin agar plates 
and the rest of the transformation reaction was stored at 4 °C. 
For each transformation, three single colonies were selected at random from a selective plate 
and grown into a 10 ml LB medium containing 10 µl of ampicilin antibiotic. The culture was 
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incubated overnight at 37 °C with vigorous shaking. Several APP695 plasmid candidates 
containing the mutation of interest were isolated using Qiagen Miniprep Purification kit (Qiagen 
Ltd, West Sussex, UK) according to manufacturer’s instructions. Confirmation of the right 
plasmid was only possible after sequencing. 
 
3.2.4  Sequencing 
 
DNA sequencing with the APP1441 sequencing primer and two vector-specific primers at a 
concentration of 10 µmol/µl confirmed the fidelity of the mutated constructs. This allowed to 
ascertain that each DNA contained only the desired mutation without any other mutations 
(Eurofins MWG, Cambridge, UK). Oligonucleotide sequences used for mutagenesis and the 
sequencing are shown in the supplementary information (Appendix I). 
 
3.3  Generation of a stable cell line  
 
SK-N-SH cells stably expressing either the wild-type APP695 (APPWT), the Swedish mutation alone 
(APPS) or APP with both the Swedish and the Indiana mutation (APPS-I) were obtained by 
transfection using Lipofectamine 2000TM (Invitrogen Ltd, Paisley, UK) according to the 
manufacturer’s protocol. More specifically, four days prior to transfection, cells were plated in 
serum-containing growth medium in six-well plates (1.5 ml per well) to obtain 95% confluence. 
For each well, 246 μl of OptiMEM was combined with 1 mg/μl DNA and allowed to sit at room 
temperature for 5 min. Then 238 μl of OptiMEM was combined with 12 μl of 1 mg/ml 
Lipofectamine 2000TM and allowed to sit at room temperature for 5 min. The two solutions 
were then mixed and incubated at room temperature for 20 min and then 500 μl of this 
solution was plated in each well. A control well was used for each plate, containing OptiMEM 
and Lipofectamine solution but not the DNA plasmid.  
At 48 h post transfection, colonies were selected using 500 µg/ml of G418 (Sigma-Aldrich, 
Dorset, UK). When cells in the control well died and the transfected cells reached confluence, 
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the latter were progressed to 25 m2 tissue culture flasks and subsequently into 75 m2 tissue 
culture flasks. The stable SK-N-SH cells overexpressing APPWT, APPS and APPS-I were maintained 
in the same medium as the non-transfected SK-N-SH cells, supplemented with 50 µg/mL of 
G418. 
 
3.4  Freeze/Thaw 
 
Cells for long-term storage were placed in cryovials suspended in a solution of 5% Dimethyl 
sulfoxide (DMSO) (Sigma-Aldrich, Missouri, USA) and 95% complete growth medium at a 
concentration of 107 cells/ml. The vials were subsequently placed in a cryo-freezing ‘’Mr Frosty’’ 
container with isopropyl alcohol and stored at -80 °C for 24 h prior to transferring the cells in 
liquid nitrogen (at -160 °C) for freezing them down. For revival, cells were thawed rapidly in a 
water bath of 37 °C, mixed with 4 ml fresh media (10% FBS/90% MEM) and centrifuged at 2000 
rpm for 5 min. DMSO-containing supernatant was aspirated and the cell pellet was re-
suspended in fresh FBS-containing growth medium.  
 
3.5  Optimisation of cellular differentiation 
 
Cells were grown in 6-well plates to reach 90% confluence and were then induced for 
differentiation with all-trans retinoic acid (RA) (Sigma-Aldrich, Dorset, UK). Treatment with a 
range of RA concentration including 3 μM, 5 μM and 10 μM was performed to evaluate the 
optimal amount needed for their differentiation. Phenotypic characteristics were assessed by 
the following tools 1) microscopic examination of the overall shape of the cells and 2) 
transcripts (mRNA levels) of differentiation markers with quantitative real time PCR (qRT-PCR) 
in order to determine the successful differentiation of the cultures. The mRNA levels were 
assessed with qRT-PCR as described below. 
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3.6  Stress protocol 
 
For all experiments, SK-N-SH cells ~80% confluent were used in order to rule out the influence 
of overgrowth inducing stress. Cultures were differentiated for 5 days using 10 μM RA 
supplemented to the culture medium. On the day of stimulation, the culture medium was 
renewed 1 h before the stress experiment to create uniform conditions. Cells were stimulated 
with 1 μg/mL TM [130] (Sigma-Aldrich, Dorset, UK) in culture medium containing RA. 
 
3.7  Cell viability and metabolic activity 
 
3.7.1  Trypan Blue exclusion method 
 
Cells were trypsinised and following their neutralisation were mixed with trypan blue. Cells 
were resuspended in trypan-blue solution and counted in a haemocytometer under a light 
microscope. Live and dead cells wells were counted by looking at their clear cytoplasm or their 
blue staining respectively. In order to avoid counting errors arising from incorrect dilutions, it 
was ensured that the cells counted in each 1 mm2 chamber were in the range of 15-50. 
Identification of live and dead cells as well as enumeration was possible with the following 
calculations: 
 
1. The total number of cells was defined by considering the following: 
a) The number of cells in each big corner square of the haemocytometer being equal 
to: 𝑇𝑇ℎ𝑒𝑒 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑒𝑒𝑛𝑛 𝑜𝑜𝑜𝑜 𝑐𝑐𝑒𝑒𝑐𝑐𝑐𝑐𝑐𝑐 ×  104 cells/ml. 
 
b) Total cell count =  𝑁𝑁𝑢𝑢𝑁𝑁𝑁𝑁𝑒𝑒𝑁𝑁 𝑇𝑇𝑓𝑓 𝑐𝑐𝑒𝑒𝑇𝑇𝑇𝑇𝑠𝑠 𝑥𝑥 𝐷𝐷𝐷𝐷𝑇𝑇𝑢𝑢𝑇𝑇𝐷𝐷𝑇𝑇𝐷𝐷
𝑁𝑁𝑢𝑢𝑁𝑁𝑁𝑁𝑒𝑒𝑁𝑁 𝑇𝑇𝑓𝑓 𝑠𝑠𝑠𝑠𝑢𝑢𝑇𝑇𝑁𝑁𝑒𝑒𝑠𝑠 𝑐𝑐𝑇𝑇𝑢𝑢𝐷𝐷𝑇𝑇𝑒𝑒𝑓𝑓  ×  104 cells/ml  
  
2. Total percentage of viable cells was calculated with the formula:   
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                % Viability =  𝐴𝐴𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝐷𝐷𝑢𝑢𝑁𝑁𝑁𝑁𝑒𝑒𝑁𝑁 𝑇𝑇𝑓𝑓 𝑇𝑇𝐷𝐷𝑙𝑙𝑒𝑒 𝑐𝑐𝑒𝑒𝑇𝑇𝑇𝑇𝑠𝑠
𝐴𝐴𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑐𝑐𝑒𝑒𝑇𝑇𝑇𝑇 𝑐𝑐𝑇𝑇𝑢𝑢𝐷𝐷𝑇𝑇  ×  100 
 
3.7.2  MTS assay  
 
In vitro cytoxicity of TM was determined with the MTS ((3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulphenyl)-2H- tetrazolium, inner salt)) tetrazolium salt/phenazine 
methosulfate solution (Promega, Hampshire, UK) according the manufacturer’s instructions. 
Differentiated cells in 6-well plates were exposed to TM (1 μg/mL) for 0 h to 24 h. MTS solution 
(0.25 mg/mL) was added, incubated for 2 additional hours at 37 °C. The optical density (OD) 
was measured directly at 490 nm using an automated ELx808TM absorbance microplate reader 
(BioTek, Bedfordshire, UK). 
 
3.8  Molecular Biology techniques  
 
3.8.1  RNA isolation and cDNA construction 
 
Total RNA was isolated from actively growing cell cultures by harvesting them either in 1) 100 
µL cell lysis buffer from the Cell Sure cDNA kit (Bioline Ltd, London, UK), 2) in 400 µL RNA lysis 
from the peqGOLD (Peqlab, Southampton, UK) or 3) 400 µL lysis reagent from the High Pure 
RNA isolation kit (Roche, Applied Science), all followed by spin column purification according to 
the manufacturer’s instructions. RNA integrity was verified electrophoretically with GelRed 
staining and by quantification of the OD260/OD280 nm absorption ratio ranged from 1.8-2.2 with 
NanoDrop 1000 (Fisher Scientific, Loughborough, UK). The cDNA was prepared by reverse 
transcription of 1 μg total RNA using the Sensiscript® reverse transcription kit (Qiagen Ltd, West 
Sussex, UK).  
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3.8.2  Optimisation of qRT-PCR conditions 
 
The concentration of cDNA generated was determined by measuring the optical density at 260 
nm using the NanoDrop 1000 and samples were then stored at -20 °C. Conditions for all primer 
pairs were optimised by gradient PCR at 8 different temperatures and verified by gel 
electrophoresis (using the appropriate primers and goTaq DNA polymerase) and melting curve 
analysis to assess whether the primers amplified only the target amplicon. 
 
3.8.3  Primer design 
 
For each of the target genes analysed with qRT-PCR, a number of primer pairs were designed 
using Primer-Blast (NCBI, Bethesda MD, USA) until a single PCR amplification product of interest 
was generated at 64.5 °C. The designed considerations were a) the amplicon size 60-500 bp; the 
smaller the better b) the melting temperature of the product and c) the GC content (the 
number of G’s and C’s in the primer as a percentage of the total bases) to be 40-60%. All primer 
stocks were diluted to a concentration of 10 μM. 
Primer efficiencies were determined by performing serial dilutions of cDNA 2-fold up to 6 points 
followed by qRT-PCR reactions performed in duplicate using 4 different cDNA concentrations. 
Efficiency calculation was performed according to Pfaffl et al. [262] and primers were all 
optimised to have a similar annealing efficiency at 64.5 °C.  
The average Cycle threshold (Ct) values with respect to qRT-PCR (an average calculated from 
the triplicate qPCR reactions) obtained during the amplification reactions and determined by 
Mastercycler ep realplex software (Eppendorf, Stevenage, UK) were plotted against the log10 of 
the cDNA dilutions. The equation from the linear regression line was used to test the efficiency 
and the coefficient of determination (R2), which indicated how well the experimental data fitted 
the line (>0.99) were assessed (Appendix II).  
1. Amplification efficiency was calculated by the following formula: 
𝐸𝐸 = 10 1−𝑔𝑔 
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             Where g is the slope of the linear regression 
2. The percentage of the efficiency was calculated as:   %𝐸𝐸 = (𝐸𝐸 − 1) × (100%) 
3. Coefficient of determination: >0.98 
The quantity of the PCR product would ideally double after each exponential cycle of the 
amplification, which is a 2-fold increase in the copy number after each cycle. In other words the 
values of 𝐸𝐸 were considered to be within the range of 1.93 to 2.08. Primers whose reaction was 
reaching efficiency close to 100% (close to 𝐸𝐸 =2) and a great R2 were used for gene expression 
analysis. 
In order to verify that the amplified product is the desired one, melting curve analysis was 
performed immediately after the qRT-PCR reaction. Finally, the size of the amplicon was 
confirmed via agarose gel electrophoresis.  
 
3.8.4  Quantitative reverse transcription polymerase chain reaction  
 
Individual qRT-PCR reactions were performed using a mastermix containing SYBR® Green 
JumpStart™ Taq ReadyMix™ (Qiagen Ltd, West Sussex, UK), 100 ng cDNA and a final primer 
concentration of 1600 nM. Each reaction was performed in triplicate in 96-well plates (Fisher 
Scientific, Loughborough, UK) sealed with thermal film (Bioline, London, UK) and run in 
Mastercycler® ep Realplex 4S device (Eppendorf, UK). The conditions for the 2 step PCR were as 
follows: single denaturation cycle at 92 °C for 2 min followed by 40 cycles of 92 °C for 30 sec, 
64 °C for 30 sec and a final extension cycle of 72 °C for 1 min. Amplified products were 
validated by melting curve analysis (62.7 °C to 92 °C with 0.025 °C per second increment). Ct 
values were determined by the Mastercycler ep Realplex software with a threshold of 100 
(arbitrary fluorescence units). For each cell line, the mRNA levels of the ER stress markers (e.g. 
BiP, CHOP) mRNA levels were normalised for the expression of the endogenous housekeeping 
gene 18S rRNA.  
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3.8.5  Housekeeping genes 
Three potential housekeeping genes were tested which were β-actin, GAPDH and 18S rRNA 
(Invitrogen Ltd, Paisley, UK). 
3.8.6  Agarose gel electrophoresis 
Electrophoretic mobility of DNA fragments was assessed on a 1-3% (w/v) gel electrophoresis. 
Agarose particles were added in 1 x TAE solution (40 mM Tris-acetate, 1 mM EDTA pH 8.0) and 
heated up until the particles were dissolved. The solution was cooled down to 60 °C and 0.05 μl 
GelRed/ml (GelRed™ nucleic acid stain) was added to stain the DNA bands. For each gel, 5µl per 
lane of the DNA Hyperladder V (500 bp) (Bioline, London, UK) was loaded to reference the size 
of the observed fragments. Samples which were mixed with GoTaq® reaction buffer 5X 
(Promega, Madison, USA), loaded and electrophoresed at 120 V for 45 min. Gels were cast in a 
horizontal Gel Electrophoresis apparatus (BioRad, Hempstead, UK). They were then imaged by 
placing them in a UV light box, illuminated with a short UV and visualised using ImageJ software 
(Java image processing program).  
3.9  Protein methods 
3.9.1  SDS-PAGE and Western blot 
Cells that were stored at -80 °C in a freeze mix containing 10% DMSO at a final concentration of 
7.5x106 were thawed. They were then centrifuged at 2,000 rpm for 5 min and pellets were 
harvested using the Mem-PER® extraction kit (Fisher Scientific, Loughborough, UK). For analysis 
concentrated NuPage sample buffer (4X) and 1M DTT were added to the samples which were 
heated at 90 °C for 10 min. Equal amounts of protein were analysed on a gradient 4-20% 
precise protein gel (Fisher Scientific, Loughborough, UK) in Tris-Hepes running buffer at 120 V 
for 50 mim. The proteins were transferred to a PVDF membrane (Merck Milipore, 
Hertfordshire, UK) at 25 V for 1 h 30 min using a semi-dry transfer system (BioRad, Hempstead, 
 93 
Materials and Methods 
UK). The WesternBreeze® Chemiluminescent Kit (Life Technologies, Paisley, UK) was used for 
western blotting. Membranes were incubated with 1:200 diluted rabbit monoclonal APP (Fisher 
Scientific, Loughborough, UK), and with 1:5000 diluted mouse monoclonal β-actin (Abcam, 
Cambridge, UK) the last one used as a loading control. Primary antibodies were detected using 
alkaline phosphatase-conjugated secondary antibodies and bands visualised using a LAS-3000 
luminescent image analyser (Fuji Photo Film). 
3.10 Statistical analysis 
Statistical analysis was conducted using SPPS software (Statistical Package for Social Sciences 
SPSS Inc., Chicago, IL). To assess whether chemical treatment had a significant effect on the 
mRNA expression levels between the time points of a specific cell line (within a cell line) or the 
time points between the cell lines (between the cell lines) the one-way analysis of variance 
(ANOVA) was used. In order to compare the variances among treatments and determined 
whether they were equal or not (homogeonous or heterogenous respectively), Levene’s test 
was applied. When the variances were homogeneous (p≥0.05) ANOVA was employed, and 
when they presented heterogeneity (p<0.05) Welch ANOVA procedure was applied. To find the 
relationships (equal or unequal means) of the different subgroups post-hoc analysis was used. 
In the case where ANOVA test set results indicated significant difference (p<0.05) Tukey’s post-
hoc test was used. In case where Welch ANOVA was used and indicated significant effects 
(p<0.05), Games-Howell post-hoc was used. Significance has been considered at * p<0.05, 
** p<0.01 and  *** p<0.001, as indicated in each case. 
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A cell model system of familial 
Alzheimer’s disease 
4.1  Introduction 
No treatment is available to cure AD, so a worldwide quest for innovative cures is under way in 
order to slow down, stop or even prevent this perplexing disease. Strong evidence implicates ER 
stress in AD, making it a possible treatment avenue. For instance, AD diminishes the ER’s ability 
to deal with stress and this may possibly account for a shift in the balance of cellular fate 
towards cell death rather than survival. Increasing the chaperones to enhance protein folding 
and/or inhibit cell death with specific small-molecules [26] may provide a likely therapeutic 
avenue. In order to do this, it is necessary to develop convenient tools, which would detect the 
cellular responses and work as the framework for investigating such effects. Such tools include 
experimental (Table 3) and computational (Table 12) models allowing for the quick screening of 
small molecules for drug discovery. 
While up to date biochemical and gene expression analyses have been successful in uncovering 
the UPR mechanisms, research on the UPR remains hampered by the lack of clear biological and 
computational models representing these features in mammalian cells [138]. Furthermore, Ron 
and Walter [25] proposed that the quantitative evaluation is essential in the understanding of 
the timing of the UPR. 
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Key pathological hallmarks of FAD are APP-linked mutations affecting the APP breakdown and 
subsequently the onset and the progression of AD. Therefore, an in vitro model of 
neuroblastoma cells stably expressing wild-type APP695 isoform (APPWT) and cells harbouring 
the APP695 Swedish (APPS) or Swedish-Indiana (APPS-I) mutation was generated (Table 3). 
Swedish mutation located at the N-terminus of the Aβ domain favours the cleavage of APP by 
β-secretase as seen in vitro experiments [263], and is associated with elevated levels and 
deposition of Aβ42 in AD brains [264]. On the other hand Indiana mutation is, located in the 
transmembrane domain of APP and associated with abundant senile plaques, NFT and mild 
cerebral amyloid angiopathy in AD brains [265]. The latter mutation was used in conjunction 
with the Swedish in order to evaluate their synergistic effect in UPR, a complex network 
implicating three main downstream signalling pathways. The UPR markers along with their 
biological relevance were assessed as presented in Table 3. 
Table 3: Outline of the experimental setup. 
Type of model 
studied 
UPR Signalling 
branches 
UPR markers 
assessed Biological relevance 
 Experimental 
• WT
• S
• S-I
IRE1, ATF6 BiP, GRP94 Chaperones (protein-folding) 
IRE1 Spliced XBP1 
Encodes pXBP1s, a TF for ER 
chaperones  & ERAD genes 
ATF6 
Total XBP1 
Encodes pXBP1u, 
a negative regulator of pXBP1s 
CHOP Pro-apoptotic stimulus 
PERK 
ATF4 Inhibits protein synthesis 
Nrf-2 Antioxidant response 
CHOP Pro-apoptotic stimulus 
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4.2  Methodological diversity in the generation of stable cell lines 
Several transfection methods have been developed to introduce foreign nucleic acids into the 
cells depending on the cell type and the purpose of the study. When short-term effects of the 
gene expression are studied transient transfection is preferred, while for long-term effects such 
as evaluation of wild-type or mutant APP overexpression in human neuroblastoma cells, stable 
transfection is preferred. There are multiple approaches that can be taken to generate stably 
transfected mammalian cells, broadly categorised into biological (i.e. virus-mediated), chemical 
(i.e. cationic polymer) and physical (i.e. microinjection).  They all have their own advantages 
and disadvantages so the best approach is based on the experimental design choice. 
The approach used to generate our FAD cell model system was based on the chemical –
liposome mediated transfection – an easy to use, non-viral and highly efficient method, which is 
commonly used in SK-NSH cells. Hence, a polyclonal SK-N-SH cell model system constitutively 
overexpressing APP-associated mutations (further explained in 4.3.4) was generated. However, 
a major drawback of this method is the variability in transfection efficiency among different 
cells, which have distinct gene-expression patterns.  
A possible approach to take in overcome this problem would be to clone the cells with one of 
the major strategies named cloning ring technique, dilution technique or the robotic cell 
transfer. The cloning procedure will thus enable us to obtain a pure culture of a particular cell 
type of interest. Alternatively, the transfection vector may contain a fluorescent protein such as 
GFP reporter gene activated from the APP promoter. The GFP-tagged cells may be analysed 
with fluorescence activated cell sorting (FACS) and provide information on the levels of the 
target gene. Another method could also be the use of an inducible type of overexpression of 
wild type or mutant APP. More specifically, APP expression would rely on an additive-controlled 
transcription activation of the APP gene. The most common inducible systems are the Tet-off 
and Tet-on, in which transcription remains either inactive or active respectively in the presence 
of tetracycline (Tet) or Doxocycline antibiotics. 
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4.3 Results 
4.3.1  Generation of the construct 
As many previous studies have demonstrated that mutations in APP protein are critical for the 
formation of plaques in FAD, site-directed mutagenesis was used to produce mutated APP695 
recombinant plasmids. The wild-type APP695 cloned into the commercially available pCI-neo 
expression vector (Figure 21) was kindly provided by Dr. Jane Saffell. Site-directed mutagenesis 
was then performed. Expression of wild-type or mutant APP695 in the host human 
neuroblastoma cells was controlled by the human cytomegalovirus (CMV) strong constitutive 
promoter of the pCI-neo vector [266]. The neomycin phosphotransferase gene allowed for the 
generation of stable transfectants by selecting the cells with the use of G418 antibiotic (Figure 
21). 
Figure 21: pCI-neo mammalian expression vector and sequence reference points. Neo=neomycin 
phopshotransferase, CMV I.E.=cytomegalovirus immediate-early (Promega, Hampshire, UK). 
The first two mutations were performed by PCR using complementary primers with the desired 
mutation inserted into the wild-type APP695 containing plasmid (Appendix I). Inserting the 
Indiana mutation form into the Swedish mutated plasmid generated the double mutation. 
Mutant DNA was in all cases amplified with the high fidelity proofreading enzyme ‘Pfu 
polymerase', which generated a PCR product with a nicked circular DNA. Following the PCR, a 
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restriction enzyme DpnI specifically targeted for methylated and hemi-methylated DNA sites 
digested the template (non-parental) DNA while leaving the amplification product untouched. 
Both the wild-type and the mutant APP695 containing plasmids were transformed into E. coli, 
where they were methylated and therefore susceptible to DpnI digestion. Finally, amplification 
of the APP695 mutant DNA product of 8000 bp long was successful in all cases (Figure 22).  
4.3.2  DNA purification for sequencing 
The targeted APP695 plasmids were transformed in E. coli and subsequently purified using three 
minipreps for each of the transformed DNAs. In order to examine whether the DNA from the 
miniprep products was sufficient to proceed with the analysis, samples were assessed on a 1% 
w/v agarose gel. 
Figure 22: DNA isolation from E. coli culture with Qiagen miniprep. Bands of 8000 bp long were selected and 
sequenced in order to test if the plasmid has incorporated the desired mutation. All miniprep bands are very 
bright showing the high concentration of the plasmid. The bands in the first well correspond to the APP695 
plasmid while the other three bright bands correspond to APP695 mutant DNA product. 
Figure 22 clearly shows that all vectors (APP695 plasmids) have the same size and are equally 
bright, thus have approximately the same concentration. In the wild-type vector there are two 
PCR amplified products in the three corresponding lanes; from which the larger band 
 99 
A cell model system of familial Alzheimer’s disease 
corresponds to the non-supercoiled DNA. Mutant and wild-type APP695 variants with the 
expected 8000 bp band size were validated by DNA sequencing.  
4.3.3  DNA purification for transfection 
Maxiprep Qiagen kit was used to purify the DNA prior to transfection. Assessment of the DNA 
purity was conducted by measuring the samples 260/280 absorbance yielding ratios of ~1.8. 
The purified samples were analysed on a 1% agarose gel. The PCR amplification bands had a 
single intact product and were very bright, which depicted that all APP695 plasmids had a high 
DNA concentration as seen from Figure 23. These plasmids were then used for transfection. 
Figure 23: DNA purification with Qiagen maxiprep. All bands are 8000 bp and they are very bright corresponding 
to high DNA concentration.   
4.3.4  Optimising a transfection protocol for SK-N-SH cells 
Purified DNA was transfected into neuroblastoma cells with the Lipofectamine™ 2000 serum-
compatible transfection reagent. A range of different DNA:Lipofectamine ratios were tested 
prior to the cell line development. Cells that contained the recombinant plasmid with the 
desired mutation were selected with G418. As the recombinant plasmid contained a G418 
resistance gene, cells that did not incorporate the plasmid were not resistant to the antibiotic 
and thus did not grow. SK-N-SH cells overexpressing the APPWT and the mutant forms including 
APPS and APPS-I were successfully created. 
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Surprisingly, following transfection some of the cells had an altered neuronal morphology. 
Studies by Granic et al. [267] on transfected human telomerase reverse transcriptase primary 
neurons showed that overexpression or mutation in PS-1 gene (which alters APP processing) 
induce defects in chromosomal segregation and aneuploidy. From this they hypothesised, that 
secretion of Aβ peptide alone could be responsible for the cell cycle defects [267]. The 
aforementioned observation led us to speculate that overexpression or mutations of APP695 in 
SK-N-SH cells may be responsible for causing cellular morphological changes and thus mitotic 
defects (Figure 24). As the cells imaged in the microscope were under a blue fluorescent field, a 
blue background was present which however did not affect the cellular structures observed. 
Confirmation of the aneuploidy hypothesis in the transfected cells could occur with further 
experiments such as a karyotype or fluorescence in situ hybridization analysis directly after 
harvesting of the cells. The first technique could allow the identification of chromosome 
abnormalities at the metaphase, while the second to assess chromosomes at all phases of the 
cell cycle. Such experiments could provide us conclusive proofs on these speculations. 
However, as these experiments were outside of the scope of this project, they were not 
conducted.  
Figure 24:  Representative pictures of successfully or unsuccessfully transfected SK-N-SH cells with APP695.  In 
the case of successful transfection, the 40X magnification microscopy pictures of cells overexpressing wild-type 
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(APPWT) or Swedish (APPS) APP demonstrated their neuronal shape and thus their normal morphology. 
However, in the case of unsuccessful transfected cells, the 40X magnification pictures of both APPWT and APPS 
depicted that cells bear morphological defects and thus an abnormal morphology. 
4.3.5  Optimisation of total RNA extraction protocol 
Total RNA isolation was achieved by lysing an actively grown SK-N-SH culture. A range of RNA 
extraction kits was evaluated for their ability to produce RNA with high yield and purity, an 
essential requirement for the cDNA synthesis. Spectrophotometric analysis of the RNA isolated 
from a) the CellSure b) peqGOLD and c) High Pure isolation determined each of the kits’ 
efficiency reported in Table 4. 
Table 4: Quality assessment of RNA isolated with different kits was conducted using spectroscopy, from cells 
overexpressing the wild-type (WT), Swedish (S) or Swedish-Indiana (S-I) APP695 variant.  
Cell type WT S S-I
(a) Cell Sure kit
RNA concentration (ng/μl) 108.5 88.9 109.1 
Absorbance 
260/280 1.27 1.32 1.28 
260/230 1.54 1.62 1.54 
(b) peqGOLD kit
RNA concentration (ng/μl) 98.9 95.9 152.1 
Absorbance 
260/280 1.31 1.34 1.35 
260/230 1.62 1.59 1.55 
(c) High Pure isolation kit
RNA concentration (ng/μl) 266.2 294.5 282.5 
Absorbance 
260/280 2.02 2.01 2.00 
260/230 2.11 2.09 2.29 
The integrity of the total RNA isolated with the most successful protocol ‘high pure isolation kit’ 
was evaluated by gel electrophoresis (Figure 25). The RNA visualised on the denaturing gel had 
discrete and sharp 28S and 18S ribosomal RNA (rRNAs) bands and a wide band bellow the 18S 
rRNA representing the 5S tRNA. The mass ratio of 28S: 18S rRNA was of 2:1. 
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Figure 25: Evaluation of the quality of a total RNA sample isolated with the High Pure RNA kit by gel 
electrophoresis. 
 
As the ‘high pure isolation kit’ provided the most successful RNA extraction, it was selected for 
all subsequent experiments. The isolated RNA was reverse transcribed into cDNA and was used 
to amplify specific genes including housekeeping genes (i.e. β-actin and 18S rRNA) as well as 
UPR markers (i.e. BiP and CHOP). Each of the amplification products was assessed by gel 
electrophoresis (Figure 26). 
 
4.3.6  Optimisation of primer annealing temperatures 
 
In order to investigate the mRNA levels of 18S rRNA, β-actin, APP, ATF4, BiP, CHOP, GAPDH, 
GRP94, Nrf-2, XBP1T, XBP1s via qRT-PCR, the specific conditions (annealing temperature and 
number of cycles) for each of the genes were tested via gradient PCR from 50-65 ºC. The 
amplified temperatures tested were the followings:  49.5, 49.8, 51.7, 54.7, 59.7, 62.7, 64.4 and 
64.5 ºC.  
Determination of the cellular mRNA levels of the housekeeping genes 18S rRNA (Figure 26a) β-
actin (Figure 26c) and GAPDH (Figure 26g) was achieved by firstly designing specific primers to 
amplify a 171 bp, 383 bp, and 102 bp product respectively. The PCR at 64.5 ºC amplified a single 
bright band of the correct size for each of the housekeeping genes. Next, evaluation of whether 
the transfections were successful was achieved by a comparison of the APP mRNA levels of the 
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transfected with the nontransfected cells. To do this, primers specific for APP (Figure 26c) were 
designed to amplify a 199 bp product and did so successfully at 64.5 ºC as seen by the bright 
and intact PCR product on the gel electrophoresis. 
Analysis of the PERK activation was achieved by investigating ATF4 (Figure 26d), CHOP (Figure 
26f) and Nrf-2 (Figure 26i) expression levels. Specific primers for these genes were designed to 
amplify a 226 bp, 62 bp and 171 bp PCR product respectively. Gel electrophoresis provided 
evidence that all of the aforementioned primer pairs successfully amplified the correct product. 
The primers for CHOP although they did not amplify the template at 54.7 °C, an amplification 
product with the correct size was observed at 64.5 °C. 
In order to assess the expression of the chaperones BiP (Figure 26e) and GRP94 (Figure 26h), 
specific primers were designed to amplify a 232 and 220 bp product respectively, which did so 
as determined by the yield of the PCR product. 
Analysis of ATF6 activation was performed in part by examining the XBP1T and CHOP mRNA 
levels whereas of IRE1 activation by the XBP1s mRNA levels. Primers of the XBP1T were 
designed on one side of the intron so that the amplifying products derived from the XBP1s and 
XBP1u were of the same size (single band). The first primer pair designed to produce a 513 bp 
product (Figure 26j), however it amplified more than one band at 64.5 ºC, which was the 
highest temperature used. For this reason, a second primer pair was designed to amplify the 
441 bp long XBP1T (Figure 26k). At a low temperature (54.7 ºC), a very faint band at the correct 
size was visible while at 64.5 ºC the product was brighter. In a similar manner primers designed 
to amplify the XBP1s transcripts, produced a very faint band at a 54.7 °C while at 64.5 °C a 
brighter band was present (Figure 26l). 
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Figure 26: PCR amplification products of primers amplifying the house-keeping genes and the UPR markers with 
the following order: (a) 18S rRNA, (b) β-actin, (c) APP, (d) ATF4, (e) BiP, (f) CHOP, (g) GAPDH, (h) GRP94, (i) Nrf-2, 
(j-k) total XBP1, (l) spliced XBP1.  
 
4.3.7  Amplification efficiencies  
 
Amplification efficiencies for all primer pairs were determined by PCR. This was calculated by 
preparing serial dilutions of the initial cDNA template [262].  Following RNA extraction from SK-
N-SH cells, the mRNA was reverse transcribed and the cDNA was diluted to the following 
concentrations: 0.05, 0.1, 0.5, 1, 1.5 and 2 μg/μl which were then used for the generation of a 
standard curve and calculation of the corresponding efficiencies (Appendix II). 
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Table 5: Primer pair characteristics. 
Gene Primer Pair 
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GenBank accession N˚ 
18S rRNA 
F GTAACCCGTTGAACCCCATT 
171 64.5 40 1.96 M10098 
R CCATCCAATCGGTAGTAGCG 
β-actin 
F AAACTGGAACGGTGAAGGTG 
383 64.5 40 1.95 NM001017992.2 
R AGAGAAGTGGGGTGGCTTTT 
APP 
F GGCCCTGGAGAACTACATCA 
199 64.5 40 1.93 NM201414 
R AATCACACGGAGGTGTGTCA 
ATF4 
F TCAAACCTCATGGGTTCTCC 
226 64.5 40 1.93 NM001675 
R TGTCATCCAACGTGGTCAG 
BiP 
F TGGTGTTTGACCTGGGTGGCGGA 
232 64.5 40 1.96 NM005347 
R AGGGCCTTGGCCTTTTCTACCTCG 
CHOP 
F CTCTGGCTTGGCTGACTGA 
62 64.5 40 1.96 NM004083 
R GCTCTGGGAGGTGCTTGT 
GAPDH 
F CCACTCCTCCACCTTTGAC 
102 64.5 40 1.93 NM002046 
R ACCCTGTTGCTGTAGCCA 
GRP94 
F TGGGAAGAGGTTCCAGAATG 
220 64.5 40 1.95 NM003299 
R GTTGCCAGACCATCCGTACT 
Nestin 
F AGCCCTGACCACTCCAGTTTAG 
128 64.5 40 2.06 NM006617  [268] R CCCTCTATGGCTGTTTCTTTCTCT 
NFM 
F GTCAAGATGGCTCTGGATATAGAAATC 
104 64.5 40 2.08 NM 001105541 [269] R TACAGTGGCCCAGTGATGCTT 
Nrf-2 F GCGACGGAAAGAGTATGAGC 161 64.5 40 1.96 NM 001145412 
R GTTGGCAGATCCACTGGTTT 
XBP1T F AGGCCCAGTTGTCACCCCTCC 441 64.5 40 1.96 NM 001079539 R CCCAGCTCCGGAACGAGGTCA
XBP1s F CCGCAGCAGGTGCAGG 70 64.5 40 1.97 NM005080 R GAGTCAATACCGCCAGAATCCA
To confirm precision and evaluate reproducibility of the qRT-PCR, inter-assay variation was 
tested for all transcripts. The degree of variation was calculated for each gene by dividing the 
mean of the cycle threshold (Ct) values by the standard deviation (SD), giving the coefficient of 
variation (CV), which was presented as a percentage (%CV). All of the qPCR experiments 
displayed less than 3.9% dispersion of their Ct values indicating high expression stability 
between both the samples and the replicates. 
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Table 6: Coefficient of variation expressed as a percentage (%CV) in the qRT-PCR replicates (n=3). 
Gene of interest/ %CV Cell type 
WT S S-I 
18S rRNA 0.43 0.42 0.25 
APP 0.24 0.47 0.97 
ATF4 0.55 1.09 0.31 
BiP 0.94 0.77 1.35 
CHOP 0.18 0.52 0.20 
GRP94 0.51 1.36 0.36 
Nrf-2 0.45 0.54 0.49 
Total XBP1 0.36 0.54 1.33 
Spliced XBP1 0.90 0.82 0.70 
 
4.3.8  Housekeeping genes 
 
Quantification of the expression levels of a target gene requires the parallel transcript 
quantification of a control gene for the endogenous normalisation, which is critical for data 
evaluation. The most widely used endogenous control is β-actin as it represents a cornerstone 
of the internal architecture of the cell necessary for cellular function. However, studies have 
shown that its expression may not be stable in certain conditions such as under morphological 
cellular changes during neuronal differentiation [270].  
 
Thus, three potential housekeeping genes were tested and compared in both differentiated and 
non-differentiated cells: β-actin, GAPDH and 18S rRNA. The stability of the expression of the 
housekeeping genes under differentiated experimental conditions was evaluated with the %CV 
(Table 7) and provided evidence that 18S rRNA had the least variability. The amplification 
efficiency obtained for 18S rRNA was 1.96 and the R2 was 0.99. Out of these observations, 18S 
rRNA was judged the most suitable normalization factor for this work. Previous studies have 
also demonstrated 18S rRNA to be a superior normalizer by displaying the lower variation in 
response to a given stimulus in a wide range of cell types [271, 272].  
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Table 7: Evaluation of the variation (%CV) of (a) all the housekeeping genes compared between the different cell 
lines (APPWT, APPS and APPS-I) and (b) 18S rRNA variation in APPWT in response to a stimulus of cellular 
differentiation (RA= retinoic acid) or ER stressors (TM=tunicamycin).   
(a) Gene of interest/Ct values Cell type %CV WT S S-I 
β-actin 18.15 16.16 14.32 11.82 
GAPDH 17.94 15.25 16.20 8.29 
18S rRNA 13.80 12.30 13.21 5.77 
 
(b) Gene of interest/Ct values Conditions used in WT %CV Control RA TM 
18S rRNA 13.85 14.98 13.38 5.84 
 
4.2.4 Quantification of APP expression in transfected cells 
To establish a model system of FAD-associated genetic predisposition, three human SK-N-SH 
neuroblastoma cell lines were created, overexpressing wild-type (APPWT) and mutant; Swedish 
(APPS) and Swedish-Indiana (APPS-I, collectively called APPMUT) APP. Verification of the stable 
transfections was first examined with qRT-PCR using template from the different cell lines and 
APP primers. The APP mRNA levels were normalised to the housekeeping control 18S rRNA and 
the expression levels of the transfected cells were then compared to the non-transfected cells. 
The data confirmed that the APP expression in transfected cell lines was in all cases more than 
two-fold higher compared to the non-transfected cells (Figure 27a). Consistent with the qRT-
PCR results, Western Blot showed overexpression of APP695 in transfected cells thus defining 
the success of the transfection (Figure 27b). Thus, as was expected, the transfected cells 
demonstrated an increased expression of APP levels compared to non-transfected cells both at 
the mRNA and protein level. 
 
 
 
 
 
 
 
108 
A cell model system of familial Alzheimer’s disease  
 
 
Figure 27: Quantification of APP expression. (a) Expression levels of APP mRNA in APPWT, APPS and APPS-I 
measured with qRT-PCR and compared to the non-transfected (NT) cells (mean=3; ±SD) and (b) Western blot 
indicating APP overexpression in stably transfected SK-N-SH cells. β-actin was used as a loading control. The 
protein ladder was visualised using chromogenic detection (with white light) while the APP and β-actin proteins 
with chemilluminescence (with UV) in the same image analyser. Statistical significance of p<0.001 was denoted 
with three stars.  
 
4.2.5 Cell differentiation 
SK-N-SH cells can be differentiated with the treatment of various agents. All-trans-retinoic acid 
(RA), a vitamin A-derived small lipophilic molecule is the most common differentiation agent 
used that influences both non-transfected and transfected cells. It co-ordinately promotes 
cellular differentiation and regulates gene expression mechanisms [273-275]. Several studies 
have reported the use of RA for cell differentiation, each of them using different concentrations 
and incubation times. For instance, Irving et al. [276] induced neuronal differentiation with a 1 
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μM RA concentration for five and nine days, while Wainwright et al. [277] used 10 μM RA with 
a treatment of three to 14 days, demonstrating differentiation to occur after day three.  
To optimise the differentiation protocol cells were tested with 3 μM, 5 μM and 10 μM RA in 
order to assess the amount needed. Cells were considered as differentiated when they had at 
least one process (neurite) that was bigger in length than the cell body (Figure 28). Previous 
studies demonstrated that differentiated post-mitotic neurons derived either from wild-type or 
V642-APP (London type mutation) knock-in embryonic stem cells exhibit similar characteristics 
[278], suggesting that the use of either APPWT or APPMUT for identifying the ideal RA treatment 
conditions would provide us with the same outcome. Therefore, APPWT were used in order to 
optimise the differentiation conditions, which were kept constant for all the cell lines. Each 
experiment involved seven observations of APPWT from three biological replicates while always 
comparing them back to the control (untreated) cells using light microscopy. Control cells as 
seen in Figure 28 were highly dense after nine days of culture and exhibited a spherical shape. A 
clearer picture of their spherical shape was observed when the control cells were cultured for 
fewer days  (five days) as seen in APPS cells in Figure 30, where cell confluence was lower 
compared that after nine days of culture. 
Treatment of APPWT with RA for nine days induced their differentiation process to some extent 
even under the conditions where the lowest RA amount (3 μM) was used. It also resulted in a 
decreased confluence caused possibly either by growth inhibition or by higher rates of cell 
death rates. However, a higher RA concentration seemed necessary to achieve a higher number 
of cells with neuronal characteristics. Indeed as seen in Figure 28, a 10 μM of RA treatment was 
required to induce the phenotypical processes in most cells including neuronal differentiation 
and neurite outgrowth.  
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Figure 28: Microscopic inspection of differentiated APPWT. Technical replicates of cells cultured with different RA 
concentrations for nine days. 
 
Neuronal characterisation is often evaluated primarily by the morphological features and then 
by the biochemical properties (gene expression). Many reports have described a wide range of 
neuronal markers to aid the cellular characterisation process [279].  Some of the most common 
markers used for neuronal differentiation include the nestin and the neurofilament medium 
polypeptide (NFM) genes.  
Nestin is an intermediate filament protein of the cytoskeleton expressed early in the 
development of the CNS and induces survival and cell proliferation [280]. During the cellular 
differentiation, nestin is replaced by other specific intermediate filaments and its mRNA 
expression gets quickly downregulated [281]. On the other hand, NFM is encoded by the 
intermediate filament protein and is expressed in a wide range of neuronal cells providing both 
axonal and structural support while also modulating the axonal diameter [282].  Studies of 
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synovium-derived mesenchymal stem cells differentiated with RA treatment into neuronal cells 
showed upregulation of their NFM transcript levels [283]. Therefore, qRT-PCR analysis of nestin 
and NFM was used to confirm their differentiation. For this, cells were treated with RA for nine 
days with 3, 5 and 10 mM RA (Figure 29). 
 
 
 
Figure 29: Biochemical characteristics of differentiated APPWT. Relative expression levels of Nestin and NFM in 
APPWT under a) nine days of RA-treatment altering the RA concentration, b) 10 μM RA-treatment at different 
days of treatment. Data are presented in relation to the mRNA levels of a) the zero RA concentration or b) zero 
hours of RA treatment (n=3; mean ±SD). Statistical significant differences of the different treatments compared 
with the zero concentration or time point *p<0.05, **p<0.01, ***p<0.001.  
 
Figure 29a illustrated that the amount of 5 μM RA was enough to significantly downregulate 
the nestin mRNA expression levels after nine days of treatment. However, the NFM marker, 
which was supposed to be upregulated upon cellular differentiation, remained low. Treatment 
of cells with an increased RA concentration of 10 μM induced significant upregulation of NFM 
transcripts, as expected, but nestin mRNA levels were also high. As it has been previously 
demonstrated that nestin expression can be re-induced following injury of the CNS [284], we 
speculated that the increase in nestin mRNA levels might have been caused by a stress factor 
such as the overexpression of APP695.  
Following the optimisation protocol, the amount of 10 μM RA was used and cells were treated 
for a shortened period of time (five days) as well as for nine days used as a reference to the 
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previous experiment. Figure 29b illustrated that cells treated with 10 μM RA for five days; 
exhibited significant downregulation of nestin transcripts as well as significant upregulation of 
NFM transcripts, an expected biochemical profile corresponded to neuronal cells.  
Subsequently of the biochemical analysis, morphological evaluation of the cells treated with 10 
mM RA for five days was verified. Figure 30 shows that untreated cells (control) exhibited a 
clear rounded body while RA-treated cells possess distinguished axons and have generated 
neuronal networks.  
 
 
 
Figure 30: Microscopic inspection of differentiated APPS. Cells were treated with 10 μM RA for five days. 
 
The biochemical analysis in combination with the physiological study confirmed that 10 μM of 
RA for five days were the optimal conditions required to induce markedly morphological and 
gene expression changes and thus to successfully generate SK-N-SH cells with a neuronal 
identity. These conditions were also the ones used by Chafekar et al. [173] to differentiate SK-
N-SH cells overexpressing either the WT or Indiana APP695 isoform.   
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4.2.6  Pre-upregulation of ER stress in APP transfected cells 
 
Based on microscopic evaluation, cell confluence monitoring did not demonstrate any major 
differences with regards to the rate of growth and the viability of the transfected APP695 cells 
and the non-transfected cells. Despite that, whether APP695 overexpression and/or APP695 
point-mutations pre-upregulate ER stress in our FAD-cell lines, as has been previously 
suggested [74, 173] was not yet known. In order to assess whether transfected cells pre-
upregulated ER stress, a range of seven markers of the UPR signalling were assessed with qRT-
PCR.  
 
Initially, the expression of two chaperones (BiP and GRP94) was investigated the levels of which 
were compared between the non-transfected and the transfected with APP695 cells. The data 
(Figure 31) indicated that only APPS exhibited a significant 4.5-fold increase in BiP expression 
levels when compared to the non-transfected cells.   
 
 
 
Figure 31: Chaperones expression induced by APP overexpression. The results are presented in relation to the 
mRNA levels of the non-transfected cells (n=3; mean ±SD). Statistical significant differences of APPWT APPS and 
APPS-I compared with the non-transfected cells are indicated *p<0.05, **p<0.01, ***p<0.001.  
 
Following several experimental approaches, Laing et al. [285] indicated that ER-stress induced 
apoptosis mediated by the PERK signalling selectively promoted ATF4 and CHOP expression 
while other studies also demonstrated PERK activation to promote survival through increased 
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Nrf-2 expression [286]. We thus evaluated PERK signalling through expression of ATF4, Nrf-2 
and CHOP mRNA (Figure 32). Our results indicated APPWT and APPS to overexpress ATF4 relative 
to the non-transfected cells (p-value of 0.037 and 0.001, respectively) while the ATF4 mRNA 
levels of APPS were also significant upregulated when compared to the transfected APPWT and 
APPS-I  (p=0.04 and 0.01, respectively). The 6.5-fold upregulation of ATF4 transcripts in APPS 
probably further led to a pre-upregulation of CHOP mRNA of ~8-fold (p=0.032) compared to 
non-transfected cells. Therefore, preliminary data provided an indication of the PERK activation 
signalling in APPWT and APPS, a pathway mainly responsible for translation attenuation. 
However, as ATF4 is regulated at a translational level, analysis of its protein levels would be a 
better indication of PERK activation induced by APP overexpression. 
 
 
 
Figure 32: PERK activation induced by APP overexpression. The results are presented in relation to mRNA levels 
of the non-transfected cells (n=3; mean ± SD). Statistical significant differences of APPWT APPS and APPS-I 
compared with the non-transfected cells are indicated *p<0.05, **p<0.01, ***p<0.001. 
 
The IRE1 ER-stress sensor is an important UPR regulator as it induces splicing of XBP1 mRNA 
affecting cellular fate. On the other hand, XBP1T is regulated by the ATF6 activation, making 
analysis of both XBP1s and XBP1T of high importance. The results showed XBP1s transcripts to 
be significantly overexpressed by a ~7-fold in both APPS and APPS-I compared to non-
transfected cells (p=0.004 and 0.003, respectively) (Figure 33). The XBP1s transcripts in APPS-I 
were also significantly higher than in APPWT (p=0.043). This led us to hypothesise that the UPR 
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in mutant cells may be activated through the IRE1 pathway, which is responsible for the 
upregulation and expression of ER chaperones. On the other hand, total XBP1 mRNA levels 
were upregulated in all transfected cells when compared to the control (non-transfected cells) 
(p=0.002 for APPWT and p=0.001 for APPMUT), suggesting possible ATF6 activation in all cell 
lines. 
 
 
 
Figure 33: IRE1 and ATF6 activation induced from APP overexpression. The results are presented in relation to 
mRNA levels of the non-transfected cells (n=3; mean±SD). Statistical significant differences of APPWT APPS and 
APPS-I compared with the non transfected cells are indicated *p<0.05, **p<0.01, ***p<0.001.  
 
These preliminary data indicated the differences in the UPR genes expression levels between 
the non-transfected and the transfected cells under a non-induced environment. They 
suggested a pre-upregulation of the UPR markers caused by the overexpression of APPWT or 
APPMUT. The upregulated ATF4, XBP1s and XBP1T genes seen are known to also be responsible 
for restoration of cellular homeostasis [287]. On the other hand the pro-apoptotic CHOP 
marker exhibited an 8-fold increase only in the APPS (p=0.032).   
A possible explanation of the ER stress pre-upregulation observed in APPS and APPS-I may have 
resulted from the formation and accumulation of misfolded proteins. Their formation could 
have resulted from the APP mutant mediating protein folding destabilization [7] while their 
accumulation from the re-internalisation of protein aggregates by endocytosis [288].    
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Nishitsuji et al. [74] have previously reported E693Δ APP mutation to increase ER stress without 
the additional treatment of any agents. More specifically, analysis of p-eIF2α protein levels in 
mock-transfected cells (positive control) and cells overexpressing wild-type and E693Δ APP 
mutant demonstrated increased phosphorylation of eIF2α in the mutant cells. Wild-type cells 
also had elevated p-eIF2α levels compared to the positive control. In parallel, BiP protein levels 
were more abundant in mutant than wild-type cells and demonstrated that mutant cells have 
an increased ER stress response [74]. These show that APPWT alone or APPMUT can pre-
upregulate ER stress, which is in accordance with our observations.  
 
4.2.7  Artificial induction of ER stress 
Several drugs are available to use in order to model specific stress responses and to perturb the 
protein folding process in the ER. Examples include DTT, which affects disulphide bond 
formation, TM, which inhibit protein glycosylation, brefeldin A, which blocks the transport from 
the ER to the Golgi apparatus, and Tg, which inhibits the sarco/ER Ca2+ ATPase pump causing 
disruption of disulphide bond formation and thus mediating depletion of Ca2+ in the ER stores 
[289, 290]. TM and Tg mechanisms of action do not rely on altering the ER redox state of the 
cells. This is in contrast to the DTT mechanism, which perturbs the ER by reducing the oxidising 
species and altering the redox state, thus making DTT a non-specific ER stress-inducing agent 
[291, 292].  
As our aim was to investigate the UPR activation caused directly by the accumulation of 
unfolded proteins in the ER and not promoted by reductive stress, DTT was ruled out from our 
choices. A reductive environment (induced by DTT) could have not only lead to accumulation of 
misfolded proteins but also could have affected several protein functions and influence 
numerous cellular processes (i.e. mitochondrial dysfunction) [293]. For these reasons, TM 
(Figure 34), known for its ability to activate all three UPR branches and induce translation 
attenuation as well as cell death was chosen [294, 295].  
Induction of stress in our cell-model system was achieved by treatment with the TM ER stress- 
inducing agent. This agent is composed of a mixture of ten or more individual nucleotide sugar 
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analogues fatty-acylated with N-linked acyl chains varying in length and degree of unsaturation.  
It is naturally produced by several Streptomyces bacteria species such as Streptomyces 
clavuligerus and Streptomyces Iysosuperficus. TM-treatment is used to block the N-linked 
glycosylation, which inhibits protein folding at a slow rate, and activates the UPR [256, 296].  
 
 
 
Figure 34: Molecular structure of tunicamycin (TM) isolated from Streptomyces lysosuperficus.  
  
4.2.8 Stress activation using TM-ER stress inducing agent  
An ‘artificial’ induction of ER stress in our SK-N-SH cells was carried out with TM-treatment. The 
concentration of TM used was 1 μg/ml as it has been previously demonstrated to activate ER 
stress in differentiated SK-N-SH cells [290]. Oda et al. [290] showed that this concentration was 
the minimum amount needed to upregulate chaperones in a time-dependent manner and to 
cause a significant decrease of the cell viability at 24 h. Additionally, Samali et al. [130] used the 
same TM concentration to induce ER stress while Waechter et al. [297] showed that 1 μg/ml of 
TM inhibited protein glycosylation of neuroblastoma cells by 80-94%. In agreement with these 
findings, our data demonstrated that at 24 h of TM-treatment, the mRNA expression levels of 
the chaperones BiP and GRP94 were indeed significantly upregulated compared to untreated 
cells (Figure 35). 
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Figure 35: Expression of UPR markers in non-transfected cells. Cells were either non-stressed (0 μg/ml TM), or 
treated with 1 μg/ml of TM for 24 h. The results are presented in relation to mRNA levels of non-stressed cells 
for each respective gene (n=3; mean±SD). Statistical significant differences of the UPR associated mRNA levels of 
cells treated with TM compared with the non-treated cells are indicated *p<0.05, **p<0.01, ***p<0.001. 
 
4.2.9  Optimisation for the MTS assay 
In order to assess the metabolic activity of cells, the MTS colorimetric assay was used. This 
assay is based on the bioreduction of MTS tetrazolium compounds into coloured formazan by 
mitochondrial dehydrogenases (Figure 36). During this assay, only the viable and metabolically 
active cells reduce/cleave the MTS reagent into a water-soluble formazan product (from yellow 
to dark blue) indicating the number of cells whose metabolism is still active [298]. It further 
allows quantification of the number of cells whose metabolism has been disrupted, by a 
deduction of the signal from the controls (non-TM treated cells).  
 
 
 
Figure 36: Structure of the MTS tetrazolium compound and the conversion to formazan product.  
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As different cell lines have different metabolic activities, a serial cell dilution was performed in 
96 well microplates to test specifically whether our cell lines exhibited a linear relationship 
between the cell number and the signal produced. Recordings of the absorbance (Figure 37a) 
illustrated a good linearity (R2=0.99) with the SK-N-SH cells cultured.  
In order to eliminate the possibility of chemicals affecting the absorbance measurements, the 
recordings of non-transfected cells were evaluated with the MEM alone or in a combination of 
MEM and specific chemicals used including TM, RA, or the antibiotic G418. These drugs 
exhibited a very low background absorbance therefore they did not have a significant effect on 
the signal produced (Figure 37b). 
 
 
 
Figure 37: Examining MTS conditions. a) Linear relationship between cell number and absorbance values, b) 
effect of different chemicals in the background signal. (n=3; mean±SD) 
 
Cell numbers must be sufficient in order to provide information on possible differences in their 
metabolic activity under specific conditions, but overgrowth must be avoided as it leads to 
activation of various stresses. A total number of 5×104 cells/well in a 96 well microplate was 
used to determine and compare the absorbance at 490 nm of differentiated versus non 
differentiated non-transfected cells. There was no variability observed in the readings between 
the non-neuronal and neuronal cells (cells with RA). The non-transfected cells (without RA) 
were treated with TM for 24 h. This treatment induced a significantly lower absorbance, 
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indicating a decrease in the metabolic activity caused by either cell cycle arrest or apoptosis 
(Figure 38a). 
 
 
 
Figure 38: Optimisation of MTS assay for TM treated cells. a) Analysis of the effect of TM-treatment in 
differentiated SK-N-SH cells. The results are presented in relation to the relative absorbance of the non-
chemically treated cells (n=3; mean±SD). b) Optimisation of the lower cell number used to capture the TM-
induced effect in the MTS assay. The results are presented in relation to the relative absorbance of control cells 
(n=3; mean±SD). Statistical significant differences of cells treated with TM and/or RA compared with the non-
treated cells are indicated *p<0.05, **p<0.01, ***p<0.001. 
 
The manufacturer of the MTS kit provides a protocol for performing the assay with cells in 96-
well plates. However, as the experiments involved neuronal cells and consistency between 
seeding densities among the different experiments was preferred, cells were plated in 6-well 
plates. A range of cell numbers was assessed in different wells prior to the addition of the dye. 
The total number of 1.6×106 cells was demonstrated to be the lowest needed in the 6-well 
plates in order to be able to detect a significant effect from the TM-induction when compared 
to the untreated (control) non transfected cells (Figure 38b). 
 
4.4  Discussion 
 
To investigate the UPR induction mechanism in response to ER stress in AD pathology, a cell 
model system was generated with human neuroblastoma SK-N-SH cells overexpressing either 
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wild-type, Swedish or Swedish-Indiana APP695. Verification of successful transfection was 
performed with qRT-PCR and Western blot analysis. Expression of APP was significantly higher 
in APPWT, APPS and APPS-I relative to non-transfected cells, which confirmed the successful 
generation of a FAD-model system. The qRT-PCR data illustrated APPS to exhibit a slight but 
significant higher increase of APP levels relative to APPWT and APPS-I. The non-transfected cells 
were expressing APP, which was expected as the respective endogenous protein is ubiquitously 
expressed [299]. 
The role of APP in the induction of ER stress-induced apoptosis is a matter of current debate. 
Previous studies have indicated that in the absence of chemical ER stress inducing agents (i.e. 
TM, DTT), overexpression of APP alone can overwhelm or disrupt the protein folding machinery 
triggering ER stress [300]. More specifically, Nishitsuji et al. [300] showed that in the absence of 
a pharmacological agent, the UPR markers (BiP, p-eIF2α) and cell death markers (CSP4) were 
upregulated in HEK293 cells that were overexpressing wild-type or Swedish APP [300]. 
Furthermore, Takahashi et al. [301] found that overexpression of APP leads to induction of 
CHOP mRNA and reduction of cellular viability. 
We thus initially examined whether SK-N-SH cells overexpressing wild-type or FAD-mutant APP 
exhibited ER-stress signalling downstream UPR activation and whether its expression was 
differential relative to the APP mutations. Our findings showed that APP overexpression alone 
could trigger the pre-upregulation of ER stress. Analysis showed that not all genes were 
significantly upregulated compared to the parental cell line (non-transfected). Overexpression 
of ATF4 transcript was observed in both APPWT and APPS, increase of XBP1s transcript in APPS 
and APPS-I while increase of BiP and CHOP mRNA only in APPS. The data also suggested that the 
highest pre-upregulation of UPR markers occurred in the APPS cells. The stronger response was 
exhibited by APPS as seen by the CHOP transcripts that had a seven-fold increase. It is worth 
noting that the magnitude of the stress response was lower compared to the magnitude of 
stress from TM-induction (seen in Chapter 5), illustrating that cells were mildly stressed. The 
above data provide evidence that even in the absence of chemical ER stressors (i.e. TM) 
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overexpression of the wild-type and FAD-associated APP695 activates stress signalling and it 
does so with a low magnitude.   
Findings from other studies suggested that APP overexpression does not induce ER stress 
activation. Kogel et al. [302] demonstrated with the use of rat pheochromocytoma cell line 
PC12 that expression of wild-type or mutant APP has no effect on BiP and CHOP expression and 
thus on UPR activation. In agreement with the aforementioned study were the findings of 
Chafekar et al. [173]. SK-N-SH human neuroblastoma cells overexpressing wild-type or Swedish 
APP did not exhibit any differential basal levels of the UPR markers (BiP, CHOP and XBP1s) when 
compared to the parental cell line [173].   
The fact that various studies have reported different effects caused from the APP 
overexpression may be due to several reasons. Firstly, the expression levels of the APP probably 
differ in between the different studies. A higher APP expression level could probably induce the 
highest intracellular Aβ concentration. High concentration of the toxic Aβ may result to its 
aggregation as well as to the inhibition of the APP neuroprotective effect, which could 
eventually triggering stress. Secondly, the densities of cells studied vary among the studies. 
Cells cultured in high confluence may exhaust the nutrients in the media and cause stress, while 
a lower cell number may be insufficient to observe the stress effect.  
As the next goal of the project (Chapter 5) involved the evaluation of the ‘artificial’ induction of 
ER-stress, human neuroblastoma cells were differentiated to obtain morphological and 
biochemical characteristics of mature neurons. This was achieved by optimisation of the RA 
treatment protocol. Schule et al. [303] also reported that RA-differentiated cells consist of a 
better cellular model system compared to undifferentiated cells. This was stated as non-
differentiated cells were demonstrated to be more susceptible to toxicity compared to the 
differentiated ones and thus less suitable for the toxic studies in the nervous system [303]. 
Next, a specific pharmacological agent was chosen to artificially induce ER stress. For this effect, 
TM, which inhibits the early steps in the biosynthesis of N-linked glycans in the ER, was used. 
Based on previous studies in SK-N-SH cells, the amount of TM was confirmed along with the 
duration of treatment in our system. Metabolic activity of the cells during various time points of 
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stress was assessed with the MTS assay. This allowed us to optimise the conditions for 
conducting the MTS assay for our cell system. Overall, the above experiments enabled us to 
establish the conditions required for evaluating the stress response triggered by chemical 
induction, which is presented in the following chapter. 
 
4.5  Conclusion 
 
The findings from the characterization of UPR markers suggest that overexpression of APP695 
alone can induce mild preconditioning of ER stress and that overexpression of APPMUT induced a 
stronger stress response than APPWT. Further work is necessary to confirm these observations. 
The next chapter discusses the chemical activation of ER stress, which was carried out to 
examine whether overexpression of APPWT and APPMUT exacerbates ER stress and to elucidate 
the timing of pro-survival versus pro-apoptotic signals triggered by UPR. 
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Chapter 5 
Progression of UPR in a cell model system 
of familial Alzheimer’s disease 
 
 
 
5.1   Introduction  
 
Despite the increased number of studies focused on the role of individual steps initiated by 
distinct UPR branches, the timing and progression of the ER stress response in mammalian cells 
is not well understood. For instance, it is not well known whether all three ER stress 
transmembrane receptors (IRE1, PERK, and ATF6) are activated at the onset of ER stress or 
whether their induction follows a sequential order. Previous data have suggested that in 
response to ER stress, activation of the ATF6 signalling is rapid and precedes XBP1 splicing 
mediated by IRE1. Subsequently, the activated ATF6 pathway triggers transcriptional induction 
of ER chaperone genes prior to the IRE1-XBP1 pathway [304]. Lin et al. [305] have confirmed ER 
stress to activate all three UPR branches and to promote survival. The way that the pro-
apoptotic and anti-apoptotic responses integrate to choose between a survival and death 
decision remains unknown. Under conditions of prolonged stress, IRE1 and ATF6 signalling were 
attenuated while PERK pathway remained activated (Figure 39) [305]. It is not well understood 
whether dissociation of BiP is simultaneous from the three transmembrane receptors or 
whether IRE1 activation takes longer because XBP1 processing has multiple steps. It also 
remains unclear whether all IRE1, ATF6 and PERK pathways are fully activated or whether there 
is a synergistic effect to promote the response if the stress has not been completely resolved. 
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The timing of the stress response is important to identify specific steps that allow fine-tuning of 
the ultimate fate of the cell (survival or apoptosis). Identification of such key steps could help to 
pave the way for developing novel small target molecules for therapeutics. This chapter 
describes the investigation of the timing of stress induction by analysing the system’s response 
at early time points following the application of chemical stress. 
 
 
 
Figure 39: UPR signalling throughout time. Accumulation of misfolded proteins in the ER induces stress, which 
induces the activation of the UPR. This response induces the activation of three ER membrane sensors (IRE1, 
ATF6 and PERK) at different times in order to first restore homeostasis or trigger cell death if the response is 
prolonged. Figure adapted from [305]. 
 
The SK-N-SH human cell lines overexpressing either the wild-type or mutant APP protein were 
differentiated (with RA) and chemically treated with TM (a well-characterised ER stress 
inducer), the latter preventing protein glycosylation and causing a build-up of unfolded proteins 
in the ER [84, 306]. Differentiated cells validated by their morphology and expression of 
neuronal markers, were analysed for the stress response imposed by the intra-and extra- 
cellular stresses (mutations and TM-treatment, respectively) at six different time points (0 h, 3 
h, 4 h, 6 h, 8 h, 24 h). Seven UPR genes were examined including chaperones and markers in the 
UPR pathway downstream of all three ER-sensors receptors (IRE1, PERK, and ATF6) and 
apoptotic factors. This allowed us to assess the specific signalling pathways activated from cells 
over-expressing different APP isoforms. By inducing ER stress and capturing the response at 
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early time points in a quantitative manner, we sought to better understand the progression of 
UPR in FAD. 
Initially, cell viability at each time point was determined by the trypan blue exclusion method 
and metabolic activity was assessed with the MTS assay. Subsequently, qRT-PCR was used to 
analyse the gene expression levels of genes BiP, GRP94, ATF4, Nrf-2 spliced XBP1 (XBP1s), total 
XBP1 (XBP1T), and CHOP from a population of n=5 from two independent experiments.  
 
 
 
Figure 40: Schematic representation of the UPR-genes induced by ER stress (ATF4, Nrf-2, CHOP, XBP1T, XBP1s 
and BiP) and the interconnectivity between the different ER-stress receptors (IRE1, PERK and ATF6) 
 
5.2   Results 
 
5.2.1  Cell’s initial response to stress is an attempt at adaptation  
 
Evaluation of the effect of TM-treatment on the metabolic activity and the cellular viability was 
achieved with the MTS and trypan-blue exclusion methods, respectively. MTS assay data 
indicated a reduction in metabolic activity at six hours of TM-treatment in all APPWT, APPS, and 
APPS-I (p=0.029, p=0.002 and p=0.001, respectively) with respect to zero hours (Figure 41a). This 
decrease was ~20-25% in all cell lines, with the lowest activity being measured in APPS. This 
drop in absorbance was unusual, as the data of up to four hours of TM treatment didn’t 
indicate any gradual decrease in the cells’ metabolic activity. Further investigation in this drop 
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would include the evaluation of the cells’ activity at five as well as seven hours of TM-
treatment. However, as the scope of the project was not focused on the cells metabolic activity 
from a stress stimulus, these time points were not investigated. At eight hours of TM-
treatment, APPS and APPS-I appeared to recover, as cells exhibited a significant up-regulation of 
their metabolic activity when compared to the six hours samples (p=0.027 and p=0.011, 
respectively). Although the APPWT also seemed to recuperate at eight hours, the increase of the 
metabolic activity was not statistically significant. This may possibly be explained by the fact 
that at six hours of TM-treatment, APPWT had the lowest average reduction in activity (with 
respect to zero hours) of all the cell lines. However, 24 h of TM-treatment showed a significant 
~40% drop of the absorbance in all cell lines when compared to zero hours, which could be 
resulted either from cell cycle arrest or cell death. 
 
Further analysis with the trypan-blue dye exclusion method showed that, with one exception 
(APPS at six hours of TM-treatment), cell viability was not significantly decreased up to eight 
hours (Figure 41b). After 24 h of treatment only the APPS had a significantly reduced viability 
compared to the starting population. 
 
 
 
Figure 41: Effect of TM on proliferation and cell viability in a FAD cell-model system. Cell proliferation and 
viability of differentiated stressed cells were analysed by (a) MTS assay and (b) trypan blue dye exclusion 
method following the incubation of cells with TM for the indicated time points. Values represent the means for 
(a) n=3; ±SD and independent of (b) representing two independent experiments where the technical replicates 
for each experiment were n=3 and n=2 respectively ±SD. For 24 h the means are from the n=3 only. The results 
 
 
128 
Progression of UPR in a cell model system of familial Alzheimer’s disease  
are presented in relation to the zero hour TM-treatment. Statistical significant differences demonstrated on the 
graph are from cells treated with TM for zero hours compared with the cells treated with TM for 3 h, 4 h, 6 h, 8 h 
or 24 h respectively  *p<0.05, **p<0.01, ***p<0.001. 
 
However, as the blue coloration of cells with the trypan blue dye indicated cell death but not 
cell lysis, the live cells count was also evaluated (Table 8). All three cell lines revealed a 
significant decrease in the living cell count at 24 h of TM-treatment compared to the starting 
population, which for APPWT and APPS was p<0.001 while for APPS-I was p<0.05. These data 
suggested that a number of cells died and some of them lysed during the 24 h of stress 
induction mediated by TM. Hence, prolonged stress could also lead to cell lysis induced from 
swelling and plasma membrane rupture of the cells. Taken together the data provide evidence 
that sustained toxicity as caused from 24 h TM-treatment induces cell death. 
 
Table 8: Cell viability at zero and 24 h of TM-treatment for n=3. Student t-test analysis revealed a significant 
difference between the 0h and 24 h stress induction in all of the three cell lines. p<0.05 for APPWT and APPS (*) 
and p<0.01 for APPS-I (**). 
TM-treatment Cell type & Live cell count 
WT S S-I 
0 h Mean 1.81×106 2.95×106 3.68×106 
SD 2.23×105 5.32×105 3.02×105 
24 h Mean 1.18×106 1.72×106 1.95×106 
SD 1.25×105 3.12×105 4.20×105 
 
At first, the data suggested that by eight hours of TM-treatment the viability and metabolic 
activity of all cell lines was temporally restored to basal levels. However, 24 h of TM-treatment 
induces death as seen by the drop in the metabolic activity, cell viability and the viable cell 
count. Taken together the data provide evidence that at eight hours of ER stress mediated by 
TM, an adaptation of the stress mechanism was induced in all cell lines but that sustained 
toxicity (24 h of TM-treatment), induces apoptosis. 
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5.2.2  UPR progression in response to ER stress has a different pattern in FAD cells 
 
Analysis of the gene expression levels was conducted with qRT-PCR. For a given time point, the 
marker gene was initially normalised against the 18S rRNA housekeeping gene to address the 
variability between all the samples. This was followed by comparison with the results at zero 
hours to identify the fold change against the control sample. Thus all values presented below 
are expressed as the relative values with reference to the zero hour time point for each cell 
line, hereafter APPWT,0h, APPS,0h, APPS-I,0h. Melting curve analysis was performed in all qRT-PCR 
samples to ascertain that only a specific single product was amplified from the reaction. A 
sharply defined single peak was produced in all apart from the 24 h time point samples. At 24 h 
most of the melting curves showed a peak at a temperature other than the expected one or no 
peak at all, probably as a result of cell death and degradation of cellular mRNA [307]. For this 
reason, samples of this time point were not analysed further to avoid the inaccurate 
representation of transcript levels. 
The UPR responsive genes BiP, GRP94, ATF4, Nrf-2, XBP1s, XBP1T and CHOP were upregulated 
following TM-treatment indicating that the stress response was activated (Figures 42-44). In 
depth analysis of individual pathways both within (comparison of the mRNA levels following 
TM-treatment within a specific cell line) and among (comparison of the mRNA levels following 
TM-treatment between the cell lines) cell lines at each time point revealed differences in the 
stress-induced molecular mechanism triggered by FAD mutations. 
The expression profile of UPR markers within each of the cell lines at each time point of TM-
treatment was investigated first. This was initiated by examining the expression of BiP and 
GRP94. BiP is a major component of ER stress signalling; it acts prior to GRP94 and can be a 
negative UPR regulator by binding to ER stress receptors and keeping them in an inactive state 
while its depletion [308] leads to the activation of the three UPR arms. BiP was upregulated in 
all cell lines confirming the activation of the UPR from either the IRE1 or ATF6 pathways [309]. 
Although BiP was upregulated in all cell lines, it exhibited a different activation profile in each of 
them (Figure 42a). APPWT exhibited a 2-fold increase of BiP transcripts (p<0.05) at six hours post 
TM-induction with respect to APPWT,0h and while the average fold-change in BiP levels was still 
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elevated at eight hours, this was not statistically significant. APPS induced a 3-fold increase of 
BiP expression at three hours of TM-treatment with respect to APPS,0h. This response was 
sustained throughout the eight hours TM time-course induction and peaked at six hours post-
induction with a 16-fold increase (three-, four-, and eight-hours of TM-treatment: p<0.05, six-
hours: p<0.01) with respect to APPS,0h. APPS-I upregulated BiP at four hours of TM-treatment 
and its expression peaked at eight hours with a ~16-fold increase when compared to APPS-I,0h.  
Next, GRP94 mRNA, which often works in concert with BiP [310] was examined. GRP94 is 
generally expressed upon high demand of chaperones and under conditions where misfolded 
protein intermediates may have a deleterious effect [308]. In our time-course experiment, 
GRP94 transcript levels were increased at six hours in APPS and at eight hours of TM-treatment 
in APPS-I with respect to APPS,0h and APPS-I,0h respectively (Figure 42b).  
 
 
Figure 42: Expression profile of ER chaperones within each cell line during TM-treatment. The means are from 
two independent experiments where the technical replicates for each experiment were n=3 and n=2 
respectively and the error bars correspond to ±SD. The stars represent in APPWT, APPS and APPS-I represent the 
statistical significance compared to APPWT,0h, APPS,0h and APPS-I, ,0h respectively. Significant p-values are denoted 
as: *p<0.05, **p<0.01, ***p<0.001. 
 
PERK activation was followed by assessing the contribution of the ATF4-CHOP and Nrf-2 
signalling axes. ATF4 TF is responsible for triggering transcription of UPR markers for adaptation 
 
 
131 
Progression of UPR in a cell model system of familial Alzheimer’s disease 
such as GADD34, which induces translational recovery, while it may also promote CHOP 
expression leading to apoptosis [311]. At this point it is important to highlight that CHOP may 
also be stimulated by ATF6 activation, as a pro-survival mechanism (unlike PERK-mediated 
CHOP expression) [312]. In addition to ATF4-CHOP, PERK may also activate Nrf-2 acting as an 
antioxidant TF by inhibiting CHOP expression and promoting survival [313]. Some findings have 
suggested that the response from the two PERK-dependent UPR target genes namely ATF4 and 
Nrf-2 converge and magnify the PERK response [313]. Although the p-eIF2α promotes 
translation of ATF4 TF, this TF is also subjected to translational control as discussed in section 
2.6.3. Following PERK activation, this study focuses on investigating the ATF4 mRNA changes 
and the downstream target genes. 
APPWT revealed a 6-fold increase in CHOP expression at three hours of TM-treatment (p<0.01) 
with respect to APPWT, 0h, which was sustained throughout the time-course experiment with the 
peak expression being 11-fold at eight hours of TM-treatment (Figure 43). As ATF4 mRNA was 
not upregulated in this cell line, we hypothesised that CHOP expression was induced 
throughout the ATF6 pathway. However, as ATF4 is induced from p-eIF2α at a translational 
level and CHOP induced by ATF6 is not known to be pro-apoptotic [312] while APPWT data 
indicated at that at 24 h they underwent apoptosis, we suggest that the CHOP expression at the 
late time points (i.e. six and eight-hours) may be partially attributed to PERK activation. In 
addition, PERK is known to facilitate the synthesis of ATF6 and its trafficking to the Golgi [314], 
strengthening our hypothesis of PERK activation. The fact that ATF4 expression at the later time 
points (six and eight hours of TM-treatment) was not significantly upregulated was probably 
either due to the high variation observed and/or the transcriptional levels not reflecting the 
protein increase. 
APPS exhibited activation of both ATF4-CHOP and Nrf-2 signalling arms during the stress 
response. ATF4 mRNA showed a 7.5-fold statistically significant increase at six and eight hours 
of TM-treatment (p<0.001 at both six and eight hours) compared to APPS, 0h. CHOP transcripts 
were significantly upregulated from three to eight hours of TM-induced stress (p<0.001 at all-
time points) with an increase going from around 6- to ~62-fold respectively relative to APPS, 0h. 
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We speculated again that CHOP activation at early time points (three hours) where ATF4 was 
not upregulated was the result of ATF6 pro-survival mechanism. It may also be plausible; ATF4 
to be upregulated at the protei level but not reflected with the mRNA data. On the other hand 
CHOP activation at the later time points (six- and eight-hours) where ATF4 was upregulated was 
due to signalling of the PERK pro-apoptotic mechanism.   
APPS-I displayed a 6-fold increase in ATF4 mRNA expression at eight hours of TM-treatment 
(p<0.05) with respect to APPS-I,0h. On the other hand CHOP transcripts increased from 7.5-fold 
at three-hours to 50-fold at eight hours. Similarly with APPS, we suggested that expression of 
CHOP at early time points was due to ATF6 activation while the latter time points from PERK 
effect. Nrf-2 transcripts were not increased throughout the response implying that the Nrf-2 
pathway was not activated in this cell line.  
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Figure 43: Expression profile of PERK markers within each cell line during TM-treatment. The means are from 
two independent experiments where the technical replicates for each experiment were n=3 and n=2 
respectively and the error bars correspond to ±SD. The stars in APPWT, APPS and APPS-I represent the statistical 
significance compared to APPWT,0h, APPS,0h and APPS-I,0h respectively. Significant p-values are denoted as 
*p<0.05, **p<0.01, ***p<0.001. 
 
IRE1 activation induces XBP1 splicing, thus XBP1s mRNA levels were measured with qRT-PCR to 
detect the activity of this pathway (Figure 44a). APPWT exhibited a significant XBP1s expression 
at eight hours of TM-treatment compared to APPWT,0h. Analysis of APPS showed upregulation of 
XBP1s from a 2.5-fold increase at three hours to ~13-fold at eight hours of TM-treatment 
compared to APPS, 0h. Similarly, APPS-I exhibited increased levels of XBP1s relative to APPS-I,0h at 
three hours of TM-treatment followed by its attenuation at the later time points. 
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Figure 44: Expression profile of IRE1 and ATF6 markers within each cell line during TM-treatment. The means are 
from two independent experiments where the technical replicates for each experiment were n=3 and n=2 
respectively the error bars correspond to ±SD. The stars in APPWT, APPS and APPS-I represent the statistical 
significance compared to APPWT,0h, APPS,0h and APPS-I,0h respectively. Significant p-values are denoted as 
*p<0.05, **p<0.01, ***p<0.001. 
 
Activation of the ATF6 pathway was measured by monitoring the total XBP1 transcripts, while 
also considering the CHOP mRNA levels induced by PERK and/or ATF6. BiP mRNA levels were 
also considered for this analysis as their expression is induced by IRE1 and ATF6 signalling [315]. 
APPWT did not exhibit XBP1T overexpression, but induced CHOP mRNA in the absence of ATF4 
transcripts from three to eight hours; as well as of BiP at six hours post TM-induction. This 
suggests that APPWT activates the ATF6 pathway in response to TM-induced ER. APPS induced 
increased expression of XBP1T transcript from six to eight hours of TM-treatment when 
compared to APPS,0h (p<0.01 in both cases), which peaked at eight hours with a ~13-fold 
increase (Figure 44b). As activation of CHOP at three hours was not a result of PERK signalling 
because ATF4 was only expressed from six hours of TM-treatment, we suggested that ATF6 
activation was induced from three hours of TM-treatment and continued throughout the time-
course experiment (up to eight hours), where BiP mRNA was also expressed. In APPS-I XBP1T 
activation was detected at four hours with an approximately 8-fold increase compared to    
APPS-I, 0h. The CHOP mRNA levels induced at three and four hours of TM-treatment were not a 
result of the ATF4-CHOP axis (PERK), which was activated at eight hours. Instead, the expression 
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of CHOP in addition with BiP transcripts elevated at four hours, suggested ATF6 signalling to 
occur at three and four hours of TM-treatment. Our data provide evidence of ATF6 activation 
prior to PERK while also coincide at further time points (in APPMUT), possibly caused by PERK 
enhancement of ATF6 signalling. 
 
Table 9: ANOVA results (p-values) of the stress experiment comparing the mRNA levels between the TM-
treatment time points of a specific cell line. The highlighted colours illustrate the (p) significance: a) Green 
corresponds to p<0.05 (*), b) Yellow corresponds to p<0.01 (**) and c) red corresponds to p<0.001 (***). 
Gene 
Ti
m
e 
(h
) 
 
3 4 6 8 
WT S S-I WT S S-I WT S S-I WT S S-I 
BiP 
0 0.151 0.015 0.097 0.755 0.033 0.010 0.049 0.007 0.005 0.153 0.011 0.005 
3    1.000 0.350 0.168 0.606 0.011 0.831 0.269 0.015 0.014 
4       0.957 0.014 0.819 0.322 0.018 0.203 
6          0.200 0.427 0.083 
GRP94 
0 0.175 0.091 0.537 0.175 0.157 0.090 0.175 0.012 0.660 0.175 0.056 0.000 
3    0.175 0.841 0.781 0.175 0.031 1.000 0.175 0.077 0.001 
4       0.175 0.034 0.665 0.175 0.087 0.010 
6          0.175 0.422 0.001 
ATF4 
0 0.102 0.882 0.032 0.895 0.383 0.331 0.071 0.000 0.653 0.139 0.000 0.016 
3    0.303 0.892 0.807 0.665 0.002 0.848 0.998 0.002 0.024 
4       0.729 0.012 0.626 0.427 0.013 0.031 
6          0.839 1.000 0.017 
CHOP 
0 0.002 0.000 0.001 0.011 0.000 0.003 0.000 0.000 0.067 0.000 0.000 0.006 
3    0.916 0.015 0.011 0.860 0.000 0.274 0.326 0.000 0.010 
4       0.391 0.000 0.882 0.076 0.000 0.034 
6          0.867 0.617 0.017 
Nrf-2 
0 0.849 0.284 0.052 0.849 0.225 0.052 0.849 0.030 0.052 0.849 0.076 0.052 
3    0.849 0.858 0.052 0.849 0.057 0.052 0.849 0.138 0.052 
4       0.849 0.107 0.052 0.849 0.237 0.052 
6          0.849 0.076 0.052 
XBP1T 
0 0.168 0.990 0.320 0.168 0.869 0.014 0.168 0.006 0.233 0.168 0.002 0.091 
3    0.168 0.986 0.033 0.168 0.018 0.395 0.168 0.005 0.106 
4       0.168 0.052 0.941 0.168 0.015 0.234 
6          0.168 0.977 0.177 
XBP1s 
0 0.402 0.013 0.011 1.000 0.000 0.070 0.277 0.000 0.133 0.024 0.000 0.126 
3    0.460 0.339 0.217 0.999 0.000 0.395 0.547 0.000 0.261 
4       0.323 0.004 0.998 0.030 0.003 0.952 
6          0.703 1.000 0.891 
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5.2.3 APPMUT exhibit a similar UPR activation profile 
 
Following the observation that all cell lines activated IRE1 and ATF6 but only APPMUT triggered 
PERK activation, an analysis of the differences in the magnitude of the response between the 
FAD cell lines was performed. As explained in the 5.2.2 section, each of the genes was 
normalised against the 18S rRNA and compared with the respective transcript levels at zero 
hour of TM-treatment. Thus, the aim in this section was to compare the fold changes of APPMUT, 
with APPWT. This let us evaluate how APP695 mutations affect the magnitude of the stress 
response.  
In APPS the expression of the two chaperone genes (BiP and GRP94) demonstrated a significant 
fold increase at six hours of TM-treatment relative to both the APPWT and APPS-I with an eight- 
(p<0.001) and 4-fold (p<0.001) increase, respectively (Figure 45a).  
 
 
 
Figure 45: Expression profile of the chaperones between the cell lines during TM-treatment. The means are from 
two independent experiments where the technical replicates for each experiment were n=3 and n=2 
respectively and the bars correspond to ±SD. The stars represent the fold change compared to the APPWT at zero 
hours. Significant p-values are denoted as *p<0.05, **p<0.01, ***p<0.001. 
 
The magnitude of the PERK response was evaluated by the fold changes of the ATF4 and CHOP. 
As CHOP is also simulated by ATF6 signalling, specific PERK-signalling fold changes were 
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investigated only at times when both ATF4 and CHOP were activated. In APPS activation of 
ATF4-CHOP arm was stimulated at six and eight hours while in APPS-I at eight hours of TM-
treatment. APPS at six hours exhibited a significant fold change of ATF4 relative to both APPWT 
and APPS-I (p<0.01), and at eight hours displayed ATF4 increase only with respect to APPWT 
(p<0.05) (Figure 46a). 
The fold increase of CHOP was significant higher in APPS at six- and eight- hours of TM-
treatment with a fold increase of 5-(p<0.05) and of 5.5-(p<0.001), respectively compared to 
APPWT. Increase of the CHOP transcript in APPS-I was also significant higher at eight hours (the 
time point at which both ATF4 and CHOP were seen to be upregulated in section 5.2.2) and was 
4.5 times higher (p<0.001) with respect to the APPWT (Figure 46c). These results indicate that 
APPMUT activated PERK with a higher magnitude (Figure 43c) compared to APPWT (Figure 46c).  
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Figure 46: Expression profile of PERK markers between the cell lines during TM-treatment. The means are from 
two independent experiments where the technical replicates for each experiment were n=3 and n=2 
respectively and the error bars correspond to ±SD. The stars represent the fold change compared to the APPWT 
that has been normalised h APPWT,0h. Significant p-values are denoted as *p<0.05, **p<0.01, ***p<0.001. 
 
Next the differences in IRE1 expression markers between cell lines at each time point of TM-
treatment were assessed by measuring the fold changes of the XBP1s. APPS was previously 
shown to activate IRE1 from three to eight hours of TM-treatment. The XBP1s fold change of 
APPS when compared with the respective APPWT levels exhibited a significant increase from four 
to eight hours of TM-treatment (p<0.001) while when compared with APPS-I demonstrated a 
significant increase at six- and eight hours (p<0.01). The pattern observed was expected as IRE1 
pathway at these time points was not activated in APPS-I (Figure 47a). APPS-I analysis revealed 
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an increase of the XBP1 mRNA fold change at four hours only with respect to APPWT (p<0.01). 
These data also demonstrated that APPS activated the IRE1 branch with the highest stress 
magnitude.  
 
 
Figure 47: Expression profile of IRE1 and ATF6 markers between the cell lines during TM-treatment. The means 
are from two independent experiments where the technical replicates for each experiment were n=3 and n=2 
respectively and the bars correspond to ±SD. The stars represent the fold change compared to the APPWT. 
Significant p-values are denoted as *p<0.05, **p<0.01, ***p<0.001. 
 
The magnitude of the ATF6 response between the cell lines was evaluated by monitoring the 
XBP1T transcripts, but also by considering the fold changes of CHOP at early time points and of 
BiP levels at all time-points. APPS demonstrated ATF6 activation from three to eight-hour post 
TM-treatment. The activation at three- and four-hours was mainly observed by CHOP (in the 
absence of ATF4) and by BiP expression while at six and eight hours by XBP1T transcripts. When 
compared to APPWT, the fold increase of CHOP at four hours of TM-treatment was 5-fold higher 
in APPS (p<0.05), while the fold increase of XBP1T at six and eight hours was of a magnitude of 
7- (p<0.05) and 5.5-fold (p<0.01) higher, respectively in APPS. Finally, comparison of APPS with 
APPS-I revealed that at eight hours APPS had a 5-fold increase in XBP1T (p<0.05), (Figure 47b). 
This was expected, as at eight hours, APPS-I did not have activated the ATF6 pathway as 
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suggested in section 5.2.2. With respect to ATF6 pathway, APPS revealed a stronger activation 
of this pathway.   
 
 
Table 10: ANOVA results (p-values) of the time course stress experiment between the cell lines. The highlighted 
colours illustrate the (p) significance: a) Green corresponds to p<0.05 (*), b) Yellow corresponds to p<0.01 (**) 
and c) red corresponds to p<0.001 (***)  
Time (h) Cell line 0 3 4 6 8 
WT S WT S WT S WT S WT S 
BiP S 0.942  0.658  0.536  0.000  0.114  S-I 0.942 0.942 0.658 0.658 0.536 0.536 0.666 0.000 0.114 0.114 
GRP94 S 0.964  0.279  0.469  0.011  0.127  S-I 0.964 0.964 0.279 0.279 0.469 0.469 0.949 0.007 0.127 0.127 
ATF4 S 0.943  0.059  0.061  0.004  0.023  S-I 0.943 0.943 0.059 0.059 0.061 0.061 0.087 0.003 0.242 0.368 
CHOP S 0.981  0.107  0.024  0.012  0.000  S-I 0.981 0.981 0.107 0.107 0.001 0.110 0.243 0.012 0.000 0.575 
Nrf-2 S 0.975  0.432  0.336  0.001  0.055  S-I 0.975 0.975 0.432 0.432 0.336 0.336 0.997 0.001 0.055 0.055 
XBP1T S 0.899  0.963  0.077  0.034  0.008  S-I 0.899 0.899 0.963 0.963 0.077 0.077 0.512 0.042 0.064 0.585 
XBP1s S 0.921  0.856  0.000  0.000  0.005  S-I 0.921 0.921 0.856 0.856 0.000 0.879 0.485 0.002 0.510 0.039 
 
5.2.4  Mutant cells exhibit stronger upregulation of UPR markers in response to ER stress 
 
Each of the UPR-associated genes normalised to 18S rRNA, was now compared against APPWT 
at each of the time points of TM-treatment. Thus, all values presented below are expressed as 
the relative values with reference to the APPWT at each time-point individually. This analysis 
was performed in order to strengthen our hypothesis that APPMUT cells exhibited a stronger ER 
stress response after TM administration- than the APPWT. 
Analysis of the expression levels of chaperones illustrated their upregulation in APPMUT 
compared to APPWT. More specifically, APPS exhibited an increase in both BiP and GRP94 at six 
hours which was of around 4-(p<0.01) and 2.2-fold (p<0.01), respectively. At the same time 
point (six hours) the BiP mRNA was also around 3-fold (p<0.01) higher compared to APPS-I. 
Consistent with these data are the ones from the APPWT comparison (Figure 45) as they also 
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showed APPS to have increased levels of BiP and GRP94 at six hours of TM-treatment. Analysis 
of APPS-I showed that it displayed increased BiP transcripts levels at four hours and of GRP94 at 
eight hours of TM-treatment with a magnitude of 4.5-(p<0.001) and of around 4-fold (p<0.05), 
respectively (Figure 48) compared to APPWT. These results indicated that APPMUT induced the 
expression of chaperones with at higher levels compared to APPWT. 
 
 
 
Figure 48: Expression profile of chaperones in APPMUT compared to APPWT. The means are from two 
independent experiments where the technical replicates for each experiment were n=3 and n=2 respectively 
and the error bars correspond to ±SD. The stars represent the fold change compared to the APPWT. Significant p 
values are denoted as *p<0.05, **p<0.01, ***p<0.001 
 
PERK activation in the APPMUT was demonstrated in Figure 43. Comparison of the magnitude of 
the PERK signalling was investigated by analysis of ATF4, Nrf-2 and CHOP mRNA levels. APPS 
exhibited significant ~2.5-fold upregulation of the ATF4 and Nrf-2 transcripts at six hours and 
~2.5-fold of CHOP mRNA at eight hours of TM-treatment with respect to APPWT (p<0.001, 
p<0.01 and p<0.01, respectively) (Figure 49). In addition, APPS also had significantly increased 
Nrf-2 transcript levels of around 2-fold (p<0.05) compared to APPS-I at six hours of TM- 
treatment. Similar with these conclusions were the ones deduced from the comparison of APPS 
with APPWT,0h (Figure 46) demonstrating elevated levels of ATF4, Nrf-2 and CHOP at six hours of 
TM-treatment. APPS-I displayed a 3.5-and 2.5-fold increase (p<0.05) in the Nrf-2 and CHOP 
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levels, respectively, at eight hours of TM-treatment with respect to APPWT,0h. Interestingly, 
APPS-I also displayed increased mRNA expression of CHOP at eight hours with respect to APPWT, 
0h (Figure 46c). 
 
 
 
Figure 49: Expression profile of PERK markers in APPMUT compared to APPWT. The means are from two 
independent experiments where the technical replicates for each experiment were n=3 and n=2 respectively 
and the error bars correspond to ±SD. The stars represent the fold change compared to the APPWT. Significant p 
values are denoted as *p<0.05, **p<0.01, ***p<0.001. 
 
Comparison of the differential magnitude of IRE1 activation among cell lines was achieved by 
assessing the XBP1s mRNA levels. APPS attained a ~2.5-fold increase (p<0.01) of XBP1s 
transcripts at six hours of TM-treatment with respect to APPWT (Figure 50) and of around 2-fold 
(p<0.05) with respect to APPS-I. Similarly, APPS exhibited an upregulated XBP1s mRNA fold 
increase relative to APPWT,0h as well as to APPS-I (Figure 47a). These observations strengthen the 
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hypothesis that APPMUT exhibited a stronger activation than APPWT of the IRE1 branch, but also 
suggested APPS to have the strongest magnitude of this response. 
 
 
 
Figure 50: Expression profile of IRE1 and ATF6 in APPMUT compared to APPWT. The means are from two 
independent experiments where the technical replicates for each experiment were n=3 and n=2 respectively 
and the error bars correspond to ±SD. The stars represent the fold change compared to the APPWT. Significant p 
values are denoted as *p<0.05, **p<0.01, ***p<0.001. 
 
Evaluation of the ATF6 response among the cell lines was performed by analysis of the XBP1T 
mRNA levels as well as of CHOP (at early time points) and BiP mRNA. APPS which activated the 
ATF6 from three to eight hours, exhibited a significant 3.5-fold (p<0.05) increase of XBP1T at six 
hours with respect to APPWT and of ~2.5-fold (p<0.05) with respect to APPS-I (Figure 50). 
Similarly, when XBP1T trancripts of APPS were compared with the fold changes of APPWT,0h, 
they demonstrated an increase, which was also evident when compared to APPWT at six hours 
(Figure 47). APPS also had significant higher mRNA levels of BiP at six hours compared to APPWT. 
On the other hand, APPS-I that activated ATF6 from three to four hours post TM-induction, 
demonstrated an increase of BiP mRNA at four hours, which was significant higher compared to 
APPWT.  
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Table 11: ANOVA results (p values) of the time course stress experiment of APPMUT relative to APPWT. The 
highlighted colours illustrate the (p) significance: a) Green corresponds to p<0.05 (*), b) Yellow corresponds to 
p<0.01 (**) and c) red corresponds to p<0.001 (***). 
Time (h) Cell line 
0 3 4 6 8 
WT S WT S WT S WT S WT S 
BiP S 0.835  0.684  0.000  0.007  0.263  S-I 0.835 0.835 0.684 0.684 0.182 0.000 0.921 0.009 0.263 0.263 
GRP94 S 0.730  0.397  0.098  0.002  0.175  S-I 0.730 0.730 0.397 0.397 0.098 0.098 0.996 0.003 0.018 0.745 
ATF4 S 0.575  0.051  0.072  0.000  0.056  S-I 0.575 0.575 0.051 0.051 0.072 0.072 0.052 0.000 0.056 0.056 
CHOP S 0.053  0.115  0.124  0.098  0.018  S-I 0.053 0.053 0.115 0.115 0.124 0.124 0.098 0.098 0.013 0.996 
Nrf-2 S 0.366  0.812  0.111  0.003  0.176  S-I 0.366 0.366 0.812 0.812 0.111 0.111 0.928 0.005 0.027 0.812 
XBP1T S 0.331  0.229  0.105  0.011  0.063  S-I 0.331 0.331 0.025 1.000 0.105 0.105 0.584 0.023 0.063 0.063 
XBP1s S 0.144  0.212  0.116  0.001  0.285  S-I 0.144 0.144 0.212 0.212 0.116 0.116 0.511 0.006 0.010 0.120 
 
ER stress in our cell model system caused by the inhibition of N-linked glycosylation revealed 
that different FAD mutations activate the UPR in a specific manner. Comparison of transcript 
levels of UPR markers from distinct pathways at each time point of TM-treatment was 
performed both within and among cell lines.  
Our results demonstrated that downstream activation of the IRE and ATF6 pathways were seen 
in each of the three cell lines with the progression being different among them, but induction of 
all three branches (IRE1, ATF6 and PERK) was only demonstrated in APPMUT. It was also 
confirmed that the magnitude of the response was significantly higher in APPMUT than APPWT 
cells.  
 
5.3   Discussion 
 
In this chapter, we investigated the transcript levels of UPR targets downstream of the IRE1, 
PERK, and ATF6 pathways, namely BiP, GRP94, XBPT, XBP1s, Nrf-2, ATF4 and CHOP. These 
markers were investigated in a time-course manner by TM-treatment of differentiated 
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neuroblastoma cells overexpressing either the wild-type or mutant APP695 isoforms; including 
APP695K670N/M671L (APPS) and APP695V717F (APPS-I) experimentally. Using gene expression (qRT-
PCR), metabolic and cell viability analysis (MTS assay in combination with trypan blue exclusion 
method), the data suggested differences in the UPR mechanism and the time-scale of the 
response. Cells overexpressing APP695 bearing FAD genetic mutations activated ER stress more 
strongly compared to APPWT.  
 
5.3.1  Sequence of UPR activation revealed in a FAD cell model in response to ER stress  
 
Analysis of the APPWT revealed that the ATF6 branch was activated from three to eight hours of 
TM-treatment as indicated by the upregulation of CHOP marker in the absence of ATF4 
expression (with a pro-survival function), (Figure 43). At this point, we also speculate that the 
PERK arm may also be activated but not reflected in the ATF4 transcriptional levels. The IRE1 
arm was activated at eight hours of TM-treatment as seen by the XBP1s activation (Figure 44).  
We then examined the stress response in APPS, which appeared to be different and with a 
higher magnitude compared to APPWT. Transcriptional analysis provided evidence of IRE1 
activity starting at three hours and remaining active up to eight hours of TM-treatment (Figure 
44). At the same time-points (three to eight hours) of stress induction, the cells also activated 
the ATF6 branch. This was seen by the transcriptional upregulation of CHOP mRNA (in the 
absence of ATF4), of BiP mRNA as well as by the transcriptional upregulation of XBP1T (Figure 
44).  Activation of PERK was suggested to occur at the later time points; six and eight hours of 
TM-treatment as seen by the pro-apoptotic CHOP mRNA expression levels. All three pathways 
remained active at eight hours of TM-treatment. 
 
We next checked the order of UPR activation in APPS-I. Early activation of the IRE1 pathway was 
observed by monitoring the active XBP1s mRNA at three hours of TM-treatment, which was 
followed by a drop in its transcript level (Figure 44). ATF6 was also activated early in the time-
course experiment as seen by CHOP, BiP and/or XBP1T transcripts (Figure 44). Finally, APPS-I 
stimulated PERK activation at eight hour of TM-induced ER stress (Figure 43).  
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Further comparisons between the magnitudes of the response between the cell lines, revealed 
APPMUT to stimulate a stronger response compared to APPWT. In order to determine the 
magnitude of the pro-apoptotic stimuli, the levels of the pro-apoptotic CHOP TF mRNA were 
evaluated in all cell lines. Although CHOP was transcriptionally upregulated with statistical 
significance in all cell lines at eight hours of TM-treatment, we detected the highest increase in 
APPS, which exhibited a 62-fold increase compared to APPS,0h hour time point. The APPS-I were 
shown to have a 50-fold increase compared to APPS-I,0h and lastly the APPWT had the lowest 
increase which was of 11-fold with respect to APPWT,0h. The higher CHOP transcripts in APPMUT 
suggested a possibly higher cell loss in the cells carrying the mutant APP695 variant. However, at 
24 of TM-treatment there was not any indication of significant cell loss between APPWT and 
APPMUT. A higher difference in the cell loss between APPWT and APPMUT could probably be 
captured at a time point after 8 h and before 24 h of TM-treatment when cells have been 
directed to apoptosis.  
  
 
The data supported the following sequence of UPR activation: 
1. APPWT induced ATF6 activation at three hours continuing throughout the duration of the 
experiment, and IRE1 activation at eight hours of TM-treatment. 
2. APPS initially exhibited IRE1 and ATF6 activation at three hours, which was sustained 
throughout the time-course, and PERK activation at six and eight hours of TM-
treatment. 
3. APPS-I displayed IRE1 and ATF6 activation at three hours, with the ATF6 pathway being 
activated at the four hours too, followed by PERK activation at eight hours of TM- 
treatment. 
 
5.3.2  The key players in UPR activation induced by ER stress 
 
Several genes are responsible for protecting the ER from any physiological input. Molecular 
chaperones have a vital role in controlling protein quality and assisting with the folding process 
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of misfolded proteins. Quantification of BiP transcript levels during the time course induction 
showed that all cell lines exhibited upregulation of BiP after TM-treatment but with a different 
activation profile, showing that overexpression of the wild-type APP695 is sufficient to trigger its 
expression (Figure 42a). The earliest upregulation of BiP as well as the highest transcript 
increase was detected in APPS cells. More specifically, at six hours of TM-treatment the fold 
increase of BiP mRNA was significantly higher in APPS compared to both APPWT and APPS-I  
(p<0.001).  
 In addition to BiP, other chaperones are also needed for the protein folding control under 
stress conditions. As such, GRP94 another major UPR target was upregulated only in FAD-
associated cell lines and observed to work in conjunction with BiP. More specifically, GRP94 was 
found to be expressed at the same time as BiP as its transcripts were elevated at six hours in 
APPS and at eight hours in APPS-I of TM-treatment (Figure 42). As GRP94 has a key role under 
conditions necessitating an increased demand of protein folding machinery, this suggested that 
the unfolded protein load in APPS and APPS-I is higher compared to APPWT during the time 
course induction. 
Transcription of several genes during the UPR is controlled by XBP1s, ATF4 and the truncated-
ATF6 transcription factor [316], where each of them define a specific signalling pathway.  IRE1 
activation in both APPS and APPS-I was rapid as monitored by the increased XBP1s mRNA at 
three hours of TM-treatment. The early IRE1 signalling observed is supported by the Lin et al. 
[305] findings, suggesting this pathway to be set in motion in the beginning of the UPR 
response. Furthermore, the fact that XBP1 splicing was reported to occur during cellular 
adaptation strengthens our speculation of cellular adaptation at eight hours of TM-treatment. 
Previous reports have revealed that unmitigated cellular stress promotes the activation of IRE1, 
but persistent stress attenuates its activity. IRE1 is a key step in the cell fate decision of survival 
or cell death, with its prolonged activation being related to enhanced survival [185]. The fact 
that IRE1 which was previously reported to occur during cellular adaptation [79] remained 
activated at eight hours in APPS, may be an indicator of the enhanced survival strengthening 
our speculation of cellular adaptation at eight hours of TM-treatment. 
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Strong and sustained CHOP activation was revealed in all genetically modified cell lines from 
the beginning of the TM-treatment. Our data showed that CHOP was activated at a very early 
time points (three hours) but also at later time points (eight hours) of TM-treatment in cells 
carrying both the mutant and wild-type APP695 variant. These reinforced the key role of CHOP 
signalling in both its pro- and anti-apoptotic properties by ATF6 or PERK signalling respectively 
in the UPR. 
 
APPMUT cells provided strong evidence of PERK activation with a high magnitude at eight hours 
of TM-treatment. These data were strengthened by the observation of Hoozemans and co-
workers in post-mortem brain material that demonstrated the presence of higher levels of 
phosphorylated (activated) PERK in diseased compared to healthy individuals [42].  Exposure of 
APPS to TM also induced Nrf-2 overexpression, leading to transcription of genes regulating 
redox homeostasis. This upregulation occurred at six hours of TM-treatment and thus in parallel 
with the ATF4 activation. These observations are supported by previous findings showing ATF4 
and Nrf-2 to act together following the eIF2α phosphorylation step [313]. The same group 
postulated that ATF4 and Nrf-2 pathways converge and act together to amplify the PERK 
response. Our data showed that pro-apoptotic CHOP had the highest activation in APPS; 
suggesting a possible cross talk between ATF4 and Nrf-2 markers leading to an increased 
expression of the downstream target genes. Importantly, Nrf-2 mRNA was not upregulated in 
APPWT or in APPS-I, strengthening the hypothesis that the overall amplified PERK response in 
APPS resulted from the synergistic effect or ATF4 and Nrf-2. As this activation was indicated 
only in APPS, it reinforced the suggestion that these cells accumulated more unfolded proteins 
leading to higher stress and thus activating the PERK arm with a higher amplification signal. 
Saying this though, the significance of Nrf-2 in the progression of neurodegenerative diseases is 
still under investigation. Its activation plays presumably a protective role in the detoxification of 
ROS that promote apoptosis [317].  
 
Metabolic activity analysis demonstrated a drop at six hours of TM-treatment, which was 
however not accompanied by a further decrease during stress-induction (i.e. eight hours) 
suggesting a possible adaptation of cells to the stress response, through the upregulation of 
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specific UPR markers. However, at 24 h both metabolic activity and cell viability data provided 
evidence of cell death. Therefore, although cells appeared to achieve a new steady state of 
homeostasis at eight-hours, the prolonged stress-induction (24 h) resulted in apoptosis. 
As distinct changes in transcription of several genes may affect the progression of the disease 
[318], it was shown in vitro that different FAD mutations have transcriptional differences in the 
key regulators. The different transcriptional profiles suggest the presence of a customised 
response in the different cell types. Although the ER tries to restore homeostasis through 
transcriptional changes, it also requires short-term responses to ease the effects of stress by 
translational pause. However, re-activation of global translation along with the contribution of 
transcriptional mechanisms is essential for cells to avert death and for homeostasis to be re-
established. In addition, faithful translation of the mRNA of the UPR target genes upregulated 
under induction of stress is essential as part of the transcriptional UPR response [316, 319]. 
 
5.4  Conclusion 
 
A substantial amount of evidence suggests that stress induction in cells overexpressing wild-
type and mutant APP695, leads to a differential sequence of the UPR activation. The data 
indicated, the pattern of upregulation in APPS and APPS-I to be similar, whereas in APPWT to 
differ. APPMUT activated all three arms of the stress response (IRE1, ATF6 and PERK) with APPS 
keeping them all active at eight hours while APPS-I induced their activation at different time 
points of the TM time-course experiment. Furthermore, the APPMUT were generally more 
stressed than APPWT and demonstrated a different UPR mechanism. However, we postulated 
that these differences might be the result of an increased variability of the UPR expression 
markers, masking a similar type of response exhibited with a lower magnitude in the APPWT 
cells. It was also demonstrated that the cells’ activity appeared to adapt but following a 
prolonged stress induction (24 h) cells died showing their over-commitment to apoptosis. 
The data suggest that the tripartite response is structured as such to control stress via distinct 
branches, providing a customised approach to cells. A prolonged stress response appears to 
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have detrimental effects and make the cells unable to fully restore homeostasis and to activate 
pro-apoptotic pathways. However, it remains unclear what controls the balance of pro-
apoptotic and anti-apoptotic stimuli or whether and how this response is translated at a protein 
level.  
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Computational model of the mammalian 
UPR network  
 
 
 
6.1  Introduction 
 
The UPR forms a highly interconnected network regulating a number of genes in response to ER 
stress which encode proteins essential for the decrease of the cellular unfolded protein load 
[206].  It is difficult to address the role of UPR activation and its involvement in AD with 
experimental approaches for several reasons. Firstly, clinical symptoms of AD usually occur 
when the disease has already progressed. For instance, diagnostic biomarkers may already be 
upregulated at the time of the diagnosis, since the beginning of the pathologic process may 
take many years before the clinical onset [320]. Second, as AD affects the brain tissue, it is 
difficult to disentangle the onset and disease progression over time. When techniques for 
monitoring these activities become available, they would require longitudinal studies starting 
prior of the disease clinical manifestations and continuing to the most advance stages or even 
until death has occurred. Although in vivo and in vitro models have been established to 
interrogate the UPR mechanism, it is difficult to deduce their relevance in humans. A first step 
towards that could be adopting a ‘systems’ approach, with both biological experimentation and 
mathematical modelling. This would allow isolating the UPR signalling pathways and analysing 
the complexity of the system at hand by focusing on how component interactions control the 
UPR-system behaviour in different diseases. This information would help identify the effects of 
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specific mutations, specific points for intervention and promising therapeutic avenues. Several 
initiatives towards the application of systems biology principles to medicine have been made 
recently [321, 322].  
This chapter describes the development of a mammalian UPR computational model using semi-
quantitative data of an eight-hour TM-time course stress experiment, for each of the APPWT, 
APPS and APPS-I cell lines. The fold change of the five UPR markers (BiP, XBP1s, XBP1T, ATF4 and 
CHOP) was multiplied by the corresponding initial values of the model -which were their steady 
state concentrations obtained by simulating the model starting from an initial condition of zero- 
in order to be adjusted with the same scale. Following the scaling process, the 14 parameters 
associated with the three UPR pathways were estimated such that the model output tracked 
the values of five aforementioned UPR markers. The simulations and parameter estimation 
were performed using the gPROMS® software version 3.5.3 (Process Systems Enterprise, Ltd, 
London, UK) using the DAEs (differential-algebraic equations) solver “DASOLV” and parameters 
values exported from the literature. Subsequently, the model was used to perform case studies 
on the effect of drugs known to target UPR progression, which demonstrate the potential of 
complimenting experimental analyses with modelling to probe the system (Table 12).   
 
Table 12: Outline of the computational setup.  
Type of model studied Signalling branches 
Experimental data 
used UPR dynamics & Case studies  
Computational 
• WT 
• S 
• S-I 
IRE1 
BiP Effect of lithium & valproate in FAD 
Spliced XBP1 Effect of XBP1 complex 
formation ATF6 Total XBP1 
PERK 
ATF4 
Effect of salubrinal 
CHOP 
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6.2  General characteristics of the computational model 
 
 
The model was developed using a top-down approach. It was formulated based on single-cell 
deterministic mass-action kinetics, resulting in a set of ordinary differential equations that 
describe known features of the IRE1, PERK and ATF6 pathways. In this model we took into 
account: 1) the key UPR markers downstream of these receptors which were described as 
variables and defined as number of molecules and 2) their link in regulating one another’s 
functions described with the rate equations. The complete map of reactions and signals 
considered in the model is illustrated in Figure 51.  
 
 
 
Figure 51: Complete map of the mammalian UPR model. Each arrow represents the reaction rate of an algebraic 
equation. The input of the system is the rate of translation of unfolded proteins (red square) and the output is 
represented by i) an increase of the protein folding or ii) translation attenuation (yellow circles) responsible for 
restoring ER homeostasis or pro-apoptotic signals (transcription of CHOP). 
 
Several biochemical features were incorporated in the model and are as follows:  a) association 
and dissociation rates of BiP from the UPR receptors triggering the activation or inhibition of 
the stress cascade, b) transcription of the following components: BiP, ATF4, CHOP, unspliced 
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XBP1, and spliced XBP1, c) translation of the following components: BiP, unspliced XBP1 and 
spliced XBP1, ATF4 and CHOP mRNA, d) phosphorylation/dephosphorylation of eIF2α protein 
and, finally, e) degradation rates of BiP, ATF4, CHOP, unspliced XBP1 and spliced XBP1. 
More specifically, BiP dissociation from the receptors induces their activation while its binding 
induces the deactivation of that particular branch of the stress response. Activation of the IRE1 
pathway was examined by studying the XBP1 components, activation of the PERK pathway by 
studying the phosphorylated eIF2α and the downstream ATF4 and CHOP genes while activation 
of the ATF6 pathway by studying the XBP1u.  
 
6.2.1  Model assumptions 
 
The development of the computational model was based on the following assumptions: 
a) All three ER transmembrane sensors (IRE1, PERK, and ATF6) were bound to BiP initially. 
This assumption was made in order to have our system in starting from a point without 
stress. 
 
b) The activation of IRE1, PERK and ATF6 stress receptors occurs upon the dissociation of 
BiP from them. BiP therefore acts as a modulator for the activation and deactivation of 
the ER stress receptors. 
 
c) The binding and dissociation constants between BiP and the three receptors take the 
same values for all pathways. The values for IRE1 were extracted from the literature by 
the model of UPR in yeast by Pincus et al. [138] while PERK and ATF6 constants were 
assumed to follow the same kinetics. As the binding constant of BiP with IRE1 used by 
Pincus et al. was taken from an experimental study based on mammalian cells [323], we 
believe that the values used were valid for our mammalian UPR model.  Although we 
assumed that all three receptors had the same rate constants, our experimental data 
showed a different activation profile between the receptors. To model this activation 
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we introduced a time-delay in IRE1 and PERK pathways, which was in accordance with 
the time profile of our experimental data (described in 6.3.1a). 
 
d) The IRE1 double activation mechanism was neglected. The mammalian IRE1 isoforms 
(IRE1α and IRE1β) have been demonstrated to activate the UPR differently [324]. IRE1α, 
which is ubiquitously expressed, is activated/deactivated by the BiP 
dissociation/association. IRE1β found in the epithelium of the gastrointestinal tract is 
activated with a dual mechanism as follows: i) the direct interaction of unfolded 
proteins and ii) the dissociation/association of BiP. As we were examining the UPR in AD, 
we investigated and subsequently modelled the IRE1α (that has been referred as IRE1 
from Chapter 2), which is ubiquitously expressed. For this reason, the single activation 
mechanism was chosen.  
 
e) Changes in mRNA levels were assumed to have a linear correlation with the equivalent 
protein levels. Although in biological reality this linear relationship is not always the 
case, this assumption was made because of the lack of protein level data [325].  
 
f) PERK phosphorylation of eIF2α promotes the translation of ATF4 mRNA [314]. As ATF4 is 
also subjected to transcriptional changes, we investigated ATF4 mRNA data, even 
though the exact mechanism of these changes remains unknown.  
  
g) The number of IRE1 molecules in the ER used (2.56×102) was reported by Pincus et al. 
[138] taken from a study on yeast by Ghaemmaghami et al. [326]. The number of PERK 
and ATF6 molecules in the ER was chosen to be the same as the number of IRE1 
molecules. Evaluation of the numbers of molecules of the three receptors could be 
experimentally achieved by blotting. Furthermore, when this information becomes 
available, kinetic constants of BiP to the receptors (association and dissociation rates) 
could be assessed providing information on the natural activation procedure (which 
receptor is activated first). 
  
 
 
156 
Computational model of the mammalian UPR network  
h) The translation rate of BiP mRNA (𝛽𝛽RB) was selected to be the same as in yeast, which is 
0.25 sec-1 [138].  
           
i) The decay rate of BiP protein (γB ) is 1.39×10-4 sec-1 [327]. 
     
j) The initial values for ATF4, CHOP, eIF2α, U, U|B were chosen arbitrarily such that the 
initial state of the single-cell model reflects steady-state conditions. 
 
k) CHOP expression was induced from PERK signalling only. In reality CHOP expression, is 
transactivated by both PERK and ATF6 [328]. More specifically, PERK mediates 
expression of pro-apoptotic CHOP while ATF6-associated signals induced facilitate the 
pro-survival mechanism [312]. 
 
6.3   Model development   
 
6.3.1  Protein folding dynamics 
 
The first event we wanted to capture in our model was translational attenuation, which is 
activated by the PERK signalling pathway. With regards to the protein folding dynamics, the 
following key features were taken into account to capture this event.   
a) Following our experimental data analysis from the TM time course experiment, it was 
observed that the cells were stressed at around three hours of TM-treatment. This was 
specifically seen by the upregulation of the transcript levels of UPR markers. For this reason, 
in order to capture this behaviour in the computational model, all cell lines exhibited a time 
delay in the onset of the stress response. This was introduced in the model by inserting the 
time lag (tau) in the beginning of the ER stress to fit the experiments, a technique widely 
used in modelling and proven to be valid [329]. We also model a time-delay in the 
transcription of ATF4 and CHOP mRNA in order to fit the experimental data. This delay was 
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added to these genes, as we had no data to follow and modify the eIF2α phosphorylation as 
opposed to the data for XBP1 splicing. 
 
b) Previous studies have showed that several UPR regulatory genes exhibit their upregulation 
both prior to and post- induction of ER stress. In a similar manner, the proteins that are 
upregulated due to UPR activation, i.e. chaperones, ATF4 and CHOP, are not affected by 
translational attenuation in our model [330]. 
 
c) Activated PERK (pPERK) acts as a kinase that induces phosphorylation of the ‘α’ subunit of 
eIF2α. In our model, translational attenuation is dependent on phosphorylation of eIF2α 
[331].  
 
A progressive onset of stress was created, mimicking the accumulation of unfolded proteins in 
the ER. Therefore, the rate of unfolded proteins synthesised in the ER, Su, is given by the 
following equation: 
  
𝑑𝑑[𝑆𝑆𝑢𝑢]
𝑑𝑑𝑑𝑑
= 𝐾𝐾𝑢𝑢𝑑𝑑 
 
(1) 
 
Where Ku represents the cumulative load of unfolded proteins and t is time. Translational 
attenuation was modelled by following the approach proposed by Trusina et al. [158]. Su 
(quantity of unfolded proteins arriving in the ER per seconds) was scaled according to the 
extent of eIF2α phosphorylation: 
 
 
𝑑𝑑𝑛𝑛𝑡𝑡𝑛𝑛𝑐𝑐𝑐𝑐𝑡𝑡𝑑𝑑𝑡𝑡𝑜𝑜𝑛𝑛 𝑡𝑡𝑑𝑑𝑑𝑑𝑒𝑒𝑛𝑛𝑛𝑛𝑡𝑡𝑑𝑑𝑡𝑡𝑜𝑜𝑛𝑛: [𝑝𝑝𝑒𝑒𝑝𝑝𝑝𝑝2𝛼𝛼][𝑒𝑒𝑝𝑝𝑝𝑝2𝛼𝛼](0) 𝑆𝑆𝑈𝑈 (2) 
 
The [𝑝𝑝𝑒𝑒𝑝𝑝𝑝𝑝2𝛼𝛼]  stands for the quantity concentration of phosphorylated 𝑒𝑒𝑝𝑝𝑝𝑝2𝛼𝛼 , whereas [𝑒𝑒𝑝𝑝𝑝𝑝2𝛼𝛼](0) for the initial quantity of the total 𝑒𝑒𝑝𝑝𝑝𝑝2𝛼𝛼 protein. 
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The equation related to the unfolded protein is as follows:  
 𝑑𝑑[𝑈𝑈]
𝑑𝑑𝑑𝑑
= [𝑝𝑝𝑒𝑒𝑝𝑝𝑝𝑝2𝛼𝛼][𝑒𝑒𝑝𝑝𝑝𝑝2𝛼𝛼](0) 𝑆𝑆𝑈𝑈 − 𝐶𝐶𝑈𝑈𝐵𝐵[𝑈𝑈][𝐵𝐵] + 𝛾𝛾𝑈𝑈𝐵𝐵[𝑈𝑈|𝐵𝐵] + 𝛾𝛾𝐵𝐵[𝑈𝑈|𝐵𝐵] (3) 
 
Where [𝑈𝑈] represents the concentration of unfolded proteins, 𝐶𝐶𝑈𝑈𝐵𝐵 is the binding rate constant 
of unfolded protein binding to BiP, [𝐵𝐵] is the concentration of free BiP, 𝛾𝛾𝑈𝑈𝐵𝐵 is dissociation rate 
of BiP from unfolded protein, 𝛾𝛾𝐵𝐵 is the decay rate of BiP protein, and [𝑈𝑈|𝐵𝐵] is the concentration 
of unfolded proteins bound to BiP. Therefore, the material balance for the unfolded protein-BiP 
complex is:  
  
𝑑𝑑[𝑈𝑈|𝐵𝐵]
𝑑𝑑𝑑𝑑
= 𝐶𝐶𝑈𝑈𝐵𝐵[𝑈𝑈][𝐵𝐵] − 𝛾𝛾𝑈𝑈𝐵𝐵[𝑈𝑈|𝐵𝐵] − 𝛾𝛾𝐵𝐵[𝑈𝑈|𝐵𝐵] − 𝛾𝛾𝑓𝑓𝑇𝑇𝑇𝑇𝑓𝑓[𝑈𝑈|𝐵𝐵] 
 
(4) 
 
Where 𝛾𝛾𝑓𝑓𝑇𝑇𝑇𝑇𝑓𝑓 is the rate of protein folding. BiP mRNA is given by: 
  
𝑑𝑑[𝐵𝐵𝑁𝑁]
𝑑𝑑𝑑𝑑
= 𝛽𝛽𝐵𝐵𝑁𝑁 + 𝑁𝑁𝐵𝐵𝑁𝑁𝑜𝑜(𝑋𝑋𝑁𝑁𝑠𝑠 ) − 𝛾𝛾𝐵𝐵𝑁𝑁[𝐵𝐵𝑁𝑁] 
 
(5) 
 
The binding of the spliced XBP1 TF to the UPRE promoter was modelled as a Hill function. This 
was a convenient mathematical way to describe XBP1s transcription in the regulation of the 
other UPR genes.  
 
𝑜𝑜(𝑋𝑋𝑁𝑁𝑠𝑠 ) = [𝑋𝑋𝑁𝑁𝑠𝑠 ]2𝛼𝛼0 + 𝛼𝛼1[𝑋𝑋𝑁𝑁𝑠𝑠 ] + [𝑋𝑋𝑁𝑁𝑠𝑠 ]2 (6) 
 
Where [𝐵𝐵𝑁𝑁] is the concentration of BiP mRNA, 𝛽𝛽𝐵𝐵𝑁𝑁 is its basal transcription rate, 𝑁𝑁𝐵𝐵𝑚𝑚  is a 
constant for the upregulation of BiP transcription under the UPR, and 𝛾𝛾𝐵𝐵𝑁𝑁 is the decay rate of 
BiP mRNA. [𝑋𝑋𝑁𝑁𝑠𝑠 ] is the concentration of spliced XBP1 mRNA and 𝛼𝛼0, 𝛼𝛼1 are constants. Similarly, 
the material balance for BiP is: 
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 𝑑𝑑[𝐵𝐵]
𝑑𝑑𝑑𝑑
= 𝛽𝛽𝐵𝐵[𝐵𝐵𝑁𝑁]− 𝛾𝛾𝐵𝐵[𝐵𝐵] − 𝐶𝐶𝑅𝑅𝐵𝐵[𝑈𝑈][𝐵𝐵] + 𝛾𝛾𝑅𝑅𝐵𝐵[𝑈𝑈|𝐵𝐵] + 𝛾𝛾𝑓𝑓𝑇𝑇𝑇𝑇𝑓𝑓[𝑈𝑈|𝐵𝐵] (7) 
 
Where 𝛽𝛽𝐵𝐵 is the translation rate of BiP mRNA, 𝐶𝐶𝑅𝑅𝐵𝐵 is the rate of BiP binding to the free receptor, 
and 𝛾𝛾𝑅𝑅𝐵𝐵 is the rate of dissociation of BiP from the inactive receptor. 
 
6.3.2  IRE1 pathway 
 
The description of the IRE1 pathway follows the model proposed by Pincus et al. [138] for UPR 
activation in yeast, which consists of a single-stranded response mediated by IRE1. It has been 
proposed that IRE1 in yeast [332] and IRE1β in the mammalian cells [324] may be activated by 
dissociation from BiP or by subsequent interaction of its peptide-binding domain on its luminal 
ER side with unfolded proteins [324, 332]. These scenarios represent the single and double 
activation mechanism, respectively. As in here the IRE1α arm was modelled, the single 
activation mechanism was employed.  
Under non-stressed conditions, IRE1 is present in a complex with BiP (𝑝𝑝𝐼𝐼𝐸𝐸|𝐵𝐵) the material 
balance for which is: 
  
𝑑𝑑[𝑝𝑝𝐼𝐼𝐸𝐸|𝐵𝐵]
𝑑𝑑𝑑𝑑
= 𝐶𝐶𝑒𝑒𝐵𝐵[𝐵𝐵][𝑝𝑝𝐼𝐼𝐸𝐸𝐴𝐴] − 𝛾𝛾𝑒𝑒𝐵𝐵[𝑝𝑝𝐼𝐼𝐸𝐸|𝐵𝐵] 
 
(8) 
Where [𝑝𝑝𝐼𝐼𝐸𝐸𝐴𝐴] the concentration of activated IRE1, 𝐶𝐶𝑒𝑒𝐵𝐵 is the binding rate of BiP to activated 
IRE1, and 𝛾𝛾𝑒𝑒𝐵𝐵 is the dissociation rate of BiP from IRE1. The concentration profile of activated 
IRE1 over time is described by: 
  
𝑑𝑑[𝑝𝑝𝐼𝐼𝐸𝐸𝐴𝐴]
𝑑𝑑𝑑𝑑
= −𝐶𝐶𝑒𝑒𝐵𝐵[𝐵𝐵][𝑝𝑝𝐼𝐼𝐸𝐸𝐴𝐴] + 𝛾𝛾𝑒𝑒𝐵𝐵[𝑝𝑝𝐼𝐼𝐸𝐸|𝐵𝐵] 
 
(9) 
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While studying the behavior of IRE1 activation, the model clearly demonstrated that there is a 
link between the different UPR modules and thus that they are not exclusive of each other. 
More specifically, the BiP component is present in the protein folding module, the IRE1 
activation and is itself affected by transcription of UPR signalling branches.  
 
The transcription of the unspliced XBP1 mRNA (𝑋𝑋𝑁𝑁𝑢𝑢 ) is up-regulated by the activation of the 
ATF6 branch, prior to its splicing by the IRE1 pathway [333]. Thus, the material balance for XBP1 
mRNA is a function of ATF6 activation and is described with the following equation:                       
  
𝑑𝑑[𝑋𝑋𝑁𝑁𝑢𝑢 ]
𝑑𝑑𝑑𝑑
= 𝛽𝛽𝑋𝑋𝑚𝑚𝑢𝑢 + 𝑁𝑁𝐴𝐴𝐴𝐴𝐴𝐴6𝛼𝛼𝑜𝑜(𝐴𝐴𝑇𝑇𝑝𝑝6𝛼𝛼) 
 
(10) 
 
Where 𝛽𝛽𝑋𝑋𝑚𝑚𝑢𝑢  the basal transcription rate of unspliced XBP1 mRNA, 𝑁𝑁𝐴𝐴𝐴𝐴𝐴𝐴6𝛼𝛼 is the constant 
representing the magnitude of stress response following ATF6 activation, and 𝑜𝑜(𝐴𝐴𝑇𝑇𝑝𝑝6𝐴𝐴) is the 
following activation Hill function: 
 
𝑜𝑜(𝐴𝐴𝑇𝑇𝑝𝑝6𝐴𝐴) = [𝐴𝐴𝑇𝑇𝑝𝑝6𝐴𝐴]2𝛼𝛼0 + 𝛼𝛼1[𝐴𝐴𝑇𝑇𝑝𝑝6𝐴𝐴] + [𝐴𝐴𝑇𝑇𝑝𝑝6𝐴𝐴]2 
 
(11) 
Where [𝐴𝐴𝑇𝑇𝑝𝑝6𝐴𝐴] is the concentration of activated ATF6 and 𝛼𝛼0, 𝛼𝛼1 are constants. The material 
balance for XPB1s mRNA is a function of IRE1 activation and is represented as follows: 
  
𝑑𝑑[𝑋𝑋𝑁𝑁𝑠𝑠 ]
𝑑𝑑𝑑𝑑
= −𝛾𝛾𝑋𝑋𝑚𝑚𝑠𝑠 [𝑋𝑋𝑁𝑁𝑠𝑠 ] + 𝛽𝛽𝑋𝑋𝑚𝑚𝑠𝑠 𝑛𝑛𝑡𝑡𝑛𝑛([𝑝𝑝𝐼𝐼𝐸𝐸𝐴𝐴], [𝑋𝑋𝑁𝑁𝑢𝑢 ]) 
 
(12) 
Spliced XBP1 mRNA stability is dependent on the level of phosphorylation of 𝑒𝑒𝑝𝑝𝑝𝑝2𝛼𝛼. To capture 
this feature, we introduced a modified decay rate of XBP1s mRNA (𝛾𝛾𝑋𝑋𝑚𝑚𝑠𝑠 ) that is linearly 
dependent on the concentration of phosphorylated 𝑒𝑒𝑝𝑝𝑝𝑝2𝛼𝛼. The approach used was that at 0% 
phosphorylation, the mRNA decay rate would be the same as the one of the unspliced form 
taken from Majumder et al. [167]. In contrast, at full phosphorylation, the decay rate would be 
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the one of the spliced form as given in the same study. The decay rate of XBP1s mRNA would 
therefore become: 
 
𝛾𝛾𝑋𝑋𝑚𝑚𝑠𝑠 = 𝛾𝛾𝑢𝑢 + (𝛾𝛾𝑠𝑠 − 𝛾𝛾𝑢𝑢) [𝑝𝑝𝑒𝑒𝑝𝑝𝑝𝑝2𝛼𝛼][𝑒𝑒𝑝𝑝𝑝𝑝2𝛼𝛼](0) (13) 
 
Where �𝛾𝛾𝑢𝑢 = 5.7 × 10−4 𝑐𝑐𝑒𝑒𝑐𝑐−1
𝛾𝛾𝑠𝑠 = 8.7 × 10−5𝑐𝑐𝑒𝑒𝑐𝑐−1  
This new feature also allowed us to create a link (other than BiP and unfolded proteins) 
between the two pathways (PERK and IRE1); such links are known to be multiple. Finally, the 
addition of the downstream pathway of PERK with mRNAs and protein such as ATF4 and eIF2α 
helped us create a negative regulation loop in the PERK pathway, through the CHOP-mediated 
dephosphorylation of phosphorylated eIF2α (equation 16) [334]. 
 
6.3.3  PERK pathway 
 
While the PERK activation mechanism requires the dissociation of BiP [335], there is some 
debate on whether the unfolded proteins are also engaged with its activation of the luminal 
domain through direct binding [336]. Although some studies have shown direct activation of 
unfolded proteins with PERK [332], there is not enough evidence to prove that this mechanism 
takes place. In our model, PERK is bound to BiP under non-stressed conditions. In the presence 
of increased levels of unfolded proteins in the ER, BiP dissociates from this complex and PERK 
becomes activated. The material balances for the complex (𝑃𝑃𝐸𝐸𝐼𝐼𝐾𝐾|𝐵𝐵) and the activated PERK (𝑃𝑃𝐸𝐸𝐼𝐼𝐾𝐾𝐴𝐴) are: 
  
𝑑𝑑[𝑃𝑃𝐸𝐸𝐼𝐼𝐾𝐾|𝐵𝐵]
𝑑𝑑𝑑𝑑
= 𝐶𝐶𝐶𝐶𝐵𝐵[𝐵𝐵][𝑃𝑃𝐸𝐸𝐼𝐼𝐾𝐾𝐴𝐴]− 𝛾𝛾𝐶𝐶𝐵𝐵[𝑃𝑃𝐸𝐸𝐼𝐼𝐾𝐾|𝐵𝐵] (14) 
   
  
𝑑𝑑[𝑃𝑃𝐸𝐸𝐼𝐼𝐾𝐾𝐴𝐴]
𝑑𝑑𝑑𝑑
= −𝐶𝐶𝐶𝐶𝐵𝐵[𝐵𝐵][𝑃𝑃𝐸𝐸𝐼𝐼𝐾𝐾𝐴𝐴] + 𝛾𝛾𝐶𝐶𝐵𝐵[𝑃𝑃𝐸𝐸𝐼𝐼𝐾𝐾|𝐵𝐵] (15) 
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Where 𝐶𝐶𝐶𝐶𝐵𝐵 is the binding rate of BiP to activated PERK and 𝛾𝛾𝐶𝐶𝐵𝐵 is its dissociation rate from the 
complex. Following on from PERK activation, 𝑒𝑒𝑝𝑝𝑝𝑝2𝛼𝛼 is phosphorylated at the Ser51 residue 
[258] as part of the translation attenuation mechanism. The material balances for the 
phosphorylated (𝑝𝑝𝑒𝑒𝑝𝑝𝑝𝑝2𝛼𝛼) and non-phosphorylated 𝑒𝑒𝑝𝑝𝑝𝑝2𝛼𝛼 species are as follows: 
  
𝑑𝑑[𝑝𝑝𝑒𝑒𝑝𝑝𝑝𝑝2𝛼𝛼]
𝑑𝑑𝑑𝑑
= 𝛽𝛽𝑒𝑒𝑒𝑒𝐴𝐴2𝛼𝛼𝑛𝑛𝑡𝑡𝑛𝑛([𝑃𝑃𝐸𝐸𝐼𝐼𝐾𝐾𝐴𝐴], [𝑒𝑒𝑝𝑝𝑝𝑝2𝛼𝛼])−  [𝐶𝐶𝐶𝐶𝐶𝐶𝑃𝑃][𝐶𝐶𝐶𝐶𝐶𝐶𝑃𝑃]𝑁𝑁𝑇𝑇𝑥𝑥 𝛾𝛾𝑒𝑒𝑒𝑒𝐴𝐴2𝛼𝛼[𝑝𝑝𝑒𝑒𝑝𝑝𝑝𝑝2𝛼𝛼] 
 
(16) 
 
    𝑑𝑑[𝑒𝑒𝑝𝑝𝑝𝑝2𝛼𝛼]
𝑑𝑑𝑑𝑑
= −𝛽𝛽𝑒𝑒𝑒𝑒𝐴𝐴2𝛼𝛼𝑛𝑛𝑡𝑡𝑛𝑛([𝑃𝑃𝐸𝐸𝐼𝐼𝐾𝐾𝐴𝐴], [𝑒𝑒𝑝𝑝𝑝𝑝2𝛼𝛼]) + [𝐶𝐶𝐶𝐶𝐶𝐶𝑃𝑃][𝐶𝐶𝐶𝐶𝐶𝐶𝑃𝑃]𝑁𝑁𝑇𝑇𝑥𝑥 𝛾𝛾𝑒𝑒𝑒𝑒𝐴𝐴2𝛼𝛼[𝑝𝑝𝑒𝑒𝑝𝑝𝑝𝑝2𝛼𝛼] 
 
(17) 
 
Where 𝛽𝛽𝑒𝑒𝑒𝑒𝐴𝐴2𝛼𝛼  is the rate of phosphorylation and 𝛾𝛾𝑒𝑒𝑒𝑒𝐴𝐴2𝛼𝛼  the rate of dephosphorylation. 
Dephosphorylation of p-eIF2α is mediated by GADD34 [334], which is directly activated by 
CHOP [260]. The ratio of [𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶][𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶]𝑚𝑚𝑚𝑚𝑚𝑚 was therefore used as a modulator of the CHOP-mediated 
dephosphorylation rate.  
As part of the UPR, ATF4 is transcribed and translated. The former event is subject to regulation 
by the level of phosphorylated eIF2α, which is described as a Hill function in the material 
balance below: 
  
𝑑𝑑[𝐴𝐴𝑇𝑇𝑝𝑝4𝑁𝑁]
𝑑𝑑𝑑𝑑
= 𝛽𝛽𝐴𝐴𝐴𝐴𝐴𝐴4𝑚𝑚 + 𝑁𝑁𝐴𝐴𝐴𝐴𝐴𝐴4𝑚𝑚𝑜𝑜(𝑝𝑝𝑒𝑒𝑝𝑝𝑝𝑝2𝛼𝛼)− 𝛾𝛾𝐴𝐴𝐴𝐴𝐴𝐴4𝑚𝑚[𝐴𝐴𝑇𝑇𝑝𝑝4𝑁𝑁] (18) 
 
With 𝑜𝑜(𝑝𝑝𝑒𝑒𝑝𝑝𝑝𝑝2𝛼𝛼) = [𝑝𝑝𝑒𝑒𝑒𝑒𝐴𝐴2𝛼𝛼]2
𝛼𝛼0+𝛼𝛼1[𝑝𝑝𝑒𝑒𝑒𝑒𝐴𝐴2𝛼𝛼]+[𝑝𝑝𝑒𝑒𝑒𝑒𝐴𝐴2𝛼𝛼]2 
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Where 𝛽𝛽𝐴𝐴𝐴𝐴𝐴𝐴4𝑚𝑚  is the basal transcription rate of ATF4, 𝑁𝑁𝐴𝐴𝐴𝐴𝐴𝐴4𝑚𝑚 is a constant for the upregulation 
of ATF4 transcription under the UPR, and 𝛾𝛾𝐴𝐴𝐴𝐴𝐴𝐴4𝑚𝑚 is the decay rate of ATF4 mRNA. The material 
balance for ATF4 protein is: 
  
𝑑𝑑[𝐴𝐴𝑇𝑇𝑝𝑝4]
𝑑𝑑𝑑𝑑
= 𝛽𝛽𝐴𝐴𝐴𝐴𝐴𝐴4[𝐴𝐴𝑇𝑇𝑝𝑝4𝑁𝑁]− 𝛾𝛾𝐴𝐴𝐴𝐴𝐴𝐴4[𝐴𝐴𝑇𝑇𝑝𝑝4] 
 
(19) 
Where 𝛽𝛽𝐴𝐴𝐴𝐴𝐴𝐴4 is the translation rate of ATF4 mRNA and 𝛾𝛾𝐴𝐴𝐴𝐴𝐴𝐴4 is the decay rate of ATF4 protein.  
The next effect of the PERK pathway is the expression of CHOP. The CHOP mRNA (𝐶𝐶𝐶𝐶𝐶𝐶𝑃𝑃𝑁𝑁 ) 
mass balance is described as a function of ATF4 and is given by: 
  
𝑑𝑑[𝐶𝐶𝐶𝐶𝐶𝐶𝑃𝑃𝑁𝑁]
𝑑𝑑𝑑𝑑
=  𝛽𝛽𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑚𝑚 + 𝑁𝑁𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑚𝑚𝑜𝑜(𝐴𝐴𝑇𝑇𝑝𝑝4) − 𝛾𝛾𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑚𝑚[𝐶𝐶𝐶𝐶𝐶𝐶𝑃𝑃𝑁𝑁] 
 
(20) 
 
where 
  
𝑜𝑜(𝐴𝐴𝑇𝑇𝑝𝑝4) = [𝐴𝐴𝑇𝑇𝑝𝑝4]2
𝛼𝛼0 + 𝛼𝛼1[𝐴𝐴𝑇𝑇𝑝𝑝4] + [𝐴𝐴𝑇𝑇𝑝𝑝4]2 
 
(21) 
 
𝛽𝛽𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑚𝑚 and  𝛾𝛾𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑚𝑚 are the transcription and decay rates of CHOP mRNA, respectively. 𝑁𝑁𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑚𝑚 
is a constant for the upregulation of CHOP transcription under the UPR. Finally, the levels of 
CHOP are: 
  
𝑑𝑑[𝐶𝐶𝐶𝐶𝐶𝐶𝑃𝑃]
𝑑𝑑𝑑𝑑
= 𝛽𝛽𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[𝐶𝐶𝐶𝐶𝐶𝐶𝑃𝑃𝑁𝑁]− 𝛾𝛾𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶[𝐶𝐶𝐶𝐶𝐶𝐶𝑃𝑃] (22) 
 
Where 𝛽𝛽𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 is the translation rate of CHOP mRNA and 𝛾𝛾𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 is the decay rate of CHOP 
protein. 
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6.3.4  ATF6 pathway 
 
Under homeostatic conditions, ATF6 is bound to BiP. In the presence of increased levels of 
unfolded protein in the ER, BiP dissociates from this complex and ATF6 translocates to the Golgi 
where it gets cleaved by caspases [333]. This results in the release of its activated truncated 
form. The material balances for the complex  (𝐴𝐴𝑇𝑇𝑝𝑝6|𝐵𝐵) and the activated (𝐴𝐴𝑇𝑇𝑝𝑝6𝐴𝐴) are: 
  
𝑑𝑑[𝐴𝐴𝑇𝑇𝑝𝑝6|𝐵𝐵]
𝑑𝑑𝑑𝑑
= 𝐶𝐶𝐴𝐴𝐵𝐵[𝐵𝐵][𝐴𝐴𝑇𝑇𝑝𝑝6𝐴𝐴]− 𝛾𝛾𝐴𝐴𝐵𝐵[𝐴𝐴𝑇𝑇𝑝𝑝6|𝐵𝐵] 
 
(23) 
 
  
𝑑𝑑[𝐴𝐴𝑇𝑇𝑝𝑝6𝐴𝐴]
𝑑𝑑𝑑𝑑
= −𝐶𝐶𝐴𝐴𝐵𝐵[𝐵𝐵][𝐴𝐴𝑇𝑇𝑝𝑝6𝐴𝐴] + 𝛾𝛾𝐴𝐴𝐵𝐵[𝐴𝐴𝑇𝑇𝑝𝑝6|𝐵𝐵] 
 
(24) 
 
Where 𝐶𝐶𝐴𝐴𝐵𝐵 is the binding rate of BiP to activated ATF6 and 𝛾𝛾𝐴𝐴𝐵𝐵 is the dissociation constant of 
BiP from ATF6. 
 
6.4   Formation of the XBP1 protein complex 
 
As described in section 2.7.3, XBP1 is a major regulator in the UPR. Its function is vital as upon 
formation of the XBP1u-XBP1s complex (XBP1c), it acts as a negative regulator for the XBP1s TF, 
which promotes the synthesis of ER chaperones (Figure 13). The dynamic interplay of the 
complex formation in our model is illustrated in Figure 52. 
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Figure 52: Reaction map of XBP1 protein complex formation integrated in the model. The following letters stand 
for the different forms of XBP1 where u: unspliced, s: spliced and c: complex.  
 
In order to replicate this mechanism in silico, the equations 25 and 26 were introduced in the 
model to describe the translation of spliced and unspliced XBP1 mRNA and the formation of the 
protein complex. 
The material balance for XBP1 unspliced is: 
  
𝑑𝑑[𝑋𝑋𝑢𝑢]
𝑑𝑑𝑑𝑑
= 𝛽𝛽𝑋𝑋𝑢𝑢  [𝑋𝑋𝑁𝑁𝑢𝑢 ] −  𝛽𝛽𝑋𝑋𝑐𝑐  [𝑋𝑋𝑢𝑢][𝑋𝑋𝑠𝑠] − 𝛾𝛾𝑋𝑋𝑢𝑢  [𝑋𝑋𝑢𝑢] 
 
(25) 
 
Where [𝑋𝑋𝑢𝑢] is the concentration of XBP1u protein (pXBP1u) , [𝑋𝑋𝑠𝑠] is the concentration of XBP1s 
protein (pXBP1s), 𝛽𝛽𝑋𝑋𝑢𝑢 is ihe translation rate of XBP1u mRNA, 𝛽𝛽𝑋𝑋𝑐𝑐  is the rate of XBP1 complex 
formation, 𝛾𝛾𝑋𝑋𝑢𝑢 is the decay rate of pXBP1u. 
Similarly, the material balance for XBP1 spliced is: 
 𝑑𝑑[𝑋𝑋𝑠𝑠]
𝑑𝑑𝑑𝑑
= 𝛽𝛽𝑋𝑋𝑠𝑠  [𝑋𝑋𝑁𝑁𝑠𝑠 ] −  𝛽𝛽𝑋𝑋𝑐𝑐  [𝑋𝑋𝑢𝑢][𝑋𝑋𝑠𝑠] − 𝛾𝛾𝑋𝑋𝑠𝑠 [𝑋𝑋𝑠𝑠] (26) 
Where  𝛾𝛾𝑋𝑋𝑠𝑠 is the decay rate of pXBP1s. 
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6.4.1  Degradation of XBP1 complex 
 
Yoshida et al. [337] used transfected HeLa cells overexpressing either the spliced or unspliced 
XBP1 mRNA form and examined their half-lives with immunoprecipitation of the cell lysates 
(Figure 53). The experimental degradation study showed that although these proteins have 
different degradation rates, these rates do not vary significantly to each other as both forms 
disappear within four hours. 
 
 
 
Figure 53: Stability of pXBP1u and pXBP1s in Hella cells [337].   
 
Following the abundance of XBP1 protein motifs (measured in AU) using pulse chase analysis by 
Yoshida et al. (Figure 53), the calculation of the XBP1 degradation rates for pXBP1s (𝛾𝛾𝑋𝑋𝑠𝑠 ) and 
pXBP1u (𝛾𝛾𝑋𝑋𝑢𝑢) was as follows: 
 
𝛾𝛾𝑋𝑋𝑠𝑠  = 290−402h  = 2.08 min-1 = 0.035 sec-1 
𝛾𝛾𝑋𝑋𝑢𝑢 = 320−1002h  = 1.83 min-1 = 0.030 sec-1 
 
The values introduced in the model were 0.030 sec-1 for pXBP1u and 0.035 sec-1 for pXBP1s. 
Next, the complex degradation rate was determined. Studies have shown that degradation of 
the pXBP1s-pXBP1u complex by the proteasome occurs following the complex translocation to 
the cytoplasm. These motifs have different C-terminal regions while their only common domain 
is the leucine zipper in the N-terminus allowing DNA binding and dimerization [338]. However, 
the proteasomal degradation process requires the 209-261 region of pXBP1u, showing that its 
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presence is indispensable for the quick destruction of the complex (Figure 54) [166, 338]. In 
another study, Lee and co-workers [339] generated mutant pXBP1u forms where two or three 
lysine residues (necessary for ubiquitin dependent degradation) in the C-terminal domain were 
replaced with arginine residues. These mutations generated more stable forms of the pXBP1u 
expressed at higher levels, which is in accordance with the function of ubiquitin in regulating 
protein degradation. The stable pXBP1u inhibited the activity of pXBP1s TF, suggesting a 
potential role for pXBP1u in controlling the function of pXBP1s.  
 
 
Figure 54: Degradation rates of pXBP1u forms in HeLa cells. Cells transfected with different forms of pXBP1 and 
treated with cycloheximide as indicated for four hours. The figure illustrates the cells expressing A: pXBP1u, B: 
pXBP1u (1-208) and C: pXBP1u (1-185) [338]. 
 
In agreement with the experimental evidence from the aforementioned studies, degradation of 
XBP1c, was assumed to occur at the same rate as pXBP1u i.e. faster than pXBP1s. In order to 
examine the role of pXBP1u in regulating the pXBP1s, the degradation and the translation rate 
constants for both molecules were determined.  
 
6.4.2  Translation of XBP1 complex 
 
The translation rates for pXBP1s (𝛽𝛽𝑋𝑋𝑠𝑠) and pXBP1u (𝛽𝛽𝑋𝑋𝑢𝑢) were calculated from data of a study of 
Yoshida and co-workers [166]. In that study, the accumulation of the XBP1 proteins was 
examined in the lysates of HeLa cells treated with TM in a 12 h time-course assay (Figure 55).  
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           𝛽𝛽𝑋𝑋𝑠𝑠  = 100−207h  = 0.19 min-1 = 3.2×10-3 sec-1  
           𝛽𝛽𝑋𝑋𝑢𝑢 = 100−1012h  = 0.125 min-1 = 2.0×10-3 sec-1  
 
 
Figure 55: Formation of pXBP1u, pXBP1s and XBP1 mRNA following TM-treatment in HeLa cells [166]. 
 
As it was observed from the degradation rates (𝛾𝛾𝑋𝑋𝑢𝑢  and 𝛾𝛾𝑋𝑋𝑠𝑠 ), pXBP1u and pXBP1s exhibit 
different stability. Further analysis, this time on the translation rate constant, illustrated 
pXBP1u rate to be lower compared to the pXBP1s. Once the two translation rate constants 
were found, it only remained to determine the complex degradation rate. A sensitivity analysis 
was performed in section 6.7.1 to verify that the XBP1 complex behaviour is truthful and the 
magnitude of the response is in a roughly correct range. 
 
6.5   Model calibration 
 
In order to enable model simulation, most parameter values were determined based on 
literature values taken from Pincus et al. [138] and maintained constant for all three cell lines 
studied experimentally. Some of these parameters such as the binding rate of BiP to IRE1 
receptor (taken by Pincus et al. [138]) were from studies on mammalian cells by Bertolotti et al. 
[323]. All values are shown in Table 13. Certain parameters were estimated using the 
experimental data presented in Chapter 5 using the maximum likelihood formulation of the 
parameter estimated entity in gPROMS (PSE Ltd., U.K.) as described in section 6.5.1. The initial 
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conditions used for model simulation are shown in Table 14. Finally, the values of parameter 
estimation for each of the three cell lines are presented in Table 16.    
The parameters related to the kinetic rates of UPR progression were fixed for all the three cell 
lines. However the parameters representing the magnitude of the stress response, the folding 
rate and the unfolded protein load were re-estimated separately for each cell line. This was 
decided as 1) the key UPR markers (ATF4, BiP, CHOP and XBP1) provided a different 
upregulation profile upon UPR activation, 2) the folding rate of a protein is known to be 
affected by the mutation and 3) the APPMUT appeared to be more stress than APPWT and thus 
had probably a higher load of unfolded proteins. 
 
Table 13: Parameter values taken from literature sources. 
Model parameters Value Units Reference 
CAB 1/0.35 mol-1 sec-1 
 
[138] 
CPB 1/0.35 mol-1 sec-1 
CIB 1/0.35 mol-1 sec-1 
CRB 1/0.35 mol-1 sec-1 
CUB 1/0.35 mol-1 sec-1 
n 4.50 AU 
SU 0 mol sec-1 
𝛽𝛽𝐴𝐴𝐴𝐴𝐴𝐴4 0.25 sec-1 
𝛽𝛽RB 0.25 sec-1 
𝛽𝛽𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 0.25 sec-1 
𝛽𝛽𝑒𝑒𝑒𝑒𝐴𝐴2𝛼𝛼 0.16  sec-1 
𝛽𝛽𝑋𝑋𝑠𝑠  3.20×10-3  sec-1 [166] 
𝛽𝛽𝑋𝑋𝑢𝑢    2.0×10-3  sec-1 
𝛾𝛾𝐴𝐴𝐴𝐴𝐴𝐴4 7.70×10-3 sec-1 Value re-used from fitted 𝛾𝛾𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 
𝛾𝛾𝐵𝐵 1.39×10-4 sec-1 [327] 
𝛾𝛾𝑒𝑒𝑒𝑒𝐴𝐴2𝛼𝛼 8.33×10-4 sec-1 
[138] 
γAB 1.96×102 sec-1 
γ IB 1.96×102 sec-1 
γPB 1.96×102 sec-1 
γRB 1.96×102 sec-1 
γUB 1.96×102 sec-1 
𝛾𝛾𝑋𝑋𝑠𝑠   3.50×10-2 sec-1 [337] 
𝛾𝛾𝑋𝑋𝑢𝑢   3.00×10-2 sec-1 
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6.5.1 Model calibration 
 
The experimental qRT-PCR data represented in relative values were first adjusted to the model 
data by a scaling process. As in our experimental results the actual mRNA quantities of the 
specific markers were not obtained, the relative values (AU) of the UPR markers were fitted to 
describe their fold increase. Scaling was achieved by multiplying the fold change experimental 
values with the values of the corresponding model variables when it reached its steady state, 
obtained by simulating the model starting from an initial condition of zero, which was assumed 
to be that at time zero. The standard deviation (𝜎𝜎) of the model was also transformed by 
applying the following formula: 
  𝜎𝜎(𝑑𝑑) =  σ (t=0)
𝑅𝑅𝑒𝑒𝑇𝑇𝑇𝑇𝑇𝑇𝐷𝐷𝑙𝑙𝑒𝑒 𝑒𝑒𝑥𝑥𝑝𝑝 𝑙𝑙𝑇𝑇𝑇𝑇𝑢𝑢𝑒𝑒 (𝑇𝑇=0) + σ (t)𝑅𝑅𝑒𝑒𝑇𝑇𝑇𝑇𝑇𝑇𝐷𝐷𝑙𝑙𝑒𝑒 exp𝑙𝑙𝑇𝑇𝑇𝑇𝑢𝑢𝑒𝑒 (𝑇𝑇)  ×   𝑛𝑛𝑜𝑜𝑑𝑑𝑒𝑒𝑐𝑐 𝑡𝑡𝑛𝑛𝑡𝑡𝑑𝑑𝑡𝑡𝑡𝑡𝑐𝑐 𝑣𝑣𝑡𝑡𝑐𝑐𝑛𝑛𝑒𝑒 (27) 
 
Where σ (t = 0) is the initial value and σ (t) 𝑡𝑡𝑐𝑐 the value at time point (t) for each variable. 
Following the transformation of our data, they were incorporated in the parameter estimation 
entity in gPROMS. The complete raw code in gPROMS language is provided in Appendix III. The 
initial conditions used for model simulation are described in Table 14. 
Table 14: Initial conditions used for model simulation.  
Variable Initial condition (molecules) Reference 
ATF4   0 Reflect steady state conditions 
ATF4m  3.16×103 Our experimental data (time 0 h) 
ATF6A 0 Reflect steady state conditions 
B 4.30×105  [138] 
Bm 2.00×102 Our experimental data (time 0 h) 
CHOP    0 Reflect steady state conditions 
CHOPm  1.10×105  Our experimental data (time 0 h) 
eIF2a 2.0×102 [138] 
IREA  0 Reflect steady state conditions 
IRE|B  2.56×102 [138] 
peIF2a 0 Reflect steady state conditions PERKA  0 
PERK|B 2.56×102 [138] 
U 0 Reflect steady state conditions U|B  0 
𝑋𝑋𝐴𝐴𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇  1.52×102 Our experimental data (time 0 h) 
Xsm 27.54 Our experimental data (time 0 h) 
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Parameters pertaining to the kinetic rates of UPR progression were estimated from the 
experimental data of the APPS cells. Estimation was performed in order to find the parameters 
allowing the model to fit our experimental data. These were fixed for the other two cell lines, 
with the exception of six parameters that were estimated separately from the data set for each 
cell line. These comprised the parameters representing the magnitude of the stress response 
for each cell namely 𝑁𝑁𝐵𝐵𝑁𝑁,𝑁𝑁𝐴𝐴𝐴𝐴𝐴𝐴4𝑚𝑚 , 𝑁𝑁𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑚𝑚 ,𝑁𝑁𝐴𝐴𝐴𝐴𝐴𝐴6𝐴𝐴 , the folding rate 𝛾𝛾𝑓𝑓𝑇𝑇𝑇𝑇𝑓𝑓 and the unfolded 
protein load Ku. The difference in transcription rates under the UPR was evident from the 
different upregulation profiles of the key UPR indicators, namely BiP, ATF4 and CHOP. The 
change in the folding rate was appropriate as protein folding studies have shown that some of 
the site-mutations in the APP protein may affect its tertiary structure while others do not cause 
any effect in the folding shape [340]. As the rate at which proteins fold is determined by their 
native state [341], estimation of  𝛾𝛾𝑓𝑓𝑇𝑇𝑇𝑇𝑓𝑓  was performed for each cell line separately. It was 
further hypothesised that the mutant APP proteins might require longer time to fold compared 
to the wild-type.  
 
The parameters were fitted in the order shown in Table 15 to obtain the relevant initial 
estimates but not the final values. In this approach the values that were firstly estimated 
corresponded to the IRE1 pathway, which were the transcription and degradation rates of BiP 
and then of XBP1 (Step (i) and (ii) in Table 15). These were used to continue the estimation of 
parameters related to the PERK pathway. The parameters related to the PERK pathway were 
the ATF4 and CHOP transcription and decay rates and their estimation was done simultaneously 
(Step (iii) in Table 15).  
 
Table 15: Steps followed for parameter estimation 
Order of estimated parameters 
(i) 
Parameters 
(ii) 
Parameters 
(iii) 
Parameters 
(iv) 
Parameters 
(v) 
Parameters 
𝛽𝛽RBm 
𝛽𝛽𝑋𝑋𝑚𝑚𝑠𝑠  𝛽𝛽𝐴𝐴𝐴𝐴𝐴𝐴4𝑚𝑚 𝑁𝑁𝐵𝐵𝑚𝑚               𝛾𝛾𝑓𝑓𝑇𝑇𝑇𝑇𝑓𝑓 𝛾𝛾𝑋𝑋𝑚𝑚𝑠𝑠  𝛾𝛾𝐴𝐴𝐴𝐴𝐴𝐴4𝑚𝑚 𝑁𝑁𝐴𝐴𝐴𝐴𝐴𝐴4𝑚𝑚  
𝛾𝛾𝐵𝐵𝑁𝑁 
𝛽𝛽𝑋𝑋𝑚𝑚𝑢𝑢  𝛽𝛽𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑁𝑁 𝑁𝑁𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑚𝑚 𝐾𝐾𝑢𝑢 𝛾𝛾𝑋𝑋𝑚𝑚𝑢𝑢  𝛾𝛾𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑚𝑚  𝑁𝑁𝐴𝐴𝐴𝐴𝐴𝐴6𝐴𝐴  
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At step (iv) of Table 15 the parameters representing the magnitude of the stress response 
namely 𝑁𝑁𝐵𝐵𝑚𝑚 ,  𝑁𝑁𝐴𝐴𝐴𝐴𝐴𝐴4𝑚𝑚 , 𝑁𝑁𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑚𝑚 ,𝑁𝑁𝐴𝐴𝐴𝐴𝐴𝐴6𝛼𝛼 were fitted for each cell line separately, followed by the 
folding rate 𝛾𝛾𝑓𝑓𝑇𝑇𝑇𝑇𝑓𝑓 and the unfolded protein load 𝐾𝐾𝑢𝑢  presented in Table 16. A step-by-step 
approach was used to estimate the parameters. The optimal estimates were obtained as 
presented in Table 16, with the respective SDs as presented in Tables 17 and 18. 
 
Table 16: Estimated parameter values. 
Model Parameters WT S S-I Units 
𝛼𝛼0 18.19x104 AU 
𝛼𝛼1 23.73 AU 
𝛽𝛽𝐴𝐴𝐴𝐴𝐴𝐴4𝑚𝑚 0.24 mol sec
-1 
𝛽𝛽𝐵𝐵𝑚𝑚  5.00×10
-2 mol sec-1 
𝛽𝛽𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑚𝑚 41.43 mol sec
-1 
𝛽𝛽𝑋𝑋𝑚𝑚𝑠𝑠  1.42×10
-4 sec-1 
𝛽𝛽𝑋𝑋𝑚𝑚𝑢𝑢  9.19×10
-3  mol sec-1 
𝛾𝛾𝐴𝐴𝐴𝐴𝐴𝐴4𝑚𝑚 4.67×10
-7 sec-1 
𝛾𝛾𝐵𝐵𝑚𝑚  1.03 sec
-1 
𝛾𝛾𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 7.70×10-3 sec-1 
𝛾𝛾𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑚𝑚  7.73×10
-6 sec-1 
𝛾𝛾𝑋𝑋𝑚𝑚𝑠𝑠   3.69×10
-8 sec-1 
𝛾𝛾𝑋𝑋𝑚𝑚𝑢𝑢   6.39×10-4 sec-1 
𝑁𝑁𝐴𝐴𝐴𝐴𝐴𝐴4𝑚𝑚  4.89 18 11 AU 
𝑁𝑁𝐵𝐵𝑚𝑚               4.00 1.84 1.48 AU 
𝑁𝑁𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑚𝑚 71.88 378.30 138.76 AU 
𝑁𝑁𝐴𝐴𝐴𝐴𝐴𝐴6𝐴𝐴       1.00×10
-2 1.09 0.57 AU 
𝐾𝐾𝑢𝑢  35.10×103 76.19×103 50.04×103 mol sec-1 
𝛾𝛾𝑓𝑓𝑇𝑇𝑇𝑇𝑓𝑓 2.58×10-4 2.57×10-4 2.39×10-4 mol sec-1 
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Table 17: (a) The standard deviation values of the estimated parameters, the same for all three cell lines. 
 
 
 
 
 
 
 
 
 
Table 18: (b) The standard deviation values of the estimated parameters, different for each cell line. 
Fitted parameters  ±SD 
(a) WT 
𝑁𝑁𝐵𝐵𝑚𝑚               2.29 
𝑁𝑁𝐴𝐴𝐴𝐴𝐴𝐴4𝑚𝑚  75 
𝑁𝑁𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑚𝑚 109 
𝑁𝑁𝐴𝐴𝐴𝐴𝐴𝐴6𝐴𝐴       0.50 
𝐾𝐾𝑢𝑢  1.17×103 
𝛾𝛾𝑓𝑓𝑇𝑇𝑇𝑇𝑓𝑓 1.28×10-5 
(b) S 
𝑁𝑁𝐵𝐵𝑚𝑚               9.00×10-2 
𝑁𝑁𝐴𝐴𝐴𝐴𝐴𝐴4𝑚𝑚  3.80 
𝑁𝑁𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑚𝑚 3.97 
𝑁𝑁𝐴𝐴𝐴𝐴𝐴𝐴6𝐴𝐴       7.00×10
-3 
𝐾𝐾𝑢𝑢  2.30×103 
𝛾𝛾𝑓𝑓𝑇𝑇𝑇𝑇𝑓𝑓 1.49×10-5 
(c) S-I 
𝑁𝑁𝐵𝐵𝑚𝑚               9.62×10-2  
𝑁𝑁𝐴𝐴𝐴𝐴𝐴𝐴4𝑚𝑚  1.89 
𝑁𝑁𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑚𝑚 2.94 
𝑁𝑁𝐴𝐴𝐴𝐴𝐴𝐴6𝐴𝐴     0.11
  
𝐾𝐾𝑢𝑢  1.41×103  
𝛾𝛾𝑓𝑓𝑇𝑇𝑇𝑇𝑓𝑓 1.19×10-5 
 
Fitted parameters ±SD 
WT / S / S-I 
𝛽𝛽𝐴𝐴𝐴𝐴𝐴𝐴4𝑚𝑚  2.00×10
-2 
𝛽𝛽𝐵𝐵𝑚𝑚  4.00×10
-3 
𝛽𝛽𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑁𝑁 1.94 
𝛽𝛽𝑋𝑋𝑚𝑚𝑠𝑠  1.22×10-5 
𝛽𝛽𝑋𝑋𝑚𝑚𝑢𝑢  4.90×10
-3 
𝛾𝛾𝐴𝐴𝐴𝐴𝐴𝐴4𝑚𝑚  9.98×10
-5 
𝛾𝛾𝐵𝐵𝑚𝑚  9.95×10
-6 
𝛾𝛾𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1.02×10-6 
𝛾𝛾𝑋𝑋𝑚𝑚𝑢𝑢    9.59×10-6 
𝛾𝛾𝑋𝑋𝑚𝑚𝑠𝑠   4.04×10
-6 
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The UPR-related genes ATF4, BiP and CHOP, which exhibited changes in their transcription 
rates, also demonstrated different estimated values of the related parameters Table 16. More 
specifically, APPS exhibited an increase of 3.68- and 5.25-fold in their 𝑁𝑁𝐴𝐴𝐴𝐴𝐴𝐴4𝑚𝑚 and 𝑁𝑁𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑚𝑚 
parameter values, respectively, when compared to APPWT, while APPS-I rates were in the same 
order of magnitude as APPWT. Changes in 𝑁𝑁𝐴𝐴𝐴𝐴𝐴𝐴6𝐴𝐴  were also observed and they were 76 and 57 
times higher in APPS and APPS-I, respectively, compared to the values for the wild type cell line. 
The next parameter estimated was 𝛾𝛾𝑓𝑓𝑇𝑇𝑇𝑇𝑓𝑓, the values of which were found to be similar in all cell 
lines. Along with the protein folding rate, the rate of unfolded protein synthesis was also 
estimated separately in each of the cell lines. The program was run for each cell line individually 
to allow for the possibility that different cell lines have different unfolded protein load. Indeed, 
the changes in 𝐾𝐾𝑢𝑢 showed a 3.83- and 1.43-fold increase in APPS and APPS-I when compared to 
APPWT.  All of the estimated parameter values used are presented in Table 16.  
 
6.6   Model simulation results 
 
The model was simulated with the initial conditions and parameter values presented in Table 
14 and the results were compared to the experimental data. The agreement for the UPR target 
genes, namely BiP (Figure 56 a-c), XBP1s (Figure 56 d-f), ATF4 (Figure 57 a-c), CHOP (Figure 57 
d-f) and XBP1T (Figure 58 a-c) for the APPWT (a, b), APPS (c, d) and APPS-I (e, f) cell lines is 
satisfactory. Looking at the data obtained from the IRE1 markers in Figure 56, they demonstrate 
the model capability to reproduce the experimental data accurately.  
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Figure 56: Comparison of model simulation results with experimental data for BiP and XBP1s mRNA. The dots 
correspond to the experimental data while the solid lines show the model simulation results. 
 
Moving on to the data from the PERK pathway, Figure 57 suggested the need to improve the 
response of ATF4, which was very sharp, and the signal of the downstream target CHOP. This 
sharp increase might be associated with the induction of CHOP expression by both ATF6 and 
PERK pathways. More specifically, the experimental data suggested that CHOP mRNA at early 
time points of TM-treatment was induced from ATF6 and not from PERK signalling and 
demonstrated that PERK activation occurred at later time points of TM-treatment. This suggests 
the bend in ATF4 response (Figure 57 a, c and e) to be a reflection of the onset of PERK 
activation while the bend in CHOP (downstream of ATF4) (Figure 57 b, d and d) to be a sum of 
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both ATF6 and PERK signalling. By allowing the regulation of CHOP by ATF6 and PERK activation 
in the model, a smoother response may be obtained. Another explanation for the ATF4 
response may be its upregulation at a protein level but not at the mRNA level. 
 
 
Figure 57: Comparison of model simulation results with experimental data for ATF4 and CHOP mRNA. The dots 
correspond to the experimental data while the solid lines show the model simulation results. 
 
Looking at the data for the ATF6 pathway (Figure 58), a good fit of the XBP1T mRNA was 
achieved in the APPS and APPS-I cell lines and a less satisfactory fitting for APPWT caused by the 
high variability of the experimental data. A better model response could be obtained by 
including protein data of the activated ATF6 molecule p50 that directly correlates its activation.  
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Figure 58: Comparison of model simulation results with experimental data for XBP1T mRNA. The dots 
correspond to the experimental data while the solid lines show the model simulation results. 
 
The simulation results obtained show the model’s ability to reproduce the desired shape of the 
UPR response for each of the three cell lines studied. It stands to reason that the computational 
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model can reflect biological reality and with further validation, could provide a better 
understanding of the UPR mechanism.  
 
Along with the estimated parameter values, the respective SDs were also reported (Tables 17 
and 18. In some cases such as for 𝛾𝛾𝐴𝐴𝐴𝐴𝐴𝐴4𝑚𝑚 the standard deviation (SD) was high reflecting the 
increased variation of the experimental data. In other parameters such as 𝛽𝛽𝑋𝑋𝑚𝑚𝑢𝑢  the high order of 
magnitude of SD showed that, either our experimental data were not sufficient to make the 
estimation or that the system was not sensitive enough to identify this parameter. As the 
model represents a highly complex biological system, it is evident that some of the parameters 
could not be accurately determined. Identification and assessment of the absolute rates of 
specific substrate molecules is a process that would require their isolation from the cell for 
accurate measurements.   
Most biological systems are very complex and have many interconnected components, making 
them difficult to define. For this reason, the attempt to model the structure of models such as 
the mammalian UPR may not precisely reflect the biological relevance for all parameters 
estimated. Future model improvement would include a parameter sensitivity analysis prior to 
the estimation in order to find the key kinetic parameters of our model and fix them to their 
normal values. 
 
6.7   Simulation analyses reflecting the UPR mechanism   
 
6.7.1  ATF6 sensitivity analysis  
 
The model simulations results of XBP1T reflect the experimental data with reasonable accuracy 
as shown in Figure 58. APPS showed a pronounced increase in the magnitude of the stress 
response of ATF4 (𝑁𝑁𝐴𝐴𝐴𝐴𝐴𝐴4𝑚𝑚), the pro-apoptotic marker CHOP (𝑁𝑁𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑚𝑚), as well as following 
ATF6 activation (𝑁𝑁𝐴𝐴𝐴𝐴𝐴𝐴6𝐴𝐴). Due to the lack of experimental data for the ATF6 pathway, a 
sensitivity analysis was conducted in each of the cell lines by increasing the  𝑁𝑁𝐴𝐴𝐴𝐴𝐴𝐴6𝐴𝐴 and 
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following the relative amount of XBP1T mRNA (Figure 59). This successfully showed that during 
stress, a higher  𝑁𝑁𝐴𝐴𝐴𝐴𝐴𝐴6𝐴𝐴  causes an increased expression of the XBP1T transcripts levels.   
 
 
Figure 59: Sensitivity analysis output for ATF6 pathway for each cell line. Figures correspond to a) APPWT, b) 
APPS and c) APPS-I. The plot illustrates the effect of the magnitude of stress response following ATF6 activation (NATF6A) on the relative amount of XBP1 total mRNA levels. The gradient colour scale reading (darker to lighter) 
reflects the higher to lower  NATF6A  values.  
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These simulation results were in agreement with recent studies by Yoshida et al. [337] which 
have illustrated that XBP1 mRNA regulation is induced by ATF6 activation under stress 
conditions, and is spliced upon IRE1 activation. Figure 59 also provided information on the 
magnitude of the ATF6 signalling in the different cell lines. APPWT required a very high 
transcription rate of the ATF6 under UPR (NATF6A=10.24) to achieve a similar trend of the 
response with the other cell lines. This rate was three-fold higher relative to the APPMUT 
(NATF6A=3.05 and 4 for APPS and APPS-I, respectively). However, the XBP1T mRNA levels in 
APPWT were observed to be the lowest compared to the other cell lines. This provided further 
evidence that the magnitude of the stress response regarding ATF6 signalling was stronger in 
the APPMUT cell lines. 
 
6.7.2  Quantitative analysis of unfolded protein load 
 
Subsequently, the simulation results for BiP (𝑁𝑁𝐵𝐵𝑁𝑁) also suggested that APPWT were more 
resistant to stress as they had a sharper transcriptional response of this gene and the lowest 
unfolded protein flux 𝐾𝐾𝑢𝑢 compared to the FAD mutant cells. The latter parameter, the value of 
which is indicative of the cumulative load of unfolded proteins in the ER, demonstrated a fold 
increase of 2.18 and 1.43 in APPS and APPS-I respectively, when compared to APPWT  (Figure 60). 
 
Figure 60: Quantitative analysis of the unfolded protein distribution. Protein load of APPWT, APPS, and APPS-I 
following eight hours of TM-treatment. The plot shows the absolute levels of unfolded proteins during the stress 
time course. 
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6.7.3  Effect of XBP1 protein complex 
Unspliced XBP1 mRNA can be translated and the resulting protein (pXBP1u) has been reported 
to form a complex with the XBP1s TF (pXBP1s). Specifically, pXBP1u, which shuttles between 
the nucleus and the cytoplasm, can heterodimerise with pXBP1s in the nucleus to form a 
complex (pXBP1u-pXBP1s) that is trafficked to the cytoplasm where it is degraded. The complex 
is therefore a negative regulator of pXBP1s [342]. Degradation of pXBP1s consequently causes 
reduced transcriptional activation of its target genes. Understanding this interplay may 
facilitate the modulation of the UPR in terms of intensity and duration [166, 337, 342]. 
In order to replicate this mechanism in silico, the equations 25-26 were introduced in the model 
to describe the translation of spliced and unspliced XBP1 mRNA and the formation of the 
protein complex. Different degradation rates were also introduced for each of the two proteins, 
0.030 sec-1 for pXBP1u and 0.035 sec-1 for pXBP1s, the values of which were determined from 
an experimental degradation study described in section 6.4.1 [337]. Finally, the complex was 
assumed to degrade at the same rate as pXBP1u, i.e. faster than pXBP1s, in agreement with the 
experimental evidence in the aforementioned study. 
A sensitivity analysis was then performed for the value of 𝛽𝛽𝑋𝑋𝑐𝑐 , which represents the rate at 
which the complex is formed. We specifically assessed the impact of this value on the number 
of pXBP1s molecules (Figure 61). The simulation results showed that at the highest rate of XBP1 
complex formation (𝛽𝛽𝑋𝑋𝑐𝑐  =5.5×10-3 sec-1), pXBP1s levels were significantly lower due to pXBP1s 
degradation within the complex. Furthermore, in (Figure 61) a quicker increase of the pXBP1s 
was observed from three to eight hours (12,000 to 18,000 sec), which reflected the duration of 
the stress response induced experimentally with TM. This observation is in accordance with the 
fact that the splicing process and thus accumulation of pXBP1s is a result of the ER stress 
response [166]. Finally, the aforementioned results clearly fit the theory, which suggests that 
pXBP1u functions as a negative regulator for pXBP1s by modulating its function [166]. This 
feature can improve the dynamic behaviour of the model allowing a better representation of 
the biological processes after appropriate experimental confirmation. 
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Figure 61: Effect of XBP1 protein complex formation rate on the XBP1s protein levels. Spliced XBP1 protein 
levels are upregulated during ER stress (12,000-18,000 sec) in a) APPWT, b) APPS and c) APPS-I. The pXBP1s levels 
are directly affected by the XBP1 protein complex formation (𝛽𝛽𝑋𝑋𝑐𝑐). 
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6.8   The computational model used as a basis to explore treatments in silico 
Therapeutic strategies that modulate ER function represent a promising approach for 
prevention or treatment of neurodegeneration. Manipulation of the UPR can induce cellular 
adaptation and improvement of the disease phenotype [257, 343]. Specific targets for ER 
regulation identified through screening of several compounds could act as potential inhibitors 
of ER stress. These vary from inhibitors of the IRE1 pathway, PERK phosphorylation or protein 
synthesis through the ATF4 pathway. 
An IRE1 inhibitor was found to be the 4μ8C [239], which blocks the splicing of XBP1 mRNA 
causing inhibition of protein synthesis of the downstream genes. Investigation of the PERK arm 
signalling demonstrated several inhibitors of PERK such as GSK2606414, [344] a compound 
inhibiting selectively the PERK phosphorylation and exhibiting neuroprotective functions. 
Pharmacological compounds that selectively increase the protective effects of the UPR acting 
through the eIF2α-ATF4 arm are salubrinal [345] and guanabenz molecules [222, 223]. 
Salubrinal enhances eIF2α phosphorylation levels by inhibiting the eIF2α phosphatases while 
guanabenz selectively deactivates only the stress-induced eIF2α phosphatase [222, 224]. 
Another strategy involves increasing protein-folding capacity without triggering other stress 
mechanisms. Selective mood altering drugs such as lithium [208, 346], VPA and 
supratherapeutic doses of carbamazepine are known to upregulate BiP expression without 
activating other stress markers [210] (Table 19). 
Table 19: Drug targets for ER stress regulation 
Drug Targeted pathway Effect Ref. Date 
4μ8C IRE1 Blocks XBP1s mRNA splicing [239] 2012 
GSK2606414 PERK Inhibits pPERK/p-eIF2α & translation attenuation [344] 2013 
Salubrinal 
Guanabez PERK 
Enhances p-eIF2α & 
decreases translation rates 
[345] 
[222] 2005 
Valproate 
Lithium 
IRE1 
ATF6 
Upregulates BiP 
but not the other UPR markers 
[208] 
[210] 2002 
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We subjected the mathematical model to a series of case studies representing the biological 
effect of known therapeutics in order to assess whether their effects can be captured in silico. 
The computational model for each of the cell lines was simulated individually for each case 
study. 
6.8.1  Case study 1: Effect of salubrinal 
Salubrinal inhibits eIF2α dephosphorylation and protect cells from stress [345]. The 
computational model was modified to simulate this by removing the reaction of eIF2α 
dephosphorylation (equation 17). In other words, once an eIF2α molecule was phosphorylated, 
it would remain in that state. This had implications for equation 16, in which the influx of new 
proteins to the ER was reduced with a decreasing number of non-phosphorylated eIF2α 
molecules. According to that equation, inhibition of eIF2α dephosphorylation was expected to 
shut down protein translation. Indeed, the model simulation results in Figure 62 a, c and d 
demonstrated that salubrinal significantly reduced the load of unfolded proteins in cells. 
Consequently, the stress response was predicted to be less sharp compared to the response of 
the untreated cells.  
As the accumulation of unfolded proteins in each cell line occurred at different time points 
from the stress induction, the effect of salubrinal was not simulated from the same time point. 
More specifically, dephosphorylation was halted at 14400 sec in APPS, at 17000 sec in APPS-I 
and lastly at 18500 sec of stress in APPWT. The accumulation of unfolded proteins in the non-
salubrinal treated cells was in accordance with Figure 60, validating the repeat of the above 
simulations of stress. In all cell lines, addition of salubrinal caused a sharp fall in the simulated 
unfolded protein distribution, demonstrating that the ultimate effect of this drug was the same 
independently of whether cells were carrying the wild-type or mutant APP695 variant. 
Simulation results also showed that BiP mRNA levels were upregulated upon the addition of 
salubrinal compared to the levels at the beginning of the response of the salubrinal treated 
cells (Figure 62b, d and f). These results are in agreement with the experimental observations of 
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Lee and co-workers [347] in SK-N-SH human neuroblastoma cells treated with Aβ, where 
salubrinal activated the PERK–eIF2α pathway and significantly increased BiP levels. Therefore, 
they suggested that this compound could be used as a potential treatment in 
neurodegenerative conditions. Even though BiP mRNA levels were higher than prior to 
salubrinal addition, they were lower than in the control case, in which BiP mRNA was expected 
to increase further (Figure 62 b, d). This is in agreement with recent studies on a rat model of 
ischaemic preconditioning by Gao et al. [348], which showed that salubrinal inhibited the ER 
stress response and reduced the levels of BiP compared to the non-treated group. This is 
evident from Figure 62 b, d and f as salubrinal treated cells exhibited reduced BiP mRNA 
compared to the non-treated cells that were undergoing stress. 
Finally, the model predicted that the overall trend and, thus, effect on the unfolded protein 
load and the BiP mRNA levels following addition of salubrinal was the same in all cell lines. Its 
experimental validation could demonstrate the consistency in the drug effect.   
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Figure 62: Effect of salubrinal during TM-treatment. Figures (a) and (b) correspond to APPWT, (c) and (d) to APPS, 
(e) and (f) to APPS-I cells treated with or without (control) TM. The graphs show the simulation results for the
distribution of (a) unfolded protein and (b) BiP mRNA levels in control (untreated) and in salubrinal-treated cells
at 14000 sec.
6.8.2  Case study 2: Effect of lithium and valproate (VPA) 
Pioneering studies have demonstrated that some mood stabiliser drugs such as lithium and VPA 
have a neuroprotective role against cell death. For instance, the addition of the 
aforementioned drugs in Tg-treated human neuroblastoma cells offered neuroprotection 
through a variety of cellular mechanisms [349]. Both of the aforementioned drugs have been 
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found to alter the expression of BiP mRNA and protein levels in neurons, bringing up the 
possibility of their therapeutic use [350].   
We have performed a model-based case study to determine the level of BiP upregulation 
necessary in order to process all the proteins in the ER without activating the UPR. In practice, 
the value of parameter 𝛽𝛽𝐵𝐵𝑚𝑚, representing the transcription rate of BiP, was increased in the 
model for cells producing APPWT, APPS   and APPS-I until no further XBP1 mRNA splicing 
occurred.  
The simulation results presented in Figure 61 illustrated that all three cell lines have the same 
pattern of response, which was that the higher the transcription rate of BiP the lower the 
spliced XBP1 mRNA. It was also clear that when the transcription rate of BiP was at the lowest 
level, the relative spliced XBP1 mRNA levels in APPS and APPS-I were demonstrated to be 
similar, while being significantly higher than levels exhibited by APPWT. This observation 
reflected the reality of the experimental system with the mutant cells displaying a stronger 
response to UPR markers with respect to stress relative to APPWT. 
Results in Figure 61a showed that a seven-fold increase in BiP transcription would be sufficient 
for folding the APPWT protein without inducing stress. This increase was within the capabilities 
of the system, which experimentally exhibited a 12-fold increase in BiP mRNA levels under 
conditions of stress. Similarly, a nine-fold increase in transcription of BiP would be enough for 
the folding of APPS and APPS-I, which experimentally displayed a 23- and 17-fold increase, 
respectively, in BiP mRNA during stress induction. 
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Figure 63: Effect of valproate during TM-treatment. The simulation results in (a) APPWT, (b) APPS and (c) APPS-I 
show the effect of VPA on spliced XBP1 mRNA levels by means of varying BiP transcriptional rates (𝜷𝜷𝑩𝑩𝒎𝒎). 
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6.9  Discussion 
To better understand the dynamics of the elaborate mammalian UPR system, we constructed a 
computational model integrating the response of three signalling branches: PERK, IRE1 and 
ATF6. The model was fitted to the mRNA experimental data of the first eight hours of the TM- 
time course stress experiment for each of the APPWT, APPS and APPS-I cell lines. As from the 
qRT-PCR experiments no absolute values were obtained, the data used for the computational 
model were semi-quantitative. 
The developed kinetic model gave us not only the desired shape of the response, but was also 
able to fit the relative increase for the five mRNAs whose upregulation was measured 
experimentally (BiP, ATF4, total XBP1, spliced XBP1 and CHOP). Following the parameter 
estimation, our model was able to reproduce our experimental data.  These included pre-
existing genetic factors (mutations in APP-associated with FAD) and a mimic of environmental 
triggers (chemical induction of stress) consequently triggering the stress response. Although the 
comparison of the model simulation results with the experimental data was satisfactory, it may 
be valuable obtaining more experimental data from additional time points to produce more 
reliable fits especially for the PERK pathway. For instance, by introducing gene expression data 
from additional TM-treatment time points could be beneficial. These measurements could be 
performed from around three to eight hours (11,000 sec to 30,000 sec) of TM-treatment, which 
was the time where the response got sharper. An additional experimental method could 
involve investigating the dynamics of the PERK-BiP from its deactivation. These data would 
verify whether the Hill function was the right equation to use.   
Simulation results of the model reflected the UPR mechanism and revealed its dynamics. Firstly, 
the sensitivity analysis performed for ATF6 demonstrated that an increase in the transcription 
under stress causes an increased expression of the XBP1T mRNA levels. Secondly, a quantitative 
analysis of the unfolded proteins in an eight hours TM-time course revealed a higher unfolded 
protein load in APPMUT compared to APPWT with highest load in APPS.  This is an interesting 
finding as the unfolded protein load was estimated from the data on UPR markers (rather than 
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APP expression data), but is still able to reflect the increased expression in APPs measured by 
qRT-PCR. Thirdly, evaluation of the function of XBP1 protein complex in silico confirmed its 
function as a negative regulator of pXBP1s.  
In silico analysis of salubrinal- and lithium/valproate-treatment case studies, successfully 
validated their therapeutic effects demonstrating the model’s ability to reproduce the effect of 
known drugs. Simulation of the inhibition of eIF2a dephosphorylation caused by salubrinal, 
demonstrated an inhibition of the unfolded protein load, which is in accordance with the global 
translation attenuation effect of this drug.  The data although they showed upregulation of BiP 
mRNA than prior to the addition of the drug, these levels remained lowered compared to the 
control cells, which are in agreement with previous experimental studies. Next, simulation of 
the lithium effect known to upregulate the levels of chaperones without activating the stress 
cascade revealed the fold increase of BiP mRNA required for the correct folding of APPWT and 
APPMUT upon induction of UPR. 
6.10 Conclusion 
The kinetic model that we developed reflects the biological reality of the UPR in mammalian 
cells and shows the dynamics effects of this molecular pathway which wold have been difficult 
to obtain with solely an experimental approach. Following the fitting simulation results, the 
model was subjected to a series of case studies that were able to capture the therapeutic effect 
of several drugs. Therefore, this computational model could be used to evaluate the response 
to drugs with a known effect with respect to the UPR.  
Although the simulations results we obtained are promising, the model is a simplification of the 
reality with one of the limitations being the use of mRNA data, which in reality do not linearly 
correlate with the protein levels. More specifically, BiP mRNA results did not capture the effect 
of ATF6 activation neither the increase of the unfolded protein load. Despite that, certain 
events including the XBP1 splicing occur at the mRNA level and thus changes in these events 
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were directly observed. To conclude, generation of a closer to reality UPR model would include 
validation at protein concentration level obtained possibly with the aid of protein detection 
tools such as ELISA (enzyme-linked immunosorbent assay), western blot or powerful techniques 
on detecting phosphorylation events such as immunohistochemistry and flow cytometry.  
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Discussion 
The aim of this project was to assess the progression of UPR in response to ER stress in FAD, 
using an experimental approach combined with a computational model. In particular, emphasis 
was placed on the early response following the application of chemical stress, an area that has 
been underexplored in the literature. 
7.1  Summary of results 
In the current study the first goal was to generate a cell model system of human neuroblastoma 
cells overexpressing either wild-type or FAD-associated APP695 mutants, the latter constructs 
containing either a single mutation (APPS) or a combination of two (APPS-I). Successful gene 
expression and protein levels analysis confirmed the significant upregulation of APP695 in the 
transfected cells compared to non-transfected, with qRT-PCR data suggesting a slight, but 
significant, APP increase in APPS compared to APPS-I and APPWT  (Chapter 4). These cell lines 
were used as the cell model system to provide quantitative data on i) whether FAD-mutations 
induce a preconditioning of ER-stress, ii) the timing of the UPR response, by treating the cells 
with an ER-stress inducer pharmacological agent and iii) the UPR dynamics by generating a 
mathematical model for mammalian UPR. 
The expression of eight UPR-responsive genes was analysed. These included: a) the ER 
chaperones BiP and GRRP4, b) the gene downstream of IRE1 pathway XBP1s, in addition to BiP, 
which is regulated by XBP1s TF, c) genes downstream of PERK signalling: Nrf-2, ATF4 and the 
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apoptotic CHOP TF and d) the downstream target genes of the activated ATF6 TF, XBP1T, BiP 
and CHOP were monitored in the three cell lines. As activation of ER stress can be triggered 
both by overproduction of APP alone but also by pharmacological intervention (TM-treatment), 
both of these methods were employed for the purpose of this project (Chapters 4 and 5, 
respectively).  
APP overexpression induced the upregulation of certain UPR markers even in the absence of 
additional stress. More specifically, APPWT exhibited increased expression levels of ATF4 mRNA, 
APPS of BiP, ATF4, XBP1s and CHOP mRNA and APPS-I of XBP1s transcripts, all with respect to 
the non-transfected cells (Chapter 4). It is evident that all cell lines were preconditioned for ER 
stress. The APPS that had higher APP levels compared to the other cell lines induced UPR with a 
higher magnitude. The increase of UPR markers observed in APPS was still mild in comparison 
to the respective one following pharmacological treatment (Chapter 5). The data indicate that 
overexpression of APP induces ER stress preconditioning and that a higher APP load (as seen in 
APPS) affects the level of the response. APPWT and APPS in a stress free environment also affect 
the mitochondria morphology, which among other dysfunctions trigger an increase in ROS in 
the cell [351]. As preconditioning of stress may provide a protective effect against the harmful 
effects stimulated by oxidative stress (as opposed to ER stress) [352], we postulated that 
activation of this mechanism might be beneficial for cells to counteract the increased of ROS 
production.  
Evaluation of the early events in the progression of UPR triggered by ER stress was achieved by 
following the UPR expression markers of a FAD-cell model in a TM-time course assay. At eight 
hours of TM-treatment, the cells metabolic activity along with their viability was restored to 
basal levels confirming cellular adaptation to ER stress. However 24 h of TM-treatment caused 
cell death confirming that prolonged stress induces cellular toxicity and apoptosis [3].  
Upregulation of the eight ER stress-induced UPR-responsive markers indicated activation of the 
UPR. An initial comparison of the fold increase within each of the cell lines, confirmed APPMUT 
to activate all three ER-stress sensors while APPWT to activate primarily the IRE1 and ATF6. The 
pattern of the response was similar in APPMUT with an early IRE1 and ATF6 activation at three 
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hours of TM-treatment followed by PERK activation at eight hours while APPWT demonstrated 
an early ATF6 activation followed by IRE1 activation at eight hours of TM-treatment. We 
postulated that all three pathways may be also activated in APPWT but masked by the increased 
variability of the UPR expression markers and specifically of ATF4 transcripts. Therefore, as the 
effect is translational, it could lead to higher protein levels even if there is no effect on the 
mRNA levels. 
Comparison of the fold increase in UPR markers among the cell lines provided further evidence 
that APPMUT activate ER stress in a similar manner to each other and with a stronger magnitude 
compared to APPWT. More specifically, at four hours of TM-treatment both APPS and APPS-I 
exhibited a significant fold increase of XBP1s, while at eight hours an upregulation of the fold 
levels of XBP1T and of the pro-apoptotic CHOP (ATF4-CHOP axis) respectively, compared to 
APPWT. Relative analysis of the UPR-markers of APPMUT to the APPWT demonstrated the levels of 
chaperones to be upregulated in APPMUT. More specifically BiP (at six and four hours of TM-
treatment for APPS and APPS-I, respectively) and GRP94 (at six and eight hours of TM-treatment 
for APPS and APPS-I, respectively) transcripts were significantly higher. At eight hours of TM-
treatment they both exhibited relative upregulation of CHOP as well as Nrf-2 mRNA relative to 
APPWT transcripts at the same time point. On the other hand, relative overexpression of XBP1s 
and XBP1T transcripts compared to APPWT at the same time point was only reported in APPS. 
Therefore, the data confirmed APPMUT to exhibit stress with higher magnitude and APPS to 
display the highest stress response. The higher APP levels expressed by APPS provide evidence 
that transcriptional variation may be the result of the higher amount of APP protein produced 
rather than caused by the specific mutation.   
In order to obtain a more complete and accurate understanding of the elaborate mechanism of 
UPR, a computational model integrating the three known ER-stress signalling branches was 
generated (Chapter 6). The experimental data of the gene expression levels of five UPR markers 
(BiP, XBP1s, XBP1T, ATF4 and CHOP) from eight hours of TM-treatment (Chapter 5) were fitted 
for each of the APPWT, APPS and APPS-I. Construction of the model was as such to allow 
evaluation of each of the UPR-signalling arms.  
 
 
195 
Discussion  
Several general considerations were made for this system and were successfully represented. 
First, the model demonstrated the high cross signalling of the three UPR signalling pathways. 
Second, the system was activated upon ER stress and was shut down when stress was resolved. 
Third, in case of prolonged stress the system restored homeostasis. Fourth, the model included 
the dynamic interplay of the translation of XBP1s and XBP1u mRNA and the formation of the 
XBP1 protein complex (XBP1c). Other important features were the incorporation of 
chaperones, which aid in the protein folding as well in the activation/deactivation process of 
the UPR. In addition, attenuation of protein synthesis was also included, lowering the amount 
of protein synthesised in the ER. 
Additionally of the general features, some more specific UPR considerations were made prior to 
fitting the experimental data with the model. As our cells exhibited stress at around three hours 
of TM-treatment, a time lag was introduced to follow this effect. The key indicators of UPR 
named BiP, ATF4, CHOP and XBP1T demonstrated different transcription upregulation profiles 
during the TM-induction and thus different transcription rates were considered to represent 
the stress response. As mutations in proteins affect the rate at which they are folded, these 
rates were estimated separately for each of the cell lines. Taken these assumptions into 
consideration, the model was expected and indeed demonstrated to provide the correct shape 
of the response as well as to fit with satisfaction the experimental fold increase of the UPR-
transcripts. Both the general as well as the more specific considerations provided details for the 
effective functioning of the UPR.  
Model simulation also reflected the UPR mechanism and dynamics, which included a sensitivity 
analysis of ATF6, a quantitative analysis of the unfolded protein load and evaluation of the 
function of XBP1 protein complex. The model was further used to perform case studies on the 
effect of known drugs targeting the UPR progression, which included the effect of salubrinal, 
lithium, and valproate. It also replicated in silico the effect of the XBP1 complex formation. 
These studies successfully demonstrated the model’s ability to replicate the effect caused by 
specific drugs while also predicting their outcome. By testing other molecules with known 
effect on the UPR, it could provide a better understanding of how different mutations affect the 
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activation of the response. This information gained could possibly assist in identifying point of 
interventions for therapeutics.  
 
7.2  Main conclusions   
 
Our analysis suggested that neuroblastoma cells overexpressing APP695 bearing FAD associated- 
genetic mutations activated ER stress signalling differently, than those overexpressing wild-type 
APP695. The genetic predisposition of these mutants might therefore be responsible for to their 
different effect on the UPR action.  
As distinct changes in transcription of several genes can have an effect on the progression of 
the disease [353], here we proved in vitro that different FAD mutations have transcriptional 
differences in the key regulators BiP, GRP94, ATF4, XBP1, Nrf-2 and CHOP. This might be also 
the case for FAD patients. Our data also confirmed that ER stress can be triggered only within a 
few hours since upregulation of UPR markers occurred at around three hours of TM-treatment, 
which was in accordance with the findings of previous studies [292]. Although the ER tries to 
restore homeostasis through transcriptional changes, it also requires short-term responses to 
ease the effects of stress by translational pause. However, the re-activation of global translation 
along with the contribution of transcriptional events is required to prevent cell death and allow 
homeostasis to be re-established. Additionally, faithful transcription of the mRNA of UPR target 
genes upregulated under the induction of stress is also essential as part of the transcriptional 
UPR response [319, 354]. 
Following the experimental analysis, we established a computational model that explores the 
role of UPR in mammalian cells expressing wild type APP and FAD-associated APP mutations. 
Our model was able to reproduce our experimental data, which included pre-existing genetic 
factors (mutations in APP-associated with FAD) and a mimic of environmental triggers (chemical 
induction of stress) consequently triggering the stress response. The model gave us not only the 
desired shape of the response, but was also able to fit the relative increase for the five mRNAs 
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whose upregulation was measured experimentally (BiP, ATF4, XBP1T, XBP1s and CHOP). 
Another utility for this model would be to use it in order to identify novel specific proteins in 
the stress response as targets for therapeutic intervention. For instance, salubrinal drug acts 
selectively on the PERK-mediated signalling pathway by specifically inhibiting the phosphatases 
responsible for its dephosphorylation. This compound maintains elevated eIF2α 
phosphorylation levels providing protection to cells against stress-induced apoptosis [345]. 
Thus if the mechanism of action is known, the present model can be used to simulate the 
corresponding effect.  
The switch to apoptosis in ER stress remains unclear; however, evidence shows that it is linked 
with the timing of the UPR [305]. Lin et al. [305] showed that a tailored combination of 
individual UPR branches determine susceptibility to stress which is in accordance with our data. 
More specifically, our experimental data depicted a stronger stress response in the cells 
carrying the mutant APP695 providing evidence for FAD mutations affecting the cellular 
susceptibility to stress. Our data also validated APPMUT to exhibit a strong induction of CHOP 
transcripts, which subsequent to a sustained UPR activation (24 h of TM-treatment) triggered 
apoptotic cell death. Several lines of evidence suggest APPWT to be more resistant to apoptosis 
compared to FAD-associated APPMUT [355] [355]. Previous studies revealed APPMUT to generate 
increased Aβ42 levels inhibiting the protective effects of the wild-type APP [355]. Hence, we 
hypothesise that the significant upregulation of UPR markers in APPMUT may have occurred as a 
result of the increased accumulation of the toxic intraneuronal Aβ42 peptides in the ER. These 
toxic molecules by forming intracellular soluble oligomers increased the APPMUT susceptibility 
to stress.  
Our data demonstrated that the cells carrying the Swedish APP695 mutation exhibited the 
strongest response to stress. This molecular process was probably the result of the slight, but 
significant, higher expression of APP in APPS compared to APPS-I. In addition, the model also 
depicted that APPMUT had a higher unfolded protein flux compared to APPWT with APPS having 
the highest amount of unfolded proteins. APPMUT exhibited elevated levels of GRP94, usually 
expressed upon high demand of chaperones and thus under conditions of increased unfolded 
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protein load. This strengthens the model simulation results showing higher accumulation of 
unfolded proteins in cells carrying the FAD APP695 mutations. In the case of APPWT, the 
computational model also demonstrated a sharper transcriptional response of BiP under 
conditions of stress, confirming to have the lowest unfolded protein load compared to APPMUT. 
Thus, the effect captured with the UPR transcript data (strongest UPR activation) was in 
accordance with the model results, validating further our system.  
Nevertheless, in silico analysis illustrated that even in APPMUT, the levels of unfolded proteins 
returned to their initial values upon UPR activation, showing that UPR successfully resolves 
stress. This adaptive mechanism was also evident from the increase in transcription of the UPR 
markers during the stress response. Each of the cell lines customised this upregulation showing 
their attempt to gain adaptation. However, in an extensive or chronic stress situation (where 
stress is not alleviated), neuronal cells could get irreversibly damaged resulting in cell death [34, 
356] as was observed at 24 h of TM-treatment. 
The metabolic recovery observation was confirmed experimentally and computationally in the 
case study of cells treated with an inhibitor of eIF2α de-phosphorylation inducing down-
regulation of unfolded proteins. Hence, in silico analysis of drug-treatment scenarios validated 
that the concentration of unfolded protein was decreased to the initial levels. This study thus 
proposes a multidisciplinary platform that could be used in future development strategies for 
therapeutics with respect to UPR, to inhibit the onset or/and progression of AD.  
 
7.3  Limitations  
 
Even though the cell model system we studied provided information on the progression of UPR 
in FAD, it had several limitations. One of the main drawbacks was the use of polyclonal cell 
lines. Each of the stably transfected cell lines were composed of a heterogeneous mixture of 
cells, which probably had different susceptibility to the TM stress stimulus. More specifically, 
during the TM time course treatment, some cells within the same culture might have 
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experienced stress differently altering the background and increasing the variability of the 
expression changes of UPR-related genes. These possible effects caused by the non-
homogenous cell populations make it harder to provide solid conclusions on the UPR profile as 
well as our ability to observe trends. The development of a monoclonal FAD-cell line could 
reduce this variability, as all cells would be derived from a single colony and would have the 
same levels of expression throughout the population. In that case, TM addition should affect all 
cells in a culture in the same way causing the same level of accumulation of the UPR markers. 
Evidence on the progression and the dynamics of UPR was provided based on mRNA 
experimental data from in vitro and in silico studies. Despite the fact that the transcription of a 
gene provides information on the gene expression patterns, the level of transcription gives only 
a rough estimate of the protein expression levels. This is because the mRNA levels of a target 
gene that may be produced in abundance either can be rapidly degraded or be inefficiently 
translated. Therefore, increased mRNA levels do not necessarily demonstrate high protein 
levels. Importantly, some UPR events occur at a protein level. For instance, the stress induced 
p-eIF2α upregulates ATF4 at a translation level. Our analysis on the PERK arm during UPR 
evaluated the ATF4 mRNA levels which are known to be upregulated upon stress as well as 
evaluated the transcripts of its downstream target genes (i.e. CHOP). Future investigation of the 
ATF4 protein levels would ascertain the activation of the PERK pathway.  
Another limitation in this project is the activation of ATF6, which was evaluated by quantitative 
analysis of the expression levels of its direct targets and not of the p50 TF.  Although direct 
analysis of ATF6 protein cleavage was attempted with WB, the outcome was unsuccessful 
probably due to the very low concentration of the ATF6 protein in this cell line (data not 
shown). In previous studies, evaluation of ATF6 activation under the induction of stress was 
accomplished either with a flag-tagged form of the full length ATF6 [185, 357] or with 
overexpression of the reported gene [358]. As our model cells were already genetically 
modified (with the APP mutations), it was preferred not to induce any further stress on the 
secretory pathway by including the overexpression of ATF6. To ascertain ATF6 activation, a flag-
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tagged form of the full length ATF6 could be generated in our cell model system and through 
quantification of the fluorescence verify its progression in the UPR. 
 
7.4 Future directions 
 
The experimental data showing the increase of the UPR markers during stress demonstrated 
APPS to exhibit the highest magnitude of the stress response. Subsequently the computational 
model provided evidence of APPS having the highest unfolded protein load compared to APPWT 
and APPS-I. This could be validated by experimental studies such as with the use of BLItz™ 
system, which uses fluorescence to measure the thermal stability of a protein in real-time 
kinetics. Thus, by measuring the unfolded transition temperature of a protein, it could provide 
real-time quantification of the relative percentage of folded versus unfolded proteins in a time-
course assay. This assay could be performed at each of the time points of TM-treatment time-
course experiment in all cell lines and the obtained signal could be subtracted from time zero 
hour. A control pre-heated sample could be used as a reference for the 100% unfolded protein 
load. This experiment could provide us information on the relative changes of the amount of 
unfolded proteins in the system throughout the progression of ER stress.   
Following analysis of the UPR adaptation phase, a subsequent investigation of the late stages of 
ER stress could be performed. This would require analysis of the activated apoptotic CPS such 
as CSP12 which has been previously suggested to be essential in the ER stress induced 
apoptosis [151] eventually activating the CSP3.  
Additionally with the effect of unfolded proteins in inducing ER stress, an altered ER redox 
environment or Ca2+ concentration could also trigger stress and induce the generation of its 
stress-mediated ROS [359]. As these intracellular oxidants may be induced in upstream events 
of the stress response and have deleterious consequences by creating vicious cycles in the 
onset and the progression of AD, their detection is of high importance. A semi-quantitative 
method for detecting oxidised proteins in a western blot format is with the use of the 
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commercial OxyBlot™ kit (Millipore, Massachusetts, USA). Oxidative stress can cause changes in 
the levels of glutathione (GSH) - an important antioxidant - indicating the potential of cells 
undergoing cell death, making the measurement of their levels also critical. GSH changes in our 
in vitro model can be detected at different time points of TM-treatment by using the 
GSH/GSSG-Glo™ assay kit (Promega, Hampshire, UK). This assay would measure the total 
glutathione in the reduced (GSH) and oxidised state (GSSG) and subsequently the ratio of 
GSH/GSSG would be estimated. This technique would allow us to evaluate the link between ER 
stress and oxidative stress.  
As the oxidative species which play an important role in the disease have short half-lives and 
alter quickly the cellular redox state, it would be ideal to monitor the redox changes in real-
time. The development of biosensors could be used as a tool to measure redox alterations in 
our FAD model system. In addition, of the redox changes, such a tool will be able to directly 
detect changes in gene expression levels from IRE1, PERK, and ATF6 and assess which of them 
is/are active after a specific treatment. Generation of these biosensors would be achieved by 
transfecting the cells with a construct vector containing a fluorescent protein (e.g GFP) reporter 
gene and promoter element for the target genes involved in the UPR (e.g chaperones). They 
would also contain inserted reporter elements such as UPRE or ERSE that have binding motifs 
specific for XBP1 and ATF6 transcription factors. The set of biosensors should contain different 
natural promoter sequences such as for chaperones, anti-oxidant and ERAD transcription 
factors influenced by ER stress. The data generated (level of fluorescence) would then be tested 
against the already obtained qRT-PCR data in order to correlate the fluorescent sensor with the 
gene expression data. This approach would allow us to follow the ER stress activation of the 
biosensors by the fluorescence levels. If the results are comparable, the biosensor system could 
be further used to test causes of and treatments for FAD. 
Changes in the environmental conditions causing ER stress can be measured by the increase in 
fluorescence. More specifically we would be able to test different conditions which occur in 
cells of FAD patients, including hypoxia [360] and glucose deprivation [361, 362]. Therefore, we 
will be able to examine the time points and the levels of glucose deprivation that cause stress 
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and results in cell death. Monitoring with high-throughput screening assays cellular events that 
can change over time or under different conditions could give us spatiotemporal information of 
neurodegenerative diseases. This could eventually help us determine the key steps needed to 
be targeted by small molecule therapies. 
Even though the ER organelle may act as a site generating several apoptotic signals, the 
mitochondria are also implicated at different stages of the ER stress response ranging from the 
adaptation process to cell death. It would thus be of great importance to investigate this 
interplay between ER dyshomeostasis and mitochondrial dysfunction at the beginning of ER 
stress. This could be achieved by measuring the UPR markers such as BiP (by western blot) and 
CytC release concentration with the Cytochrome C ELISA kit (MBL, Watertown, MA, USA) for ER 
and mitochondria, respectively.   
Although our computational model gives a good representation of the biological system 
studied, we are conscious that it is oversimplified. A high fidelity model of the mammalian UPR 
could be achieved by estimating protein-level parameters when they become available, as the 
increases in mRNA levels are not always indicative of the changes at the protein levels. Protein 
data will also allow a better fit. More specifically, they will enable the fitting of more constants 
including of the eIF2α of the PERK pathway, whose fitting was not possible in our model due to 
the lack of data. Furthermore, quantification of several mRNA decay kinetic profiles would 
increase accuracy for some of the estimated degradation parameters (i.e. for ATF4 mRNA). This 
would involve blocking the new transcriptional events and measuring the rate at which the 
mRNA is degraded. This would let us establish the individual decay profiles of the mRNA levels 
and include these experimental data to our system. 
To reflect the complexity of the UPR system better, negative regulators should also be included 
in the model. For instance the GADD34 protein stimulated by CHOP and dephosphorylating 
eIF2α in a negative feedback loop that causes translational repression in response to ER stress 
[363]. Another of great-importance feature to consider in the model would be the influence of 
ER stress in a dose dependent manner. This experimental approach would involve treating the 
cells with a variety of stressors (such Aβ or TM) in a range of different concentrations and 
 
 
203 
Discussion 
incorporating the data in the model. These data could provide information on the changes in 
the dynamics of the accumulation of unfolded proteins in the ER and deliver additional 
quantitative data on the impact of ER stress in FAD. 
Medical intervention of AD patients sharing similar symptoms but different mutations may be 
more efficient in certain subpopulations, emerging the need of a new era of personalised care 
[364]. The mammalian UPR model could be coupled with an individualised experimental system 
taking into consideration specific mutations. This approach may be a good basis to provide a 
better and safer drug discovery tailored to specific individuals. An individualised system of 
familial (carrying the E693Δ APP mutation) and sporadic AD was recently established [365] 
using induced pluripotent stem cells derived from AD patients. This study demonstrated that 
treatment of AD patients with the ER-stress specific docosahexaenoic acid, that failed clinical 
studies, could be effective in a subpopulation of AD patients [365]. This clearly shows that 
determination of patient-specific parameters would allow a more accurate identification of 
treatments based on personalised pharmacotherapeutics. 
7.5  Outlook 
In summary, we showed that FAD APP mutations trigger UPR more quickly than the cells 
overexpressing wild-type APP. The cells overexpressing APPMUT were the most sensitive to 
stress, activating all three ER membrane receptors with a similar profile. Experimental and 
computational studies suggested that all cells exhibited an adaptation to stress by eight hours 
of TM-treatment but when the stress persisted, UPR signalling induced cell death. The 
computational model reflects the biological reality of ER stress activation in mammalian cells 
and can be used to test the behaviour and efficiency of various drugs with a known effect. In 
conclusion, the UPR is an attractive target for neurodegenerative diseases and future 
investigations may provide insight into the major challenge of finding a prominent target for 
drug discovery. 
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Appendix I: Plasmid and primers for site-
directed mutagenesis 
 
 
 
Sequences 
 
1.  APP695 A33292.1  
 
ATGCTGCCCGGTTTGGCACTGCTCCTGCTGGCCGCCTGGACGGCTCGGGCGCTGGAGGTACCCACT
GATGGTAATGCTGGCCTGCTGGCTGAACCCCAGATTGCCATGTTCTGTGGCAGACTGAACATGCAC
ATGAATGTCCAGAATGGGAAGTGGGATTCAGATCCATCAGGGACCAAAACCTGCATTGATACCAAG
GAAGGCATCCTGCAGTATTGCCAAGAAGTCTACCCTGAACTGCAGATCACCAATGTGGTAGAAGCC
AACCAACCAGTGACCATCCAGAACTGGTGCAAGCGGGGCCGCAAGCAGTGCAAGACCCATCCCCAC
TTTGTGATTCCCTACCGCTGCTTAGTTGGTGAGTTTGTAAGTGATGCCCTTCTCGTTCCTGACAAGTG
CAAATTCTTACACCAGGAGAGGATGGATGTTTGCGAAACTCATCTTCACTGGCACACCGTCGCCAAA
GAGACATGCAGTGAGAAGAGTACCAACTTGCATGACTACGGCATGTTGCTGCCCTGCGGAATTGAC
AAGTTCCGAGGGGTAGAGTTTGTGTGTTGCCCACTGGCTGAAGAAAGTGACAATGTGGATTCTGCT
GATGCGGAGGAGGATGACTCGGATGTCTGGTGGGGCGGAGCAGACACAGACTATGCAGATGGGA
GTGAAGACAAAGTAGTAGAAGTAGCAGAGGAGGAAGAAGTGGCTGAGGTGGAAGAAGAAGAAG
CCGATGATGACGAGGACGATGAGGATGGTGATGAGGTAGAGGAAGAGGCTGAGGAACCCTACGA
AGAAGCCACAGAGAGAACCACCAGCATTGCCACCACCACCACCACCACCACAGAGTCTGTGGAAGA
GGTGGTTCGAGTTCCTACAACAGCAGCCAGTACCCCTGATGCCGTTGACAAGTATCTCGAGACACCT
GGGGATGAGAATGAACATGCCCATTTCCAGAAAGCCAAAGAGAGGCTTGAGGCCAAGCACCGAGA
GAGAATGTCCCAGGTCATGAGAGAATGGGAAGAGGCAGAACGTCAAGCAAAGAACTTGCCTAAAG
CTGATAAGAAGGCAGTTATCCAGCATTTCCAGGAGAAAGTGGAATCTTTGGAACAGGAAGCAGCCA
ACGAGAGACAGCAGCTGGTGGAGACACACATGGCCAGAGTGGAAGCCATGCTCAATGACCGCCGC
CGCCTGGCCCTGGAGAACTACATCACCGCTCTGCAGGCTGTTCCTCCTCGGCCTCGTCACGTGTTCA
ATATGCTAAAGAAGTATGTCCGCGCAGAACAGAAGGACAGACAGCACACCCTAAAGCATTTCGAGC
ATGTGCGCATGGTGGATCCCAAGAAAGCCGCTCAGATCCGGTCCCAGGTTATGACACACCTCCGTG
TGATTTATGAGCGCATGAATCAGTCTCTCTCCCTGCTCTACAACGTGCCTGCAGTGGCCGAGGAGAT
TCAGGATGAAGTTGATGAGCTGCTTCAGAAAGAGCAAAACTATTCAGATGACGTCTTGGCCAACAT
GATTAGTGAACCAAGGATCAGTTACGGAAACGATGCTCTCATGCCATCTTTGACCGAAACGAAAACC
228 
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ACCGTGGAGCTCCTTCCCGTGAATGGAGAGTTCAGCCTGGACGATCTCCAGCCGTGGCATTCTTTTG
GGGCTGACTCTGTGCCAGCCAACACAGAAAACGAAGTTGAGCCTGTTGATGCCCGCCCTGCTGCCG
ACCGAGGACTGACCACTCGACCAGGTTCTGGGTTGACAAATATCAAGACGGAGGAGATCTCTGAAG
TGAAGATGGATGCAGAATTCCGACATGACTCAGGATATGAAGTTCATCATCAAAAATTGGTGTTCTT
TGCAGAAGATGTGGGTTCAAACAAAGGTGCAATCATTGGACTCATGGTGGGCGGTGTTGTCATAGC
GACAGTGATCGTCATCACCTTGGTGATGCTGAAGAAGAAACAGTACACATCCATTCATCATGGTGTG
GTGGAGGTTGACGCCGCTGTCACCCCAGAGGAGCGCCACCTGTCCAAGATGCAGCAGAACGGCTA
CGAAAATCCAACCTACAAGTTCTTTGAGCAGATGCAGAACTAG 
2. Indiana APP695 mutation:
a) V717F s  GCGACAGTGATCTTCATCACCTTGG
b) V717F as CCAAGGTGATATAGATCACTGTCGC
3. Swedish APP695 mutation:
a) K670N,M671L s  GATCTCTGAAGTGAACCTGGATGCAGAATTC
b) K670N,M671Las GAATTCTGCATCCAGGTTCACTTCAGAGATIC
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Appendix III: Mammalian UPR Code in 
gPROMS® 
 
1. Computational model: Mammalian UPR for cells overexpressing Swedish APP695 
 
PARAMETER 
 
#Folding module 
 
Cb as REAL 
Cub AS REAL 
Gub AS REAL 
#Cd0 AS REAL 
#Cpdi AS REAL 
Gb AS REAL 
 
#IRE1 activation, XBP1 splicing, splicing reporter module 
 
Ci1b AS REAL 
Gi1b AS REAL 
 
Grsm as real 
Brs as real 
Grs as real 
 
#ATF6 pathway 
 
GAFB AS REAL 
 
#BiP transcription module 
 
Bb as real 
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#PERK activation/pathway 
n AS real 
I0 as real 
Cpkb AS REAL 
Gpkb AS REAL 
Cup AS REAL 
Be2a as real 
Ge2a as real 
GpE2a as real 
BpE2a as real 
#ATf4 pathway 
Bcp as real 
Gcp as real 
Ba4 as real 
Ga4 as real 
a0 as real 
a1 as real 
tau as real 
#fit? 
# DISTRIBUTION_DOMAIN 
# DomainName AS [ LowerBound : UpperBound ] 
# DomainName AS ARRAY ( Size < , ... > ) OF [ LowerBound : UpperBound ] 
# UNIT 
# UnitName AS UnitModelName 
# UnitName AS ARRAY ( Size || OrderedSet < , ... > ) OF UnitModelName 
# PORT 
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# PortName AS ConnectionType 
# PortName AS ARRAY ( Size || OrderedSet < , ... > ) OF ConnectionType 
VARIABLE 
t as concentration #time 
Bm as mRNA #BiP mRNA 
B as concentration #BiP 
I1AB as concentration #Ire1 linked to BiP 
I1A as concentration #Ire1 active 
Xu1m as mRNA   
pXu1 as concentration 
pXs1 as concentration 
pXc1 as concentration 
Xs1m as mRNA 
AFB as concentration #ATF6 linked to BiP 
AFa as concentration #activated ATF6 
#ATF6 as concentration #ATF6 active 
#Ge2a as mRNA # for salubrinal 
Xtotal as mRNA #total XBP1 
U as concentration # unfolded protein 
UB as concentration # folding complex 
Rsm as mRNA #Reporter mRNA 
Rs as concentration #reporter GFP 
Pka as concentration #activated PERK 
PkB as concentration #PERK-BiP 
E2a as concentration #eIF2a 
pE2a as concentration #phospho eIF2a 
Cp as concentration # CHOP 
A4 as concentration #ATF$ 
Cpm as mRNA # CHOP mRNA 
A4m as mRNA # ATF4 mRNA 
Su as concentration # variable ER stress 
#fitting 
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Na4m as fit 
Ba4m as fit 
Ga4m as fit 
 
Bbm as fit 
Nbm as fit 
Gbm as fit 
 
Bcpm as fit 
Gcpm as fit 
Ncpm as fit 
 
GXu1m as fit 
GXs1m as fit 
GpXu1 as fit 
GpXs1 as fit 
GpXc1 as fit 
 
BXs1m as fit 
BXu1m as fit 
BpXs1 as fit 
BpXu1 as fit 
BpXc1 as fit 
 
ku as fit 
Gfold as fit 
NAFa as fit 
 
# rates  
Rtransl, Rdecay, Rbind, Rdissoc AS rate 
 
# SELECTOR 
# SelectorName AS ( Flag < , ... > ) < DEFAULT Flag > 
# SelectorName AS ARRAY ( Size || OrderedSet < , ... > ) OF ( Flag < , ... > ) < DEFAULT 
Flag > 
# SelectorName AS DISTRIBUTION ( DomainName < , ... > ) OF ( Flag < , ... > ) < DEFAULT 
Flag > 
 
 
236 
Appendix III: Mammalian UPR Code in gPROMS®  
 
 
# SET 
# ParameterPath := Expression ; 
# ParameterPath := [ Expression < , ... > ]; 
# ParameterPath := "<ForeignObjectClass::>ForeignObjectValue"; 
# ParameterPath := [ "Name" < , ... > ]; 
# DomainPath := [ BFDM || CFDM || FFDM || OCFEM , Order , NumOfElements ]; 
 
 
# BOUNDARY 
# Boundary condition equations 
 
 
# TOPOLOGY 
# Unit connection equations 
Selector 
UpRegul as (NoRegul, Regul) DEFAULT NoRegul 
Transcription as (NoTransc, Transc) default NoTransc 
 
EQUATION 
#time reporter 
$t=1; 
 
#PERK activation/pathway 
 
$PkB=Cb*B*Pka-Gpkb*PkB; 
$Pka=Gpkb*PkB-Cb*B*Pka; 
 
 
$E2a=-Be2a*min(Pka,E2a)+Ge2a*pE2a ; 
$pE2a=+Be2a*min(Pka,E2a)-Ge2a*pE2a;  
 
 
#Salubrinal case study 
 
#Case UpRegul OF 
#When NoRegul : 
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#$E2a=-Be2a*min(Pka,E2a)+Ge2a*pE2a ; 
#$pE2a=+Be2a*min(Pka,E2a)-Ge2a*pE2a;  
#Switch to Regul if t=15000; 
#when Regul: 
#$E2a=-Be2a*min(Pka,E2a); 
#$pE2a=+Be2a*min(Pka,E2a)-Ge2a*pE2a;  
#End 
 
#ATF4 pathway 
 
Case transcription of 
When NoTransc :  
$A4m=Ba4m-Ga4m*A4m; 
$Cpm=Bcpm-Gcpm*Cpm; 
Switch to Transc if t>tau; 
When Transc : 
(a0+a1*pE2a+(pE2a)^2)*$A4m=Ba4m*(a0+a1*pE2a+(pE2a)^2+Na4m*(pE2a)^2)-
(a0+a1*pE2a+(pE2a)^2)*Ga4m*A4m; 
$Cpm=Bcpm+Ncpm/(a0+a1*A4+(A4)^2)*(A4)^2-Gcpm*Cpm; 
End 
$A4=Ba4*A4m-GA4*A4; 
$Cp=Bcp*Cpm-Gcp*cp; 
 
#protein folding dynamics 
$Su=ku/(3*3600);  
#$U=E2a/200*Su-Cb*U*B+Gub*UB-Cd0*D0*U+Cpdi*PDI*Ud+Gb*UB; 
$U=E2a/200*Su-Cb*U*B+Gub*UB+Gb*UB; 
#$UB=Cb*U*B-Gub*UB-Cd0*D0*UB+Cpdi*PDI*UdB-Gb*UB-Gfold*UB; 
$UB=Cb*U*B-Gub*UB-Gb*UB-Gfold*UB; 
 
 
#Ire1, XBP1 mRNA and splicing reporter 
$I1AB=Cb*B*I1A-Gi1b*I1AB; 
$I1A=-Cb*B*I1A+Gi1b*I1AB; 
 
$Xs1m=-(GXu1m-(GXu1m-GXs1m)*pE2a/200)*Xs1m+BXs1m*min(I1A,Xu1m); 
 
$Rsm=-Grsm*Rsm+BXs1m*min(I1A,Xu1m); 
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$Rs=-Grs*Rs+Brs*Rsm; 
 
#new equations: 
$pXu1=BXu1m*Xu1m-BpXc1*(pXu1*pXs1)-GpXu1*pXu1; 
$pXs1=BXs1m*Xs1m-BpXc1*(pXu1*pXs1)-GpXs1*pXs1; 
$pXc1=BpXc1*(pXu1*pXs1)-GpXc1*pXc1; 
#$GpXs1=GpXs1*pXs1; 
#$GpXu1=GpXu1*pXu1; 
#$GpXc1=GpXc1*pXc1; 
 
 
#BiP dynamics 
 
Case UpRegul OF 
When NoRegul : 
$Bm=Bbm-Gbm*Bm; 
Switch to Regul if Xs1m>30; 
when Regul: 
(a0+a1*Xs1m+(Xs1m)^2)*$Bm=Bbm*(a0+a1*Xs1m+(Xs1m)^2)+Nbm*(Xs1m)^2-
(a0+a1*Xs1m+(Xs1m)^2)*Gbm*Bm; 
end 
$B=Bb*Bm-Gb*B-Cb*U*B+Gub*UB+Gfold*UB; 
Rtransl = Bb*Bm ; 
Rdecay = Gb*B ; 
Rbind = Cb*U*B ; 
Rdissoc = Gub*UB + Gfold*UB; 
#(a0+a1*Xs1m+(Xs1m)^2)*$PDIm=Bpdim*((a0+a1*Xs1m+(Xs1m)^2)+Npdim*(Xs1m)^2)-
(a0+a1*Xs1m+(Xs1m)^2)*Gpdim*PDIm; 
#$PDI=Bpdi*PDIm-G*PDI; 
 
#ATF6 activation/pathway  
 
$AFB=Cb*B*AFa-GAFB*AFB; 
$AFa=-Cb*B*AFa+GAFB*AFB; 
 
$Xtotal=$Xu1m + $Xs1m; 
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$Xu1m* (a0+a1*AFa+(AFa)^2)=BXu1m* (a0+a1*AFa+(AFa)^2)+NAFa*(AFa^2); # -
GXu1m*Xu1m;  
 
#$Xu1m* (a0+a1*AFa+(AFa)^2)= BXu1m*Xs1m/200-GXu1m*Xu1m-
BXs1m*min(I1A,Xu1m)+NAFa*(AFa^2); 
# ASSIGN 
# VariablePath := Expression ; 
# VariablePath := [ Expression < , ... > ]; 
 
 
# PRESET 
# < RESTORE " > 
# VariablePath := InitialValue ; 
# VariablePath := InitialValue : LowerBound : UpperBound ; 
 
 
# INITIALSELECTOR 
# SelectorPath := FlagPath ; 
# SelectorPath := [ FlagPath < , ... > ]; 
 
# INITIAL 
# Equations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
240 
Appendix III: Mammalian UPR Code in gPROMS®  
2. Process: Mammalian UPR for cells overexpressing Swedish APP695  
 
        # ParameterName 
 
 AS INTEGER || REAL || LOGICAL < DEFAULT Value > 
# ParameterName AS ARRAY ( Size < , ... > ) OF INTEGER || REAL || LOGICAL < DEFAULT 
Value > 
# ParameterName AS FOREIGN_OBJECT < "ForeignObjectClass" > < DEFAULT 
"ForeignObjectValue" > 
 
 
UNIT 
ER as S_UPR_2 
 
# UnitName AS ModelName 
# UnitName AS ARRAY ( Size < , ... > ) OF ModelName 
 
 
#MONITOR 
# SYNTAX: VariablePathPattern ; 
 
 
SET 
within ER do 
 
#Folding module 
 
Cub :=.0350; #mol-2.s-1 
Cb :=1/0.350; #mol2s1 
Gub:= 196; #mol-1.s-1 
Gb :=1.39e-4; #mol-2.s-1 
 
 
#IRE1 activation, XBP1 splicing, splicing reporter module 
 
Ci1b :=0.350; #mol-2.s-1 
Gi1b :=196; #mol-1.s-1 
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Grsm :=8.33e-4; #mol-1s-1 
Brs := 8.33e-3; #mol-1s-1 
Grs :=3.47e-5; 
 
#BiP trascription module 
 
Bb :=0.25; #s-1 
Gb :=1.39e-4; #s-1 
 
#PERK activation/pathway 
 
n :=4.5; 
I0 :=45; 
Cpkb :=0.350; #mol-2.s-1 
Gpkb :=196; #mol-1.s-1 
Cup :=2.33e-4; #mol-2.s-1 
Be2a :=0.167; #s-1 
GpE2a :=8.33e-4; #s-1 
Ge2a :=8.33e-4; #s-1 
Bpe2a :=1.5e-3; #s-1 
 
 
#ATF6 pathway 
 
GAFB:= 196;  #mol-1.s-1 
 
#ATf4 pathway 
 
Bcp :=0.25; #s-1 
Gcp :=7.7e-3; #s-1 
 
Ba4 :=0.25; #s-1 
Ga4 :=7.7e-3; #s-1 
 
a0 :=181935 ; 
a1 := 23.7363  ; 
tau:=12000;  
end 
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# ParameterPath := Expression ; 
# ParameterPath := [ Expression < , ... > ]; 
# ParameterPath := "<ForeignObjectClass::>ForeignObjectValue"; 
# DomainPath := [ BFDM || CFDM || FFDM || OCFEM , Order , NumOfElements ]; 
 
 
# ASSIGN 
# VariablePath := Expression ; 
# VariablePath := [ Expression < , ... > ]; 
 
 
# PRESET 
# < RESTORE " > 
# VariablePath := InitialValue ; 
# VariablePath := InitialValue : LowerBound : UpperBound ; 
 
 
# INITIALSELECTOR 
# SelectorPath := FlagPath ; 
# SelectorPath := [ FlagPath < , ... > ]; 
 
ASSIGN 
within ER do 
 
Na4m :=18.0;  
Ba4m :=0.24; #mol.s-1 
Ga4m  :=4.67112E-7; #s-1 
Nbm :=1.8473; # 
 
Bbm :=0.05;  
Gbm :=1.03873E-4;  
Ncpm :=378.305;  
Gcpm :=7.73116E-6; #s-1 
Bcpm :=41.435 #mol.s-1 
Gfold :=2.5704E-4; #mol-1.s-1 
ku:=76.123E3;  
GXs1m :=3.69151E-8;  
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GXu1m :=6.37986E-4; #s-1 
BXs1m :=1.4E-4; #0.0024; #0.000242457; 
BXu1m :=0.00919444; #s-1 
BpXs1 :=0.0032;  
BpXu1 :=0.002;  
GpXu1 := 0.03; #s-1 
GpXc1 :=0.03;  
Gpxs1 :=0.035;  
 
BpXc1 :=1.33E-07;  
 
NAFa := 1.09 ;  
 
#Ge2a :=8.33e-4; #salubrinal 
                                                                                                                                             
end 
 
INITIAL 
 
Within ER do 
t=0; 
B=430000;  
#PDI=0; 
I1AB=256; #256 
I1A=0; 
U=0; 
UB=0; 
Rs=0; 
Rsm=0; 
Pka=0; 
PkB=256; 
E2a=200; 
pE2a=0; 
Cp=0; 
A4=0;  
Su=0; 
Xu1m=151.88618-27.547108; 
pXu1=0.05; # 
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pXs1=0.07; # 
pXc1=0.05; 
 
AFB=256;       
AFa=0; 
 
#Fitted  
Bm= 200; 
Xs1m=27.547108;  
Xtotal=151.88618; 
A4m=3160.3965; 
Cpm=109562.414; 
end 
 
# Equations 
# STEADY_STATE 
 
 
 SOLUTIONPARAMETERS 
   REPORTINGINTERVAL := 300; #300 ; 
    OUTPUTLEVEL := 4 ; 
    gRMS := ON ; 
    BLOCKDECOMPOSITION := ON ; 
 
 
SCHEDULE 
# salubrinal case study 
#Sequence 
#Continue for 14400 
#Reassign 
#ER.Ge2a:=0; 
#End 
Continue for 40000 
#End 
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